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Type 2 diabetes mellitus (T2DM) is a leading non-communicable disease with 
increasing health, socio-economic implications and with pharmacological agents that 
fail to replicate the success of bariatric surgery. This thesis aims to evaluate the 
therapeutic potential of customised gastrointestinal (GIT)-derived peptide hormones, 
namely glucose-dependent insulinotropic polypeptide (GIP), xenin and neurotensin 
(NT) in the hope of advancing the therapeutic repertoire. GIP has important glucose-
lowering endocrine and exocrine actions that become impaired in T2DM. Xenin is co-
secreted with GIP and known to potentiate its biological actions. Thus, the biological 
and therapeutic potential of twice daily administration of a previously characterised 
GIP/xenin hybrid, (DAla2)GIP/xenin-8-Gln, both alone and in combination with 
exendin-4 was assessed in high fat fed and db/db mouse models of T2DM. In HFF 
mice, treatment with (DAla2)GIP-xenin-8-Gln in combination with exendin-4 was the 
most effective therapeutic strategy, although (DAla2)GIP-xenin-8-Gln alone induced 
notable benefits in this model. Interestingly, in the db/db model, (DAla2)GIP-xenin-8-
Gln alone was much less efficacious than combined treatment with exendin-4, most 
likely linked to the disease severity and notable beta cell dysfunction. Further to this, 
NT has several antidiabetic actions and is known to facilitate fatty acid absorption. 
Xenin is structurally related to NT, with similar biological actions, thought to be 
partially mediated through NT receptors. Preliminary in vitro studies revealed that the 
novel acetyl-neurotensin(8-13)-xenin-8-Gln hybrid had antidiabetic attributes that 
warranted further in vivo assessment. Twice daily administration of acetyl-
neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 to HFF mice had 
positive glucose-lowering and insulinotropic effects with beneficial actions on lipid 
metabolism. Interestingly, GIP action has been linked to the exacerbation of obesity 
and T2DM, increasing insulin resistance and fat deposition. Thus, postulation that 
inhibiting GIP action could potentially halt the progression of obesity-related diabetes. 
However, to date there is no definitively characterised peptide-based GIP antagonist. 
Manipulation of the amino acid sequence, with N- and C- termini truncation, yielded 
Pro3(3-30)GIP as a notable GIP receptor antagonistic that merits further testing. 
Overall, these data show that modified GIT peptides possess notable therapeutic 
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1.1 Peptide therapeutics 
The area of gastrointestinal endocrinology involving the study of 
gastroenteropancreatic regulatory hormones/neuro peptides and the gut brain axis has 
become pivotal to scientific research and pharmaceutical development (Rehfeld 2015; 
Röder et al., 2016). Research has focused on their locality, expression, secretory 
mechanisms, receptors, receptor binding and regulatory effects on: gastrointestinal 
motility, gastric acid secretion, pancreatic exocrine and carbohydrate metabolism to 
better understand their role under both normal and pathophysiological conditions 
(Rehfeld, 2012; 2015; Track, 1980). There is much interest in utilising these hormones 
as pharmacological agents, exploiting their pharmacokinetic and pharmacodynamic 
capabilities for the treatment of metabolic disease. As it is now understood, the 
gastrointestinal system is the largest endocrine organ, with gastrointestinal hormones 
extensively expressed outside the gut and neuropeptides expressed within the gut, thus 
it has vast potential as a major therapeutic target (Rehfeld, 2012; 2015). 
 
1.2 The pancreas 
The pancreas is a key regulatory organ located within the upper left side of the 
abdominal cavity, (behind the stomach) and comprises a head, body and tail (Figure 
1.1). Its role as an organ within the body is to regulate metabolic homeostasis by 
secreting digestive enzymes and hormones (Röder et al., 2016). Enzymes are secreted 
from exocrine cells into the accessory and pancreatic ducts and regulatory hormones 
are secreted from endocrine cells directly into the blood stream. Endocrine cells are 
located throughout exocrine tissue, where they cumulate together and assemble what 
is known as the Islets of Langerhans, which accounts for 1-2% of the whole organ and 
their secretions are key to regulating glucose homeostasis (Röder et al., 2016). Islet 
architecture consists of five cell types all secreting different key hormones; alpha cells 
(15-20%) produce glucagon, beta cells (65-80%) produce insulin, ɛ cells produce 
ghrelin (<1%), gamma cells produce pancreatic polypeptide (PP) (3-5%) and delta 
cells produce somatostatin (3-10%) (Brereton et al., 2015; Röder et al., 2016).  
Under normal conditions, it is primarily glucagon and insulin that are secreted by the 
pancreas to maintain glucose homeostasis within the ideal range (4-6 mmol/l). These 
two hormones achieve homeostasis by acting as a counterbalance to each other’s 
3 
 
regulatory actions (Figure 1.2). In times of depleted blood glucose levels, glucagon is 
secreted from α-cells, and this triggers hepatic glycogenolysis and hepatic/renal 
gluconeogenesis elevating blood glucose levels. Conversely, when blood glucose 
levels become elevated β-cells are stimulated to secrete insulin by exocytosis (Figure 
1.3). This enables insulin-dependent uptake of glucose by muscle and adipose tissue 
and therefore a lowering of blood glucose levels and initiation of glycogenesis and 
lipogenesis (Röder et al., 2016). 
 
Figure 1.1: The exocrine and endocrine function of the pancreas 
 
1.3 Type 2 diabetes mellitus an overview 
Metabolic disturbances result in disease development and at the centre of 
gastroenteropancreatic dysregulation is T2DM (Röder et al., 2016). T2DM is a 
chronic, non-communicable, multifactorial disease that is growing in prevalence. It 
occurs as a consequence of insulin resistance and impaired insulin secretion (Public 
Health England, 2018; Röder et al., 2016). The former occurs when insulin 
progressively loses its efficacy on target muscle and adipose tissue. The latter 
Pancreatic exocrine function involves secretion of digestive enzymes to the upper small 
intestine and endocrine function is to secrete several hormones from various cell types 





progresses because of a continuing decrease in glucose responsiveness causing glucose 
and lipid toxicity that results in a decrease in pancreatic beta cell mass (Kaku, 2010). 
 
Figure 1.2: Glucose homeostasis 
 
In the early stages of T2DM development, known as pre-diabetes, the body begins to 
compensate for increasing insulin resistance, by increasing the rate of insulin secretion 
(Dendup et al., 2018). As a result, pancreatic beta cell mass increases and this is 
thought to be due to an increase in beta cell number but could also be linked to beta 
cell hypertrophy (Alarcon, 2016; Weir and Bonner-Weir, 2004). Eventually, the 
insulin produced has an inability to function normally, which is characterised by 
declining beta cell function, and over time this leads to prolonged, elevated blood 
glucose concentrations, a hyperglycaemic state (Röder et al., 2016). This is 
The mechanism of how blood glucose levels are balanced by glucose and insulin. 
Postprandially, blood glucose is high, insulin is secreted to initiate glucose uptake into 
muscle and adipose tissue and to promote glycogenesis. Conversely, when blood glucose 
is low, glucagon is secreted by the pancreas by glycogenolysis to increase endogenous 
blood glucose levels (Adapted from Röder et al., 2016). 
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compounded by increased hepatic gluconeogenesis which in turn causes hepatic 
glucose production to increase thus exacerbating the hyperglycaemia (Redinger, 2007; 
Röder et al., 2016).  
Ultimately, the result is increased insulin resistance, decreased beta cell insulin 
secretion, and eventual beta cell exhaustion, thought to be induced by the increased 
stress, caused by inflammatory and oxidative states (Alarcon, 2016; Dendup et al., 
2018; Röder et al., 2016). This tandem effect, the decline of beta cell function and 
insulin production, coupled with hyperglycaemia, exacerbates insulin resistance and 
T2DM (Alarcon, 2016; Dendup et al., 2018; Weir and Bonner-Weir, 2004). The 
diagnostic criteria for T2DM is a fasting plasma of >7.0 mmol/l, an oral glucose 
tolerance of >11.1 mmol/l after 2 h and a haemoglobin A1c of 48 mmol/mol or 6.5% 
(Diabetes UK, 2018). 
 
Figure 1.3: The insulin secretion cascade 
 
 
The mechanism for pancreatic beta cell insulin release. Uptake of exogenous glucose by 
GLUT2, undergoes glycolysis. The adenosine triphosphate (ATP) levels adjust the 
ATP/ADP ratio. This causes the ATP-sensitive K+ channels to close and membrane 
depolarisation to occur opening the voltage-dependent Ca2+ channels as a response to the 
increase in intracellular calcium levels leading to vesicle fusion and ultimately insulin 




There are several causative factors in development of T2DM. These risk factors 
include a genetic and/or ethnic predisposition and/or environmental factors such as a 
sedentary lifestyle, obesity, smoking, alcohol and aging (Figure 1.4; Public Health 
England, 2018). Globally, the prevalence of diabetes in 2015 was estimated to be 415 
million adults and by 2040 this is expected to rise to 642 million (Dendup et al., 2018). 
In the UK, 3.8 million people suffer from T2DM with 200,000 new cases diagnosed 
every year and a further 5 million at high risk of development (Public Health England, 
2018). Furthermore, T2DM was listed by the World Health Organisation (WHO) as 
the sixth global cause of death in 2015 with approximately 1.6 million deaths from 
diabetes and related complications and/or diseases (Public Health England, 2018). 
Interestingly, this report also stated that diagnoses of T2DM is seven times more likely 
in obese adults than those of healthy weight and if recent trends continue, 1 in 3 people 
will be obese by 2034 and 1 in 10 will develop T2DM (Public Health England, 2018).  
 
1.3.1 Obesity and T2DM 
The primary causative factor of obesity in Western society is energy intake levels 
exceeding energy expenditure, resulting in the conversion of excess energy to fat. On 
a molecular level, excess circulating free fatty acids (FFA) are stored as triacylglycerol 
within adipocytes, which in turn cause a physiological accumulation of body fat mass. 
This simple mechanism of fat accumulation results in the manifestation of obesity and 
metabolic dysfunction (Redinger, 2007).  Pathophysiologically, obesity is thought to 
result in metabolic dysfunction through the development of insulin resistance. The 
mechanism by which this occurs was first postulated by Randle et al., (1963), where 
it was hypothesised that obesity-related insulin resistance was caused by the disruption 
of energy homeostasis, encompassing both dysregulation of lipid and glucose 
metabolism (Qatanani and Mitchell, 2007; Redinger, 2007). As obesity progresses, 
excess FFA are released from adipocytes due to enhanced lipolysis. This results in 
lipid toxicity causing insulin receptor dysfunction and a decrease in beta cell insulin 
secretion. An increase in macrophage activity along with the release of pro-
inflammatory cytokines including TNF-α and IL1β, leads to a state of low grade 
inflammation, oxidative cellular stress and mitochondrial dysfunction (Boden, 2008; 
2011; Greenberg and Obin, 2006).  
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1.3.2 The financial burden of T2DM 
Financially T2DM is considered a major public health burden, as the NHS spends 
approximately 9% of its annual budget on the treatment of T2DM and associated 
diseases. In terms of monetary value this equates to approximately £8.8 billion (Public 
Health England, 2018). These figures are expected to rise over the next 25 years to 
17% of the total annual budget (Diabetes UK, 2014; NHS, 2012). To the UK taxpayer, 
the total direct and indirect care costs are currently estimated at £23.7 billion and is 
expected to increase to £39.8 billion by 2035/6 (Diabetes UK, 2014). 
 
Figure 1.4: Development of T2DM 
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1.4 Current oral therapies for the treatment of T2DM 
As diabetes progresses, the need for therapeutic intervention is essential for the 
individuals’ well-being. The main objective is to increase insulin secretion, reduce 
hyperglycaemia and insulin resistance, along with energy regulation (Mayo Clinic, 
2014). Treatment can range from implementation of dietary restriction and/or physical 
exercise to reduce BMI and waist circumference, improve glycaemic control and 
metabolic haemostasis. Often introduction of pharmaceutical therapeutics is 
necessary, as the majority of individuals fail to strictly adhere to non-pharmaceutical 
interventions (Chaudhury et al., 2017; Olokoba et al., 2012).  
The range of pharmaceuticals available to treat diabetes is extensive and they target 
several of the pathophysiological mechanisms which lead to hyperglycaemia, and are 
given either alone or in combination. Some of these can be sub-divided into insulin 
sensitizers; biguanides and thiazolidinediones or insulin secretagogues; sulfonylureas, 
non-sulfonylureas alpha glucosidase inhibitors and incretin mimetics (Figure 1.5; 
Chaudhury et al., 2017; Olokoba et al., 2012). 
 
Figure 1.5: Current T2DM therapeutics 
Current pharmaceutical agents for the treatment of T2DM sites of action (Adapted from 




There is currently only one biguanide available on the global market, known as 
metformin, (dimethylbiguanide). It is derived from Galega officinalis or more 
commonly known at goat’s rue or French lilac (McCreight, Bailey and Pearson, 2016). 
Metformin is the initial treatment of choice for patients with obesity-diabetes (Evans 
et al., 2016). Metformin does not stimulate insulin secretion, but rather works to 
increase insulin sensitivity and decrease gluconeogenesis, thus suppressing hepatic 
glucose production and increasing glucose uptake in skeletal muscle (Chaudhury et 
al., 2017; Cheng and Fantus, 2005; Evans et al., 2016).  
Interestingly, a study by Zhou et al., (2001) ascertained that metformin has another 
mechanism of action, as it activates the adenosine monophosphate-activated protein 
kinase (AMPK) enzyme found in muscle and liver tissue. Normal activation is by 
adenosine monophosphate which is a by-product of adenosine triphosphate and a 
cellular signal for increased energy (Chaudhury et al., 2017; Cheng and Fantus, 2005). 
Activated AMPK causes phosphorylation and inhibition of acetyl-coenzyme A 
carboxylase, which acts as a catalyst to limit lipogenesis reducing the production of 
FFA (Chaudhury et al., 2017). Hepatic AMPK can also reduce the transcription factor 
expression of sterol-regulatory-element-binding-protein-1 (SREBP-1), a known 
mediator of insulin resistance and dyslipidaemia pathogenesis (Zhou et al., 2001). 
Additionally, Miller and colleagues (2013) have shown metformin to have another 
mechanism of action, reducing fasting glucose levels by antagonising glucagon action 
(Miller et al., 2013). Metformin causes AMP and nucleotides to accumulate, thus 
inhibiting adenylate cyclase, reducing the activity of cyclic AMP and protein kinases 
A (PKA), and abolishing phosphorylation of PKA targets and hepatocytes are then 
obstructed from glucagon-dependent glucose output (Miller et al., 2013).  
Metformin is known to be a safe mono-pharmaceutical and when used in conjunction 
with other T2DM therapeutics and other prescribed medications. It has proven efficacy 
not only in reducing fasting plasma glucose but also fasting plasma insulin, 
triglycerides and free fatty acids (FFA) (Evans et al., 2016).  However, with any 
medication it can have adverse effects including gastrointestinal disturbance and cause 
vitamin B12 and folic acid deficiency, as well as fatal lactic acidosis due to severe 
renal insufficiency (Chaudhury et al., 2017; Evans et al., 2016). 
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1.4.2 Thiazolidinediones  
Thiazolidinediones (TZDs) such as pioglitazone are also used to improve insulin 
sensitivity by increasing glucose uptake in adipose, liver and muscle tissue. The action 
of thiazolidinediones are thought to occur by modulating peroxisome proliferator-
activated receptor gamma (PPARγ) on adipocytes, as these regulate the expression of 
genes involved with lipid and carbohydrate metabolism. This results in enhanced 
differentiation and a reduction in lipolysis and circulating adipo-cytokine levels 
(Chaudhury et al., 2017; Evans et al., 2016). There is also an improvement in 
lipogenesis and storage and therefore reduced FFA. This results in preserving beta cell 
integrity and function, which helps to improve insulin resistance and prevent beta cell 
exhaustion (Chaudhury et al., 2017; Evans et al., 2016). Thiazolidinediones can be 
used as a monotherapy or in combination with metformin and other therapeutics. 
However, in some countries, TZDs are not approved for use in combination with 
insulin due to reported adverse effects to include peripheral oedema and congestive 
heart failure (Chaudhury et al., 2017; Evans et al., 2016). Continued use of 
pioglitazone has also been linked to bladder cancer and usage restrictions have been 
enforced by US Food and Drugs Administration (FDA) and European Medicines 




Sulfonylureas were initially developed in the 1950’s and continue to be used as 
therapeutic agents for treatment of T2DM (Evans et al., 2016). Sulfonylureas increase 
insulin release by directly targeting the beta cell and their mechanism of action is to 
cause depolarisation of the cell membrane through binding to the sulfonylurea receptor 
on the cell surface. This inhibits the potassium efflux and opens the calcium channels 
and thus insulin is released (Fowler, 2007). Furthermore, sulfonylureas can restrict 
gluconeogenesis, reduce lipogenesis and decrease the clearance rate of insulin by the 
liver (Chaudhury et al., 2017). The first-generation sulfonylureas have now been 
replaced with second generation sulfonylureas that have improved safety profiles and 
these include glyburide and glipizide (Evans et al., 2016; Fowler, 2007). This drug 
class can become self-limiting in those with late stage T2DM because there are 
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insufficient beta cells to elicit a therapeutic response (Evans et al., 2016; Fowler, 
2007). These pharmaceuticals are normally prescribed as a secondary or additional 
line of treatment but are contraindicated during pregnancy and in cases of hepatic and 
renal disease. Adverse effects include hypoglycaemia, hyponatremia and an increase 
in body weight (Chaudhury et al., 2017; Evans et al., 2016).  
 
1.4.4 Non-sulfonylureas/meglitinides  
Non-sulfonylureas also known as meglitinides, repaglinide and nateglinide work 
similar to sulfonylureas, binding to the receptor on the beta cell, although meglitinides 
have a reduced binding affinity and thus a reduced half-life. Meglitinides also have a 
reduced efficacy compared to sulfonylureas because the therapeutic effect is only 
initiated under high levels of hyperglycaemia (Chaudhury et al., 2017; Fowler, 2007). 
The adverse effects are the same as those described in sulfonylureas, although episodes 
of hypoglycaemia are less likely due to shorter duration of action.  
 
1.4.5 Alpha glucosidase inhibitors 
Alpha glucosidase inhibitors, of which only acarbose is utilised within the UK, slow 
down the rate that carbohydrates are absorbed to reduce hyperglycaemic peaks. They 
block complex carbohydrates from enzymatic degradation in the small intestine by 
competitively binding to the α-glucosidase enzymes binding site on the 
oligosaccharide and thus prevent enzymatic hydrolysis (Evans et al., 2016).  Adverse 
effects include gastrointestinal issues including, but not limited to, flatulence caused 
by the increased level of carbohydrates within the colon, bloating and diarrhoea (Evans 
et al., 2016). 
 
1.4.6 Sodium-glucose cotransporter 2 (SGLT2) inhibitors  
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of 
pharmaceutical agents for T2DM. SGLT2 inhibitors, such as dapagliflozin, have a 
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mechanism of action that is dependent on glucose not insulin. These drugs lower 
hyperglycaemia by preventing the kidney from reabsorbing glucose from within the 
proximal renal tubule by inhibiting SGLT2 (Chaudhury et al., 2017). This mechanism 
allows for other therapies to be used in combination thus utilise their insulinotropic 
therapeutic effect in tandem. Insulin can also be utilised in combination with SGLT2 
inhibitors (Ferrannini and Solini, 2012). SGLT2 inhibitors increase weight loss and 
reduce blood pressure but there is also associated adverse effects and these include; 
infections of genitourinary system, in some cases ketoacidosis and cancer. The 
efficacy of SGLT2 inhibitors can also be reduced when glomerular function is 
impaired (Chaudhury et al., 2017; Ferrannini and Solini, 2012). 
 
1.5 Bariatric surgery  
Bariatric surgery is primarily used for obesity-diabetes in those with a BMI >30-35 
kg/m2 as it can significantly increase sustainable weight loss (Meek et al., 2016; Singh, 
Singh and Kota, 2015). Currently, the main three methods used are gastric banding, 
sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB), the latter being the 
predominant choice (Figure 1.6; Meek et al., 2016; Singh, Singh and Kota, 2015). 
Gastric banding and sleeve gastrectomy methods both reduce the stomach capacity. 
The former utilises an adjustable silicone ring, forming a small pouch at the lower 
oesophagus and the latter involves the removal of a lateral section, with a reduced 
long-sleeve shape stomach remaining (Meek et al., 2016).  
RYGB alters the passage of nutrients, as a small stomach pouch is constructed using 
staples and drained directly into the segmented jejunum, forming the Roux limb (Meek 
et al., 2016). Nutrients can then move down the alimentary limb, bypassing the 
remaining stomach and duodenum. The alimentary limb is then anastomosed with the 
distal biliopancreatic limb, creating the common limb where the nutrients are 
combined, for a shorter time with the biliopancreatic secretions. Time and nutritional 
absorption are dependent on the length of the common limb (Meek et al., 2016). 
Subsequently, with this alteration to the nutritional tract and absorption time, RYGB 
is demonstrated to resolve the associated disease pathologies of T2DM, inducing 
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euglycemia and normalising glycated haemoglobin leading to remission within a 
matter of days, in approximately 80% of patients (Singh et al., 2015).  
 




There are several postulated mechanisms of action for the remission of T2DM (Figure 
1.7), including the hindgut hypothesis (Cummings and colleagues (2004)) and the 
foregut hypothesis (Rubino and colleagues (2006)) amongst others (Meek et al., 2016; 
Pok and Lee, 2014; Singh et al., 2015). The foregut hypothesis suggests that it is the 
exclusion of nutrients from the duodenum and proximal jejunum transit, inhibiting 
nutrient-induced secretion of a putative signal which augments insulin resistance and 
T2DM. One such candidate could be glucose-dependent insulinotropic polypeptide 
(GIP), that is recognised to be largely secreted from the duodenum and proximal 
jejunum (Campbell and Drucker, 2013). The hindgut hypothesis 
proposes that improved glucose control is gained by the accelerated transport of 
Gastric banding (A), the band can be altered to augment or decrease the effects. Sleeve 
gastrectomy (B), the stomach is permanently reduced by the removal of a lateral section. 
Roux-en-Y gastric bypass (C), a stomach pouch is constructed and joined to the jejunum 
along with the biliopancreatic limb to form the Y shape that ends with the common limb 
(Adapted from Meek et al., 2016). 
A C B 
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nutrients to the distal small intestine, in turn inducing secretion of a physiological 
signal that improves glucose homeostasis (Pok and Lee, 2014). Indeed, glucagon like 
peptide-1 (GLP-1) is known to be predominantly secreted from the distal small 
intestine (Campbell and Drucker, 2013), and is therefore often linked to hindgut 
hypothesis.  
Taken together, these hypotheses attribute the change in gut hormone secretion and 
action such as, but not limited to, GLP-1, peptide tyrosine tyrosine (PYY) and GIP, 
oxyntomodulin and pancreatic polypeptide (PP) (Meek et al., 2016; Singh et al., 
2015). These changes in gut hormone secretion profile positively affect appetite and 
satiety as well as energy expenditure and are thought to attribute to sustaining the 
weight loss effect as well as improved glucose homeostasis (Meek et al., 2016; 
Singh et al., 2015; Troke, 2014).  
However, initial improvement/remission is thought to be caused by dramatic reduction 
in plasma glucose levels following the surgery due to the acute negative calorie 
balance, thus within days there is normalisation of plasma glucose levels (Singh et al., 
2015). In addition, following the surgical re-direction of nutrients directly to the distal 
jejunum, which produces GLP-1 significantly increase its secretion and seems to 
augment the response to insulin, further contributing to alleviation of the disease 
pathologies (Singh et al., 2015).  
Furthermore, bariatric surgery has limitations in terms of its applicability to non-obese 
T2DM individuals (Singh et al., 2015). Thus, the duodenal-jejunal bypass liner 
(DJBL), which is a non-surgical endoscopic method was developed to replicate the 
effect of RYGB, denoted as ‘metabolic surgery’ and has now been shown to exert 
significant improvements on glycaemic control (Singh et al., 2015).  
The adverse effects associated with bariatric surgery include an increased mortality 
rate, expense of surgery and post-surgical care, as well as acute complications. These 
occur in approximately 5-10% of cases and can result in leakages, obstructions and 
post-operative infections as well as other long-term complications such as internal 
hernias and nutritional deficiencies. Post-operatively, bariatric surgery has also been 
linked to having a detrimental effect on emotional well-being (Capozzi et al., 2018; 
Pories, 2008; Singh et al., 2015; Schauer et al., 2017). 
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Figure 1.7: Suggested mechanisms for remission of T2DM 
 
 
1.6 Enteroendocrine hormones 
Enteroendocrine hormones are recognised to play an important role in the control of 
metabolism and blood glucose levels (Campbell and Drucker, 2013; Psichas, Reimann 
and Gribble, 2015). Two of the major players in this regard, termed the incretin 
hormones, are GLP-1 and GIP (Campbell and Drucker, 2013). In addition, other 
notable enteroendocrine-derived regulators of metabolic state include, but not limited 
to, oxyntomodulin, PP, PYY, xenin, somatostatin and ghrelin. This enteroendocrine 
sensory system relates to the initial secretion of enteroendocrine hormones 
postprandially, which exert physiological responses to regulate glucose homeostasis, 
islet hormone secretion, lipid metabolism as well as appetite, gastrointestinal motility 
and body weight (Campbell and Drucker, 2013; Leckstrom et al., 2009; Psichas, 
Reimann and Gribble, 2015).   
A timeline showing the suggested mechanisms of improving T2DM post-bariatric surgery 
(Adapted from Singh et al., 2015). 
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Incretins are secreted by enteroendocrine cells located within the gastrointestinal tract 
in response to increased circulating glucose levels (Campbell and Drucker, 2013). 
Activation is initiated by orally ingested glucose, which in turn stimulates insulin 
secretion from pancreatic beta cells that express the specific G-protein coupled 
receptors for respective incretin hormone (Paschetta, Hvalrug and Musso, 2011). Thus, 
the ‘incretin effect’ is said to be the difference in insulin secretory response from an 
oral glucose load compared to a similar intravenously administered glucose challenge 
(Chaudhury et al., 2017). Full proof of the incretin effect was not confirmed until 1964, 
when insulin concentrations could be determined by radioimmunoassay (RIA) 
(Creutzfeldt, 2004). Interestingly, enteroendocrine cells account for approximately 1% 
of intestinal epithelial cells yet it is estimated that 50-70% of total insulin secretion 
can be attributed to the incretin effect (Chaudhury et al., 2017; Gault et al., 2003; 
Psichas, Reimann and Gribble, 2015). 
In contrast, if the incretin effect becomes dysregulated or impaired, the 
enteroendocrine system has no compensatory mechanism, this loss is an early indicator 
and characteristic of T2DM (Al-Sabah, 2015). Loss of incretin effect contributes to a 
defective response to both GLP-1 and GIP as well as impaired secretion of GLP-1 
(Freeman, 2009). However, the insulinotropic response of GLP-1 can be restored 
through the administration of GLP-1 agonists, thus the impairment can be overcome 
and offers a valuable treatment option for T2DM. However, this is not the case with 
GIP, as T2DM progresses GIP beta cell insulinotropic response decreases. The 
mechanism underpinning this remains largely unclear, but studies have postulated that 
the progressing hyperglycaemia detrimentally affects GIP receptor (GIPR) signalling 
to a higher degree than that of the GLP-1 receptor (GLP-1R) (Al-Sabah, 2015). 
Furthermore, a study by Zhou and colleagues, (2007) using rat and human pancreatic 
islets under hyperglycaemic conditions revealed that GIPR expression, GIP-mediated 
cAMP, and insulin production were substantially decreased in T2DM (Al-Sabah, 
2015). 
GLP-1 and GIP action is also inhibited by the glycoprotein, CD26 better known as 
dipeptidyl peptidase-IV (DPP-IV). DPP-IV is a type II transmembrane protein with 4 
domains; the cytoplasmic domain (1–6), the transmembrane domain (TMD) (7–28), 
the flexible stalk segment (29–39), and an extracellular domain (40–766) (Röhrborn, 
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Wronkowitz and Eckel, 2015). DPP-IV has multiple functions including acting as a 
binding partner for several peptides, and as an exopeptidase cleaving various substrates 
including incretin hormones, reducing their bioavailability. DPP-IV exerts its effects 
on incretin hormones by selectively cleaving their N-terminal amino acids in 
circulating plasma inhibiting their insulinotropic action, and ultimately their 
therapeutic efficacy (Röhrborn, Wronkowitz and Eckel, 2015; Seino and Yabe 2011).  
 
1.6.1 Glucagon-like-peptide-1 (GLP-1) 
GLP-1 is derived from post translational cleavage of the proglucagon gene by 
prohormone convertase PC 1/3 (Campbell and Drucker, 2013). This gene also encodes 
for glucagon-like peptide-2 and glucagon, with both peptides having a 50% homology 
to GLP-1 (Campbell and Drucker, 2013). There are two bioactive forms of GLP-1, 
amidated GLP-1(7-36) and non-amidated GLP-1(7-37), and both elicit metabolic 
actions (Seino and Yabe 2011). Enteroendocrine intestinal epithelial L-cells, located 
in the distal ileum and colon, secrete GLP-1 in response to nutritional ingestion as well 
as neural and endocrine factors (Campbell and Drucker, 2013; Psichas, Reimann and 
Gribble, 2015). Secretion is mediated by the automatic nervous system including the 
vagus nerve, neurotransmitters gastrin-releasing peptide (GRP) and acetyl choline as 
well as GIP (Baggio and Drucker, 2007; Campbell and Drucker, 2013). These activate 
protein kinase A (PKA), protein kinase C (PKC), calcium and mitogen-activated 
protein kinase (MAPK). Secretion occurs in a biphasic manner with the initial phase 
lasting 10-15 minutes and the secondary phase 30-60 minutes (Baggio and Drucker, 
2007; Campbell and Drucker, 2013; Seino and Yabe 2011).  
GLP-1R’s belong to the class B family of G-protein coupled receptors (GPCRs), which 
have a large extracellular N-terminal domain (NTD) linked to a 7-transmembrane 
helical domain (Baggio and Drucker, 2007; Capozzi et al., 2018; Seino, Fukushima 
and Yabe 2010). The N-terminal receptor domain is key for GLP-1R binding and the 
third intracellular loop is essential for coupling the receptor to specific G-proteins, 
crucial for signal and activation actions (Baggio and Drucker, 2007; Seino, Fukushima 
and Yabe 2010). The GLP-1R is expressed on pancreatic alpha, beta and delta cells, 
the lungs, kidneys, heart, stomach, intestines, skin, pituitary and nodose ganglion 
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neurons, and within regions of the central nervous system (CNS) mainly the 
hypothalamus and brain stem; hippocampus/cerebral cortex etc. (Baggio and Drucker, 
2007; Campbell and Drucker, 2013; Seino, Fukushima and Yabe 2010).  
Once receptor binding occurs, the biological actions of GLP-1 include: slowing gastric 
emptying, inhibiting glucagon production and increasing insulin secretion. In addition, 
GLP-1 suppresses appetite, lowers body weight and exhibits, anti-inflammatory 
properties (Capozzi et al., 2018). Receptor binding on beta cells initiates insulin 
secretion by activating adenylate cyclase activity and production of cAMP. Other 
mechanisms are thought to include calcium and potassium ion channels, as well as 
intracellular energy homeostasis and exocytosis (Baggio and Drucker, 2007; 
MacDonald et al., 2005; Seino and Yabe 2011). GLP-1 can also preserve islet 
morphology and restore glucose sensitivity of resistant beta cells by up-regulating 
glucose transporters and glucose kinase expression (Baggio and Drucker, 2007). This 
improves the ability of the beta cell to sense and respond to glucose. Furthermore, 
GLP-1 increases beta cell proliferation, neogenesis and prevention of apoptosis, via 
the phosphoinositide 3-kinase pathway (Baggio and Drucker, 2007; Seino, Fukushima 
and Yabe 2010). Native GLP-1 has a relatively short half-life of approximately one 
and a half minutes as it is subject to enzymatic degradation by DPP-IV (Röhrborn, 
Wronkowitz and Eckel, 2015; Tulaihi and Alhabib, 2017). Therefore, biologically 
active and enzymatically resistant GLP-1 receptor agonists have been developed for 
the treatment of T2DM.  
 
1.6.2 GLP-1 receptor agonists  
Injectable GLP-1 receptor agonists (GLP-1 RA), are analogues of GLP-1 that bind to 
its receptor and stimulate bioactive effects (Tulaihi and Alhabib, 2017). There are 
several variations available including; exenatide, lixisenatide, liraglutide, albiglutide 
and dulaglutide (Marín-Penalver et al., 2016). They are classified by their therapeutic 
duration, either short-acting or long-acting, with half-lives ranging from 2.4 hours up 
to several days (Chaudhury et al., 2017; Marín-Penalver et al., 2016). The combined 
use of a DPP-IV inhibitor may also be warranted to further enhance the half-life and 
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therapeutic efficacy (Chaudhury et al., 2017; Jackson et al., 2010; Marín-Penalver et 
al., 2016).  
The first GLP-1 RA to be introduced to the market (2005), was the short-acting, twice 
daily synthetic analogue exenatide (Chaudhury et al., 2017; Hansen, Vilsboll and 
Knop, 2010; Marín-Penalver et al., 2016). It is identical to exendin-4, a 39 amino acid 
peptide derived from the venom of Heloderma suspectum lizard (Gila monster), and it 
shares a 53% sequence homology to native GLP-1 with potent agonist properties on 
the GLP-1R (Marín-Penalver et al., 2016; Seino, Fukushima and Yabe 2010; Tulaihi 
and Alhabib, 2017). Short-acting GLP-1 RA provide brief receptor activation with 
therapeutic effects primarily directed towards postprandial hyperglycaemia and gastric 
emptying, with a lesser effect on fasting glucose (Marín-Penalver et al., 2016). The 
long-acting, once daily GLP-1 RA liraglutide, and long-acting release (LAR) once 
weekly exenatide, as well as albiglutide and dulaglutide elicit their therapeutic effect 
by continuously activating the GLP-1R (Capozzi et al., 2018; Chaudhury et al., 2017; 
Freeman, 2009; Marín-Penalver et al., 2016; Tulaihi and Alhabib, 2017). Thus, 
slowing gastric emptying, inhibiting glucagon production and increasing insulin 
production (Figure 1.8). Therapeutic effects, demonstrated by clinical data include 
improved glucose homeostasis and a reduction in body weight, essential for treating 
T2DM. Also noted was a reduction in systolic blood pressure and protection against 
cardiovascular events (Capozzi et al., 2018; Chaudhury et al., 2017).  
Importantly, exendin-4 is resistant to DPP-IV degradation due to a glycine at position 
2. Exendin-4, pre-clinically, was shown to have superior potency on lowering blood 
glucose levels attributed to extended circulating ability (Tulaihi and Alhabib, 2017). 
Exendin-4 (exenatide) was also shown to reduce glycated haemoglobin, improve beta 
cell function and decrease fasting and postprandial glucose levels in T2DM patients, 
with a potency estimated to be 5000 times greater than native GLP-1 (Seino, 
Fukushima and Yabe 2010).   
More recently, studies utilising a GLP-1R antagonist exendin (9-39) propose GLP-1 
has an energy intake reducing function subsequent to bariatric surgery (Capozzi et al., 
2018). GLP-1 concentrations are elevated to supraphysiological levels and appear to 
reduce appetite. Furthermore, GLP-1 is implicated as a major contributor to improved 
glycaemic control following bariatric surgery. However, it is postulated that 
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pharmacologically GLP-1 administered to supraphysiological levels would yield 
similar therapeutic effects but these concentrations are not well tolerated and result in 
adverse effects (Capozzi et al., 2018; Nauck and Meier, 2018). GLP-1 RA are not 
prescribed to those that suffer or have a history of pancreatitis. Other adverse effects 
range from mild-to-moderate gastrointestinal disruption, nausea, vomiting and 
diarrhoea (Marín-Penalver et al., 2016). Reactions at injection sites is another common 
problem with GLP-1 RA and can cause abscesses, cellulitis and necrosis. Additionally, 
the development of antibodies to GLP-1 RA can also occur (Marín-Penalver et al., 
2016). 
 
Figure 1.8: Incretin mimetics: GLP-1 receptor agonists 
 
 
The pharmacological effects of GLP-1 receptor agonists in T2DM (Adapted from Evans 
et al., 2016). 
21 
 
1.6.3 DPP-IV inhibitors 
DPP-IV inhibitors are administered orally, usually once daily, and can be employed as 
a mono therapy, or alongside metformin, thiazolidinediones or sulfonylureas as a 
combination therapeutic (Nauck, 2016; Tulaihi and Alhabib, 2017).  DPP-IV inhibitors 
main mechanism of action is to inhibit the enzymatic degradation of endogenous 
incretins GLP-1 and GIP (Capozzi et al., 2018; Chaudhury et al., 2017; Fowler, 2007). 
They act to reduce the serum activity of DPP-IV by >80%, thus increasing levels of 
biologically active GLP-1 (Nauck, 2016). The first approved DPP-IV inhibitor was the 
non-peptide heterocyclic compound sitagliptin in 2006, which is long-acting with a 
rapid onset (Nauck, 2016). With the subsequent introduction of vildagliptin and 
saxagliptin, which are long-acting, slow onset cyanopyrrolidines. Others include 
linagliptin, a methylxanthine and the newest to the market is alogliptin, a heterocyclic 
aminopiperidine (Chaudhury et al., 2017; Nauck, 2016). Due to the variation in 
chemical structure their pharmacokinetic properties, bioavailability, half-life, plasma 
peak level and mode of excretion also differ (either renal or hepatic) (Nauck, 2016; 
Tulaihi and Alhabib, 2017).  
Additionally, treatment with the DPP-IV inhibitor sitagliptin was shown to improve 
cardiac function and coronary artery perfusion (Chaudhury et al., 2017). Adverse 
effects include acute pancreatitis and risk of hypoglycaemia, especially in those with 
reduced renal function. Certain medications are also contraindicated including 
warfarin and digoxin. Exenatide has been shown to increase the anticoagulant effect 
of warfarin and plasma levels of digoxin are increased by sitagliptin (Chaudhury et al., 
2017). 
 
1.6.4 Glucose-dependent insulinotropic polypeptide (GIP) 
Enteroendocrine K cells secrete GIP in response to ingestion of glucose and fat in an 
absorption dependent manner (Baggio and Drucker, 2007; Psichas, Reimann and 
Gribble, 2015). These cells are mainly located in the upper jejunum and duodenum 
(Campbell and Drucker, 2013). GIP is derived from the 153 amino acid proGIP 
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precursor and is processed by prohormone convertase 1 or 3 to yield a final peptide of 
42 amino acids in length (Campbell and Drucker, 2013). 
GIPR’s, like GLP-1R, also belong to the class B family of GPCRs (Al-Sabah, 2015). 
It is the N-terminal region of GIP that binds to the receptors N-terminal domain (NTD), 
thus enabling a secondary interaction to occur between the N-terminus of the peptide 
and transmembrane domain (TMD). This activates the receptor and facilitates 
interaction and activation of the heterotrimeric G proteins by the TMD (Al-Sabah, 
2015). 
However, GIP is also subject to enzymatic degradation by DPP-IV, cleaving an N-
terminal dipeptide to yield GIP(3-42) and thus the parent peptide has a half-life of 
approximately 5-7 minutes in humans and 2 minutes in rodents (Baggio and Drucker, 
2007; Hansen et al., 2015). Interestingly, there is a suggestion that GIP(3-42) may 
function as a GIPR antagonist (Gault et al., 2002), albeit perhaps not at physiologically 
relevant concentrations (Deacon and Ahŕen, 2011; Gault et al., 2002). 
GIPR activation on pancreatic beta cells mediates glucose-induced insulin secretion, 
insulin biosynthesis and inhibition of beta cell apoptosis (Baggio and Drucker, 2007).  
GIPRs are also expressed on pancreatic alpha cells, adipose tissue (mediates lipid 
metabolism) and bone (enhances bone formation) with further distribution throughout 
a broad spectrum of tissue including adrenal cortex, endothelium and brain with 
pleiotropic effects (Al-Sabah, 2015; Baggio and Drucker, 2007).  
Given the plethora of therapeutic targets that GIP may affect, there has been renewed 
interest in developing it into a viable therapeutic. Due to its relative large molecular 
weight (4983.6 Daltons), initial underpinning research focused on delineating the 
bioactive regions of GIP with the intent to develop a smaller molecule that retained 
the capabilities of native GIP (1-42) (Hinke et al., 2004). Hinke and colleagues (2004) 
determined that GIP could be split into three bioactive regions. The N-terminal, amino 
acids 1-14, the mid-region amino acids 19-30 and the C-terminus amino acids 31-42. 
Interestingly, it was the N-terminal and mid-region segments of amino acids that were 
demonstrated in perfused rat pancreas to retain GIP insulinotropic bioactivity, with 
suggestion that the C-terminus segment processed only somatostatinotropic activity 
(Hinke et al., 2004). Furthermore, a modified version of native GIP (1-14), with a 
reduced bond between Ala2 and Glu3 was shown to have a superior receptor potency 
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and DPP-IV resistance (Hinke et al., 2004). Considering this, modified GIP analogues 
warrant further investigation as T2DM therapeutics. 
However, chronic consumption of a high fat diet has been shown to induce 
hypersecretion of GIP (Paschetta, Hvalrug & Musso, 2011; Pathak et al., 2015a). 
These elevated GIP concentrations have been linked to inducing obesity by 
upregulating lipogenesis due to GIPs direct role in lipid metabolism and insulin 
resistance. This could suggest that increased action or secretion of GIP can predispose 
to obesity (Paschetta, Hvalrug & Musso, 2011). Evidence to which was demonstrated, 
even under diminished insulin action, by Zhou and colleagues (2005). The study 
determined, utilising insulin receptor substrate (IRS)-1-deficient knockout mice that if 
the action of insulin was diminished GIP could switch from fat oxidation to fat 
accumulation. This would ultimately result in increased triglyceride storage and thus 
an inflammatory response (Zhou et al., 2005). Conversely, a study by Varol et al., 
(2014) reputed these conclusions. They postulated utilising several in vivo models and 
a long-acting GIP analogue, that GIP is in fact a suppressor of inflammation (Varol et 
al., 2014). With the association of GIP and obesity, GIPR antagonism and/or 
disruption of GIP action has been at the forefront as a potential therapeutic for treating 
obesity-diabetes. There have been several in vivo studies, in dietary and genetically-
induced obese rodent models, utilising GIP antagonism with promising outcomes 
including reduction of circulating triglycerides and body weight (Gault et al., 2007; 
McClean et al., 2007; Pathak et al., 2015). To date, bariatric surgery is the only 
treatment option that delivers sustainable long-term weight loss in patients with 
obesity-diabetes (Troke et al., 2014). 
 
1.6.5 Neurotensin 
Neurotensin (NT) is a 13 amino acid peptide hormone located in the CNS and 
gastrointestinal tract where it acts as a neurotransmitter and regulatory hormone, 
respectively (Boules et al., 2013). NT is synthesised from a precursor (pro-NT/NN) 
that contains NT and a neurotensin-like peptide, neuromedin N (NN) (Kitabgi, 2006). 
Pro-NT/NN is cleaved by pro-protein convertases (PC), primarily pro-hormone 
convertases PC1, PC2 and PC5-A, giving rise to NT and NN (Kitabgi, 2006). NT is 
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expressed in neuronal synaptic vesicles within the CNS and in neuroendocrine cells 
within the gastrointestinal tract (Mazella et al., 2012). NT has also been located on 
organs such as the liver, heart, lungs spleen and pancreas (Boules et al., 2013).  
NT mediates its physiological effects through three NT receptors (NTRs). These are 
known as NTSR1, NTSR2 and NTSR3 (Boules et al., 2013; Mazella et al., 2012). 
NTSR1 and NTSR2 are neuropeptide receptors, coupled to GPCRs with a 7-
transmembrane helical domain. NTSR3 or sortilin is non-coupled to GPCRs type I 
receptor, has a single transmembrane domain, and is structurally unrelated to NTSR1 
or NTSR2 (Boules et al., 2013; Mazella et al., 2012).  
NT has been implicated as an important regulator of body weight, both centrally and 
peripherally, as it has been shown to mediate peripheral fat absorption from the 
intestinal tract and appetite via the CNS (Schroeder and Leinninger, 2018). Recently, 
it has been shown that disruption to NT signalling can cause a significant decrease in 
central NT expression within the ventromedial hypothalamus (VMH) in obese rodents 
when compared to lean counterparts and suggested that this loss could contribute to 
the pathogenesis of obesity (Schroeder and Leinninger, 2018).  
This is supported by several studies that demonstrate reduced levels of NT, primarily 
within the lateral hypothalamic area (LHA), in high-fat fed (HFF) rats and genetically 
obese mice (Schroeder and Leinninger, 2018). This suggests a commonality cross-over 
on regulation of food intake and body weight between the signalling actions of NT and 
leptin (Schroeder and Leinninger, 2018). In addition, a ten-day study by Feifel and 
colleagues (2010) in genetically obese ob/ob mice showed that an agonist of the NTR1 
could supress food intake and induce weight loss. Furthermore, circulating levels of 
NT are significantly increased following bariatric surgery and weight loss, further 
suggesting that NT contributes to decreasing food intake and therefore regulation of 
body weight (Schroeder and Leinninger, 2018).  
 
1.6.6 Xenin 
Xenin is a peptide hormone that is synthesised and secreted from the same cell type as 
GIP, enteroendocrine K cells within human gastric mucosa, primarily that of the 
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duodenum and jejunum (Feurle et al., 1998; Kerbel et al., 2018). It is also located 
within the pancreas, liver, stomach, kidneys, heart, lungs and hypothalamus (Craig, 
Gault and Irwin, 2018; Feurle et al., 1998; Parthsarathy et al., 2016). Biologically 
active xenin is 25 amino acids long and derived from the N-terminal of coatomer 
protein alpha (COPA), which is a 35 amino acid precursor known as proxenin (Feurle 
et al., 1992; Feurle et al., 1998; Kerbel et al., 2018). Proxenin is cleaved by aspartic 
proteinases including pepsin and cathepsin E, removing 10 C-terminal amino acids, 
thus xenin 25 (Craig, Gault and Irwin, 2018; Feurle et al., 1992; Kerbel et al., 2018).   
Xenin-25 is structurally related to neurotensin. As such, the C-terminus of xenin-25 
and neurotensin share a free non-amidated C-terminal isoleucine, the only difference 
is the substitution of amino acids arginine for lysine and tyrosine for tryptophan, the 
N-terminus and mid-sequence share no homologies (Craig, Gault and Irwin, 2018). 
Indeed, there has been no specific xenin receptor identified to date, and it is thought 
that its biological actions may be mediated in part through activation of neurotensin 
receptors, as well as cholinergic nerve fibres (Craig, Gault and Irwin, 2018; Feurle et 
al., 2002). 
Circulating levels of xenin are increased postprandially and xenin exerts effects on 
metabolism such as reducing the rate of gastrointestinal transit and gastric emptying 
(Anlauf et al., 2000). Xenin also has the ability to suppress appetite and modulate lipid 
metabolism by increasing lipolysis and decreasing lipogenesis within adipose tissue 
and therefore affects energy balance (Anlauf et al., 2000; Bhavya et al., 2018).   
Secretions of the endocrine and exocrine pancreas are also affected by xenin. Several 
studies have demonstrated that xenin-25 and the naturally occurring bioactive 
fragment, xenin-8, activate the secretion of insulin, glucagon and PP (Craig, Gault and 
Irwin, 2018; Gault et al., 2015; Taylor et al., 2010). Interestingly, xenin-25 can act 
independently as an insulinotropic agent stimulating pancreatic beta cell insulin 
release with the ability to increase the proliferation of pancreatic beta cells (Khan et 
al., 2017). In addition, it was initially postulated that xenin-25 directly mediates release 
of insulin and glucagon, because it has no regulatory effect on somatostatin release 
(Craig, Gault and Irwin, 2018). 
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Further to this, under normal and elevated glycaemic conditions, xenin-25 has been 
shown to induce insulin release and enhance the biological actions of GIP and GLP-1 
(Martin et al., 2012; Taylor et al., 2010). As previously discussed, the loss of GIP 
action is a major consequence of T2DM (Al-Sabah, 2015), therefore it would seem 
logical that xenin-25 has potential as an antidiabetic agent. The only thing to 
incumbent exploitation of xenin-25 is the biological half-life, like the incretins, xenin 
is subject to enzymatic degradation (Martin et al., 2012; Taylor et al., 2010). Xenin-
25 is vulnerable to enzymatic degradation carried out by trypsin-like enzymes and 
serine proteases as it contains lysine and arginine residues, thus the native peptide lacks 
stability (Parthsarathy et al., 2016). Therefore, recent research has been directed 
towards developing stable, biologically active and enzymatically resistant peptide 
analogues of xenin (Parthsarathy et al., 2016). 
Novel enzymatically resistant derivatives of xenin-25 include xenin-25-Gln, which has 
Glutamine (Gln) amino acid substitution at all Lysine (Lys) and Arginine (Arg) amino 
acids have been shown to maintain biological activity and be resistant against 
enzymatic degradation (Parthsarathy et al., 2016). Xenin-25-Gln improves blood 
glucose levels, insulin secretion and glucose tolerance along with enhancing insulin 
sensitivity and GIP-stimulated insulin-release when used to treat high fat fed diabetic 
mice (Parthsarathy et al., 2016). Fragmented forms of xenin-25 have also been utilised 
in the search for potential therapeutics. These include the mentioned C‐terminally 
truncated bioactive metabolite xenin-8, which reportedly has the equivalent metabolic 
benefits as xenin-25, as well as the truncated analogue xenin‐8‐Gln. As with xenin-25-
Gln, xenin‐8‐Gln is substituted with a Gln at amino acids Lys and Arg. Xenin‐8‐Gln 
were shown to be resistant to enzymatic degradation and elicit a significant insulin 
secretory effect in high-fat fed mice, similar to that of xenin-25-Gln, with xenin‐8‐Gln 
having a slightly superior effect (Martin et al., 2012; Martin et al., 2016). Moreover, 
this fragment displayed insulin-induced reductions of blood glucose levels in high-fat 
fed mice, not exhibited by xenin‐25[Lys13PAL] (Martin et al., 2012; Martin et al., 
2016). Furthermore, an analogue xenin-6, the last 6 C-terminal residues of xenin-25, 
with a reduced pseudopeptide bond between the amino acid residues Lys and Arg, has 




1.7 Peptide therapeutics 
Peptides are deemed to be extremely beneficial as therapeutics and offer several 
advantages in comparison to other pharmaceuticals including small molecules and 
biologics. They are highly potent, extremely selective, with low toxicity and have 
superior efficacious properties (Fosgerau and Hoffmann, 2015).  Peptides are also 
relatively easy and fairly economical to produce (Fosgerau and Hoffmann, 2015). 
Peptide technology is continually advancing to improve their utility as a therapeutic 
including; peptides with cell penetrating abilities, multiple functions and peptide drug 
conjugates alongside alternative administration routes (Fosgerau and Hoffmann, 
2015).  
 
1.7.1 Novel approaches utilising peptides 
Currently, at the forefront of pharmaceutical peptide technology is the development of 
single receptor agonists into unimolecular dual and triple receptor agonists. These 
unimolecular peptides have the potential to offer an expansive and bespoke treatment 
for T2DM and/or obesity as they combine multiple hormones with complimenting 
glucose regulating and anorectic effects (Capozzi et al., 2018; Sadry and Drucker, 
2013). Further support of this multi-targeted rationale is the efficacious utility of 
bariatric surgery to treat metabolic syndromes. The success of bariatric surgery is 
linked to alteration of several gastrointestinal hormones to reverse disease pathology. 
This multiple hormone modulation has yet to be successfully pharmacologically 
replicated and presently unimolecular dual and triple agonists offer the best 
opportunity to do so (Capozzi et al., 2018). 
The enteroendocrine system is the largest regulatory endocrine organ within the body 
and by extension, there are multiple mechanisms available for exploitation. This bring 
into question the current rational and efficacy of single target therapeutics.  Therefore, 
the potential for extending the scope from a single target to dual or triple target 
therapeutic seems a logical step.  As with the development of any novel 
pharmaceutical, the development and testing of novel unimolecular peptide 
therapeutics must take into consideration the broad tissue dissemination and 
pleiotropic effects of parent peptides (Al-Sabah, 2015). In addition, understanding of 
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peptide structure/function, knowledge of receptor and ligand binding specificity are 
required to maximise potency and efficacy, and reduce potential adverse effects.  
Studies employing unimolecular peptide mimetics such as GLP-1/GIP dual receptor 
agonist show they are biphasic. Initially, the principle strategy of these types of dual 
agonists was to augment the glycaemic control and body weight reducing ability of 
GLP-1 and facilitate re-sensitivity to GIP to further modulate glycaemic control and 
body weight (Capozzi et al., 2018; Finan et al., 2013). Alone GIPR agonists were 
shown to have no effect on body weight or fat mass and dual receptor agonism had 
superior efficacious effects than the GLP-1R agonist alone (Capozzi et al., 2018; Finan 
et al., 2013). Furthermore, recent studies by Finan et al., (2015) and Bhat et al., (2013), 
demonstrated that monomeric tri-agonist peptides had superior efficacious effects on 
glycaemic control and decreased body weight in relevant in vivo models of obesity and 
T2DM. Currently, several of these unimolecular dual and triple agonists are 
undergoing clinical trial phases with promising preliminary results for the treatment of 















Modulation of endogenous enteroendocrine and neuroendocrine peptide hormones 
yields superior therapeutic efficacy than parent peptide hormones to treat type 2 
diabetes and obesity. 
 
1.9 Thesis aims 
Aims and objectives: 
1. To assess the in vivo metabolic and therapeutic efficacy of a GIP-xenin hybrid 
peptide alone or in combination with a GLP-1 RA in a mouse model of diet-
induced obesity-diabetes. 
 
2. To evaluate the glucose-regulatory, insulinotropic activity and satiety 
enhancing properties of a GIP-xenin hybrid peptide alone or in combination 
with a GLP-1 RA in a genetically-induced mouse model of T2DM with 
established beta cell dysfunction.  
 
3. To characterise a novel neurotensin-xenin hybrid peptide and investigate its 
gluco-regulatory, insulinotropic and antidiabetic activity in a pre-clinical 
model of diet-induced obesity-T2DM mouse model. 
 
4. To design, synthesise and characterise novel N- and C- terminally truncated 































All peptides used throughout this thesis were purchased from Synpeptide Company, 
Ltd (Shanghai, China). Peptides used in Chapter 3-5 (Table 2.1) were procured at 
>95% purity. Peptides used in Chapter 6 (Table 2.1) were procured in crude form and 
subsequently purified in-house, as described in Section 2.2.2. 
 
2.2 Peptide purification and characterisation 
2.2.1 Materials 
Acetonitrile (HPLC grade), trifluoroacetic acid (TFA) (sequencing grade) and α-
cyano-4-hydroxycinnamic acid were purchased from Sigma-Aldrich (Poole, Dorset, 
UK). Distilled water (18.2 MΩ-cm purity) was used in all experiments and obtained 
from an Elga PURELAB Ultra system (Elga, Celbridge, Ireland). 
 
2.2.2 Purification of crude synthetic peptides  
All crude peptides in Chapter 6 (Table 6.1) were purified to a single homogenous peak 
by reverse-phase high performance liquid chromatography (RP-HPLC) on a Surveyor 
Plus Liquid Chromatograph/HPLC (Thermo Finnigan, San Jose, California, USA), 
using a Jupiter Proteo analytical column (250 x 4.6 mm, Phenomenex, Torrance, 
California, USA), equilibrated with 0.1% (v/v) TFA/water, flow rate 6 ml/min. 
Peptides were re-suspended in 0.1% (v/v) (TFA)/H2O and 0.1% TFA in 70% 
acetonitrile/H20 (2:1 ratio) and injected into the column. Eluting solvent, acetonitrile 
(70%), was increased using linear gradients with percentage raised from 0-30% (v/v) 
over 13 min and 70% (v/v) over 53 min. Absorbance was measured at 214 nm. Peaks 
for each run were analysed using Thermo Electron ChromQuest data collection 
software (Version 3) and eluted peptides manually collected. Peptide aliquots (3-4 ml), 
were concentrated using a Savant SPD2010 SpeedVac concentrator and freeze dried 
(-55 ˚C) by a FreeZone Benchtop Freeze Dry System (Labconco, Kansas City, 
Missouri, USA). 
 
2.2.3 Confirmation of peptide purity 
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Peptide purity (Chapters 3-6) was confirmed by RP-HPLC as described in Section 
2.2.2 with the exception that peptides were re-suspended in distilled water and a 1 ml 
solution, (900 µl of 0.1% (v/v) TFA/water and 100 µl of peptide) was injected into the 
column. Chapters 3-5 used a Jupiter C-18 analytical column (250 x 4.6 mm) 
equilibrated with 0.1% (v/v) TFA/water, flow rate 1 ml/min, percentage acetonitrile 
raised from 0-40% (v/v) over 10 min, to 60% (v/v)  over 40 min and to 70% (v/v)  over 
5 min. Chapter 6 used an Aeris XB-C18 HPLC column (Phenomenex), equilibrated 
with 0.1% TFA/water flow rate 1 ml/min and percentage acetonitrile raised from 0-
30% (v/v) over 10 min and to 70% (v/v) over 30 min. Retention times were recorded 
and sample fractions were collected for MALDI-TOF analysis (Section 2.2.4). 
 
2.2.4 Confirmation of molecular mass 
Molecular mass of peptides was confirmed by matrix-assisted laser desorption 
ionisation time of flight mass spectrometry (MALDI-TOF MS) using a Voyager-DE 
Biospectrometry Workstation (PerSeptive Biosystems, Farmingham, MA, USA). 
Each peptide was combined with a matrix solution, 10 mg/ml cyano-4-
hydroxycinnamic acid in acetonitrile/ethanol, 1:1 ratio, suspension (1.5µ l) and applied 
to a stainless-steel sample plate and allowed to dry at room temperature. The plate was 
inserted into plate holder and the mass spectra recorded as a mass-to-charge (m/z) ratio 
against relative peak intensity. The experimental molecular mass of each peptide was 
then compared to their respective theoretical mass using a peptide calculator. 
 
2.3 Metabolic degradation 
2.3.1 Materials 
All reagents used in RP-HPLC and MALDI-TOF were purchased from Sigma Aldrich 
(Poole, Dorset, UK) as stated previously in Section 2.2.1.  Purified water used in these 
experiments was obtained from an Elga PURELAB Ultra system. All other chemicals 
used were purchased from BDH chemicals (Poole, Dorset, UK).  Murine plasma was 




2.3.2 Plasma degradation 
Murine plasma was collected as described in Section 2.10. The plasma degradation 
profile of peptides was determined by method described by Taylor et al. (2010). In 
brief, 10 µl plasma was incubated with 100 µl of peptide (100 µl of 1 mg/ml) and 390 
µl Triethanolamine-HCl (50 mmol/l, pH 7.8) at 37oC with gentle agitation for 0, 2, 4 
and 6 hour(s). The enzymatic reactions were terminated by addition of 50 µl 
TFA/water 10% (v/v). Degradation products were then separated from intact peptide 
using RP-HPLC (Section 2.2.3) and fractions collected were subsequently 
characterised by MALDI-TOF MS (Section 2.2.4). 
 
2.4 Cell culture 
2.4.1 Materials  
DMEM and RPMI-1640 tissue culture media, foetal bovine serum (FBS), penicillin, 
streptomycin, gentamicin, trypsin/EDTA and Hanks Buffered Saline Solution (HBSS) 
were all purchased from Gibco Life Technologies Ltd. (Paisley, Strathclyde, UK). All 
other chemicals including trypan blue were purchased from Sigma Aldrich. 
 
2.4.2 Culture of pancreatic BRIN-BD11 cells 
BRIN-BD11 cells are an insulin-secreting, clonal pancreatic beta cell line, secreting 
insulin in a glucose-dependent manner. They express incretin receptors and are derived 
from electrofusion of New England Deaconess Hospital (NEDH) rat pancreatic islet 
cells and immortal rat insulinoma RINm5F cells (McClenaghan et al., 1996a). 
Culturing took place under sterile conditions using vented 20-175 cm2 tissue culture 
flasks (Nalgene Labware, Thermo Scientific Corporation, Denmark), pre-warmed 
RPMI-1640 growth media supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics 
(100 U/ml penicillin and 0.1 mg/ml streptomycin), maintained at 37°C and 5% CO2, 
in a LEEC incubator (Laboratory technical engineering, Nottingham, UK) as 
previously described by McClenaghan et al., (1996a). Sub-culturing at 70-80% cell 
confluency was employed before experimentation. Culture media was decanted, cells 
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washed (10 ml HBSS) and detached by incubating (3-4 min) with 3 ml 0.025% (w/v) 
trypsin/EDTA and viewed using an Olympus CX41 phase contrast microscope 
(Olympus, Southend-on-Sea, UK) at 100X magnification. Culture media (7-8 ml) was 
added to re-suspend, then pipetted into a 50 ml sterilin tube (Sterilin Ltd., Hounslow, 
UK) and centrifuged for 5 min at 900 rpm. Supernatant was decanted, and the pellet 
resuspended by culture media of a known volume and cells stained and counted using 
trypan blue and Neubauer haemocytometer (Scientific Supplies Co., UK). Routine 
sub-culture, cell suspension (1 ml) and culture media (25 ml) was added to the flask 
and maintained at 37º C until confluent.   
 
2.5 Insulin secretion from BRIN-BD11 cells 
2.5.1 Materials 
All reagents used in culturing BRIN-BD11 cells were purchased from Gibco Life 
Technologies Ltd. as stated in Section 2.4.1. Trypan blue, thimerosal, iodogen (1,3,4,6-
tetrachloro-3α,6α-diphenylglycoluril), bovine insulin, BSA, fraction V, sequencing 
grade TFA, dextran T-70 and activated charcoal and HPLC grade acetonitrile were all 
purchased from Sigma Aldrich.  Disodium hydrogen orthophosphate (Na2HPO4) and 
sodium dihydrogen orthophosphate (NaH2PO4.2H2O) were purchased from VWR 
International Ltd. (Lutterworth, Leicestershire, UK). Radiolabelled sodium iodide 
(Na125I) was purchased from Perkin Elmer (UK).  Rat insulin standard was purchased 
from Novo Industria (Copenhagen, Denmark). Dichloromethane (DCM) was 
purchased from Rathburn (Walkersburn, Scotland, UK). All other chemicals used were 
of highest purity and purchased from BDH chemicals. Water was obtained from an 
Elga PURELAB Ultra system.  
 
2.5.2 Acute in vitro insulin secretion studies in BRIN-BD11 cells 
The insulin secreting activity of peptides were assessed using BRIN-BD11 cells, 
obtained and quantified as outlined in section 2.4.2, (passage used was between 18 and 
40). The protocol as described by McClenaghan and colleagues (1996b) was followed 
for insulin secretion experiments. In brief, cells were seeded and allowed to attach 
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overnight at 37oC in 24 well tissue culture plates (150,000 cell/well). After 18 hours, 
culture media was decanted and cells pre-incubated with 1 ml of Krebs–Ringer 
bicarbonate buffer (KRBB- 115 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 mmol/l MgSO4, 
1.28 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 25 mmol/l HEPES and 8.4% NaHCO3, 
containing 0.5% (w/v) BSA, pH 7.4) supplemented with 1.1 mmol/l glucose for 40 
min at 37oC. Subsequently, the buffer was decanted and buffer containing glucose (3.3 
to 16.7 mmol/l) in the presence of test peptides (10-12 to 10-6 mol/l), were added to 
wells and incubated for 20 min at 37oC. Once complete, 950 µl of the assay buffer 
from each well was collected and stored at -20oC for measurement of insulin by 
radioimmunoassay (RIA) (Section 2.5.4). In a separate set of experiments, BRIN-
BD11 cells were incubated at 5.6 mmol/l glucose with test peptides in the presence or 
absence of appropriate receptor antagonists (receptor antagonists used are detailed in 
corresponding Chapters), and insulin measured by RIA (Section 2.5.4). 
 
2.5.3 Iodination of bovine insulin for RIA 
A modified protocol based on the method previously described by Fraker and Speck 
Jr (1978), was followed for iodination of bovine insulin. In brief, 100 μl of iodogen 
solution (1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril), 1 mg of iodogen in 10 ml of 
dichloromethane, was added to Eppendorf tubes. Tubes were incubated at 37oC until 
a thin coating formed. Bovine insulin solution; 1 mg of insulin to 1 ml of 10 mmol/l 
HCL and diluted to 125 μg/ml (1:8 dilution) in 500 mmol/l phosphate buffer (pH 7.4).  
Bovine insulin (20 µl) and sodium iodide (Na125I 100 mCi/ml stock, Perkin Elmer, 
Cambridge, UK) (5 µl) were added to iodogen coated tube and kept on ice with gentle 
agitation every 3-4 min for 15 min, and the reaction stopped by transferring to a clean 
Eppendorf tube. The reaction tube was washed with 300 μl of 50 mmol/l sodium 
phosphate buffer and added to the reaction mixture. The iodinate was separated by RP-
HPLC on a Vydac C- 8 (250 x 4.6 mm) analytical column. Flow rate; 1.0 ml/min with 
0.12% (v/v) TFA/water and the acetonitrile concentration in the eluting solvent was 
increased from 0% to 56% over 60 min and to 70% in 5 min (Figure 2.1). Fractions (1 
ml) were collected using a fraction collector (Frac-100, LKB), aliquoted (5 μl)  into 
LP3 tubes and counts measured on a gamma counter (Perkin Elmer Wallac Wizard 
1470 Automatic Gamma Counter). Fractions with the highest counts were diluted with 
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1 ml of 40 mmol/l sodium phosphate buffer (pH 7.4) containing 1 g/100 ml BSA and 
0.02 g/100 ml thimerosal. Binding capacity was determined by a series of antibody 
dilutions (1:25,000-1:45,000), and fractions were kept at 4ºC. 
 
2.5.4 Insulin RIA with modified dextran-coated charcoal 
Determination of insulin concentration by using a modified dextran-coated charcoal 
radioimmunoassay established by Flatt and Bailey (1981). In brief, stock RIA buffer, 
40 mmol/l disodium hydrogen orthophosphate (containing 0.3% (w/v) sodium 
chloride and 0.02% (w/v) thimerosal) was prepared and pH adjusted to 7.4 with 40 
mmol/l sodium dihydrogen orthophosphate and stored at 4°C. Working RIA buffer 
was prepared by adding 0.5% (w/v) BSA to stock RIA buffer. Unknown samples (200 
µl) were aliquoted in duplicate and insulin standards in triplicate (200 µl) into LP3 
tubes. Insulin standards ranged from 0.039 to 20 ng/ml and prepared by serial dilution 
of frozen stock rat insulin. Antibody, guinea pig anti-porcine from frozen stock was 
diluted (1:25000 to 1:45000) with working RIA buffer (100 µl) added to all unknown 
samples and insulin standards except for control tubes. I125-labeled tracer was added to 
working RIA buffer (10,000 counts per min (CPM) in 100 µl) and 100 µl was added 
to each tube and incubated at 4°C for 48 h. After 48 h incubation period, 1 ml of 
working DCC (1:5, stock DCC and working RIA buffer) was added to all tubes (except 
total), incubated for 20 min at 4°C, then centrifuged at 2500 rpm for 20 min at 4ºC and 
supernatant decanted. The radioactivity of each pellet was measured by a gamma 
counter and insulin concentration of unknown samples determined by rat insulin 
standard curve, generated using a spline-curve fitting algorithm.  
 
2.6 In vitro beta cell proliferation and apoptosis 
2.6.1 Materials   
All reagents used in culturing BRIN-BD11 cells were purchased from Gibco Life 
Technologies Ltd. as stated in Section 2.4.1. Paraformaldehyde (PFA), phosphate 
buffered saline (PBS), sodium citrate, TWEEN® 20, BSA, streptozotocin (STZ) and 
glycerol were all purchased from Sigma Aldrich.  Anti-Ki-67 (Abcam, ab15580) 
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primary antibody and goat anti-rabbit Alexa Fluor® 568 (Abcam, ab175471) 
secondary antibody was purchased from Abcam (Cambridge, UK). ApoLive-Glo™ 
Multiplex assay (Madison, Wisconsin, USA). Water was obtained from an Elga 
PURELAB Ultra system.  
 
2.6.2 Assessment of in vitro beta cell proliferation  
BRIN-BD11 cells were used to assess the effects of test peptides on beta cell 
proliferation. Cells were seeded at 40,000 cell/well onto a glass cover slip within a 12 
well tissue culture plate. Cells were incubated in RPMI media (section 2.4.2) 
containing test peptides (10-8 to 10-6 mol/l) and GLP-1 (10-6 mol/l) (positive control) 
at 37oC for 18 h. Following incubation period, cells were washed (PBS x 2) and fixed 
using 4% paraformaldehyde at room temperature for 30 min. Citrate buffer (sodium 
citrate and 0.05% TWEEN® 20), 1 ml at 90°C for 20 min, was used for antigen 
retrieval. Once cooled (20 min) and citrate buffer decanted, cells were washed (PBS x 
2) and 300 µl of 1.1% BSA was added for 45 minutes to block tissue. The species 
specific (rat) primary antibody; rabbit anti-Ki67 (1:250; Abcam ab16667), was added, 
200 µl/well and incubated for 2 h at 37°C. Cell were washed (PBS x 2) and a secondary 
antibody; goat anti-mouse IgG (1:400; Alexa Fluor® 594 Abcam ab150116) was 
added, 200 µl/well and incubated for 45 min at 37°C. After the final wash (PBS x 2), 
glass cover slips were removed and mounted onto glass slides using anti-fade 
mounting medium (1:1 glycerol and PBS). Slides were imaged using a fluorescent 
microscope (Olympus System Microscope, model BX51; Southend-on-Sea, UK) and 
photographed by DP70 camera adapter system. Analysis of cell proliferation 
frequency was expressed as percentage of total cells analysed, with approximately 150 
cells analysed per replicate. 
 
2.6.3 Determination of in vitro apoptosis  
BRIN-BD11 cells seeded at 20,000 cells per well were incubated in RPMI media 
(section 2.4.2) containing test peptides (10-8 to 10-6 mol/l) and allowed to attach 
overnight. The following day determination of apoptosis, via the activation of 
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biomarkers, caspase 3 and 7 was initiated by a luminogenic, tetrapeptide sequence 
DEVD Caspase-Glo® 3/7 substrate. This caused cell lysis with subsequent caspase 
cleavage of the substrate that generated luminescence proportional to the amount of 
caspase activity. Assessment of apoptosis was by ApoLive-Glow™ Multiplex assay 
kit as directed by manufacturer (Promega, Madison, Wisconsin, USA). 
 
2.7 Cyclic AMP production in BRIN-BD11 cells 
2.7.1 Materials 
The enzyme immunoassay kit for cAMP production was purchased from Bio-Techne 
(R&D Systems, Abingdon, UK) and all chemicals and reagents used are previously 
described in section 2.4.1. 
 
2.7.2 Measurement of in vitro cAMP production 
Cells were seeded and allowed to attach overnight (75,000 cells per well). The assay 
was performed the following day. Cells were treated with KRB buffer (pH 7.4) in the 
presence of test peptides at a range of concentrations, 0.1% BSA, 200 µmol/L IBMX 
and 5.6 mmol/l glucose for 60 min at 37oC. Following incubation, supernatant was 
removed, wells were washed with ice cold PBS and cell lysis buffer added (200 µl). 
To ensure complete cell lysis, plates were frozen at -80oC for 30 min and thawed using 
the orbital plate shaker at 37oC (this was repeated until all cells were lysed). The 
contents were then centrifuged at 600 rpm for 2 min and supernatant stored at -20oC 
for assessment of cAMP production by a cAMP Parameter® kit per manufacture 
instructions (R&D Systems, Abingdon, UK).  
 




Tissue culture medium (RPMI 1640), FBS, penicillin, streptomycin, gentamicin, 
trypsin/EDTA and HBSS were all purchased from Gibco Life Technologies Ltd. All 
other chemicals including trypan blue were purchased from Sigma Aldrich. 
 
2.8.2 Isolation of islets by collagenase digestion 
Pancreata from lean Swiss mice (12-14 weeks), were harvested and islets isolated by 
a modified collagenase digestion protocol described by Lacy and Kostinosky (1967). 
The collagenase and wash solution were prepared from stock HBSS by dissolving 
136.9 mmol/l NaCl, 5.4 mmol/l KCl, 1.3 mmol/l CaCl2, 0.4 mmol/l MgSO4.7H2O, 0.5 
mmol/l MgCl2.6 H2O, 0.4 mmol/l Na2HPO4.H2O, 0.4 mmol/l KH2PO4, 5.6 mmol/l 
glucose, 0.06 mmol/l phenol red and 4.2 mmol/l NaHCO3 in distilled water. The 
collagenase solution was prepared by adding 1.4 mg/ml collagenase to stock HBSS (5 
ml required per pancreas) and wash buffer. Stock HBSS with the addition of 0.1% 
BSA was prepared on the day of islet isolation. Once pancreata were harvested they 
were placed into tubes containing ice-cold collagenase solution and minced to aid with 
initial digestion. Digestion was further enhanced by placing harvested pancreata in a 
shaking water bath at 37oC for 8-12 min, the tubes were then forcefully shaken to 
dislocate islets from exocrine tissue. Tubes were then filled with ice-cold wash buffer 
and centrifuged for 2 min at 1200 rpm, the supernatant discarded, and remaining pellet 
resuspended in wash buffer (15 ml). This was repeated three times followed by 
filtering to ensure removal of unwanted tissue. The filtrate was then processed in the 
same way and the pellet obtained. It was re-suspended in pre-warmed RPMI-1640 
media (supplemented with 10% BSA and 1% penicillin/streptomycin), transferred into 
petri-dishes allowing culture of islets at 37°C and 5% CO2, in a LEEC incubator for a 
period of 2-3 days prior to use. 
 
2.8.3 Insulin secretion from isolated murine islets 
After 48 h culture, islets (n=20) were collected using a microscope and placed into 1.5 
ml Eppendorf tubes, then centrifuged for 5 min at 1200 rpm to remove excess media. 
Acute insulin secretion studies then followed a modified method of in vitro insulin 
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secretion described in section 2.5.2. Islets were preincubated in 1 ml KRBB at 1.1 
mmol/l glucose for 1 h and decanted after centrifugation for 5 min at 1200 rpm. Test 
solutions at 16.7 mmol/l glucose with a range of concentrations of peptides (10-8 to 10-
6 mol/l) were then added and incubated for 1 h. Following incubation, tubes were 
centrifuged and 950 µl of the supernatant from each tube collected, aliquoted into 200 
µl duplicates and stored at -20oC until measurement of insulin by dextran-coated 
charcoal RIA (Section 2.5.4).  
 
2.9 Animal models 
Several animal models of obesity, insulin resistance and diabetes were utilised in this 
thesis to assess the biological actions and therapeutic potential of modified peptides in 
vivo. All animal experimentation was completed in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and EU Directive 2010/63EU for animal 
experiments. Studies were also approved by University of Ulster Research Ethics 
Committee and all necessary steps were taken to reduce any potential suffering. Project 
licence number: 2804 and Personal licence number: 1692. All long-term in vivo studies 
were blinded and remained so throughout the biochemical and statistical analysis. 
 
2.9.1 Normal lean model 
National Institutes of Health (NIH) Swiss albino male mice, derived from a nucleus 
colony, were purchased from Envigo, Huntingdon, UK. The animals were housed at 
Ulster University’s Behavioural and Biomedical Research Unit (BBRU) in an air-
conditioned room (22 ± 2 °C) under a 12 h light and 12 h dark cycle. Animals were 
aged matched, individually housed and had free access to drinking water and standard 
laboratory chow (10% fat, 30% protein, 60% carbohydrate; percentage of total energy 
12.99 KJ/g; Trouw Nutrition, Cheshire, UK). This murine model was used for acute 
animal studies and chronic studies, a model that represented normal glycaemic control.  
 
2.9.2 High fat fed model 
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Male Swiss mice were purchased from Envigo and housed in the BBRU as described 
in section 2.9.1. Animals were aged matched, individually housed and had free access 
to drinking water and a high fat diet (45% fat, 20% protein, and 35% carbohydrate; 
percentage of total energy 26.15 kJ/g; Special Diet Services, Essex, UK). High fat 
feeding commenced for a minimum of three months to cause diet-induced obesity-
diabetes. The diet progressively induced an increase in body weight and 
hyperglycaemia compared to age-matched controls fed standard laboratory chow. 
Prior to beginning chronic treatment regimen, mice were grouped based on body 
weight and blood glucose. This murine model is widely utilised for assessment of 
novel obesity-diabetes therapeutic agents (Winzell and Ahrén, 2004). 
 
2.9.3 Diabetic (db/db) model  
Male diabetic mice (db/db) (BKS.Cg-+ Leprdb/+ Leprdb/OlaHsd, were purchased 
from Envigo, and housed in the BBRU as described in section 2.9.1. Animals were 
aged matched, individually housed and had free access to drinking water and standard 
laboratory chow. Mice were grouped based on body weight and blood glucose. This 
murine model was employed as a genetic representation of obesity-diabetes exhibiting 
disease characteristics including; weight gain, beta cell dysfunction, hyperglycaemia 
and hyperinsulinemia (King, 2012). 
 
2.10 Acute in vivo studies    
2.10.1 Acute effects of peptides on glucose tolerance in lean mice 
Fasted lean mice (10-12 weeks) had blood glucose measured immediately before and 
after intraperitoneal injection of glucose alone (18 mmol/kg body weight) or in 
combination with test peptides (50-100 nmol/kg bw detailed in individual chapters) at 
various time points (0, 15, 30 and 60 min). Final volume of 5 ml/kg body weight was 




2.10.2 Delayed effects of peptides on glucose tolerance in lean mice 
Fasted lean mice (10-12 weeks) had blood glucose measured before and after 
intraperitoneal injection of glucose alone (18 mmol/kg body weight) at various time 
points (0, 15, 30 and 60 min). Prior to this (-30 min), blood glucose was measured 
followed by an intraperitoneal injection of saline alone or in combination with test 
peptides (100 nmol/kg bw detailed in individual chapters). A final volume of 5 ml/kg 
body weight was administered for each test solution. 
 
2.10.3 Biochemical Analysis 
An incision to the tail vain of conscious mice was used to obtain blood samples for 
biochemical analysis. Blood glucose was measured directly by Ascencia Contour 
glucose meter (Bayer, Newbury, UK). Blood samples for plasma glucose or insulin 
were collected into fluoride micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) 
and centrifuged (Beckman Instruments, Galway, Ireland) at 13000 rpm for 3 min at 4 
°C with plasma aliquoted into Eppendorf tubes and stored at -20oC until subsequent 
biochemical analysis. Plasma insulin was determined by diluting 20 µl of plasma with 
180 µl of working RIA buffer (1:10 dilution) and measured using RIA (Section 2.5.4). 
Plasma glucose was evaluated using the GOD-PAP method determined by a glucose 
assay kit (GL 364, Randox Laboratories Ltd., UK) as directed by manufacturer. 
 
2.11 Long-term in vivo studies 
The high fat fed (HFF) and db/db animal models were used for long term studies. 
Grouping and maintenance of mice are detailed in Sections 2.9.2 and 2.9.3. 
 
2.11.1 Treatment and monitoring regime of long-term peptide administration 
Twice daily intraperitoneal injections (09:00 and 17:00 h) were administered with 
either saline alone (0.9% (w/v) NaCl) or in combination with peptides (25 nmol/kg) 
for the assessment duration. Prior to treatment, to customise the mice to injection and 
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handling anxiety, twice daily injections (4-6 days) of saline alone were administered. 
Assessment of non-fasting glucose and insulin levels (Section 2.5.4) were monitored 
every 3-4 days (from day -6 or -4 onwards), along with cumulative energy intake and 
body weight. 
 
2.11.2 Glucose profile 
Prior to cessation of treatment, a 24 h glucose profile on non-fasted mice was 
evaluated. Twice daily injection continued (Section 2.11.1) with values measured prior 
(0 h) to first daily injection and 4, 8, 12 and 24 h afterwards. 
 
2.11.3 HbA1c analysis 
Following cessation of treatment, HbA1c concentrations were assessed using whole 
blood and A1cNow®+ kits (PTS diagnostics, Indiana, USA), as directed by 
manufacturer. 
 
2.11.4 Glucose tolerance test 
Mice were fasted (10 h) prior to oral or intraperitoneal administration of glucose (18 
mmol/kg bw). Glucose and insulin were measured (Section 2.5.4), before (0 h) and 
after time points 15, 30, 60, 90 and 120 min. 
 
2.11.5 GIP tolerance test  
Mice were fasted (10 h) prior to intraperitoneal administration of glucose (18 mmol/kg 
bw) in combination with native GIP(1-42) (25 nmol/kg bw). Glucose and insulin were 
measured (Section 2.5.4), before (0 h) and after time points 15, 30, 60 and 90 min. 
 
2.11.6 Insulin sensitivity test 
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Assessed on non-fasted mice, intraperitoneal administration of bovine insulin (25 or 
50 U/kg body weight). Glucose was measured (Section 2.5.4), at various time points 
(0, 15, 30, and 60 min). 
 
2.11.7 Pancreatic insulin secretion from ex vivo isolated mouse islets 
Insulin secretion from isolated islets was assessed on cessation of treatment and 
measured as stated in Section 2.8, using known insulin secretagogues; 7.68 mmol/l 
calcium chloride, 20 mmol/l potassium chloride, 200 µmol/l IBMX and 10 nmol/l 
PMA. 
 
2.11.8 Pancreatic insulin content 
Tissue was excised, snap frozen and stored following treatment cessation until assay. 
Pancreas was thawed, washed with cold PBS, weighed and homogenised in extraction 
buffer (20 mmol/l Tris HCl, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA and 
0.5% Triton X 100, 0.1% protease inhibitor, pH 7.5) using a handheld VWR VDI 12 
homogeniser (VWR, UK). Contents were centrifuged for 5 min at 1300 rpm and 
supernatant collected. Insulin content was then measured form extracted content, 20 
µl was diluted with 180 µl of working RIA buffer (1:10 dilution) and measured using 
RIA (Section 2.5.4).  
 
2.11.9 Bone mineral density and body composition analysis by dual energy X-ray 
absorption (DXA) 
Lean mass and total fat percentage as well as bone mineral content (BMC) and bone 
mineral density (BMD) were analysed by the Piximus Densitometer (GE Medical 
Systems, LUNAR, USA). Instrument was calibrated using a phantom provided by the 
manufacturer. Mice were sedated using isoflurane and culled by cervical dislocation 




2.11.10 Lipid profile analysis 
Following the cessation of treatment terminal blood was collected. Analysis of total 
triglycerides, high-density and total cholesterol was determined by Hitachi Automated 
Analyzer 912 (Boehringer Ingelheim, Mannheim, Germany) within Ulster 
University’s NICHE department. The low-density cholesterol was calculated using 
Friedwald equation: total cholesterol - HDL - (triglycerides / 5). 
 
2.11.11 Immunohistochemistry analysis 
Following pancreatic excision, tissue was sectioned longitudinally and fixed in 4% 
parafolmaldehyde at 4oC. Tissue was then processed by automated tissue processor 
(Leica TP1020, Leica Microsystems, Nussloch, Germany) and embedded in paraffin 
wax. Tissue sections were cut (5 μm) by a manual microtome (Shandon finesse 325, 
Thermo scientific, UK) and positioned on poly-L-lysine coated glass slides (VWR 
International, Pennsylvania, USA). Tissue, prior to staining, was deparaffinised by 
xylene (Sigma Aldrich) and rehydrated using a series concentration of ethanol (100%, 
95%, 85%, 70% and 50%; Sigma Aldrich) with subsequent antigen retrieved by 
exposing tissue to sodium citrate buffer (10 mmol/l sodium citrate, 0.05% Tween 20, 
pH 6.0) for 20 min at 95oC. The sections were then blocked (2% BSA for 30 min) and 
incubated with species specific (mouse) primary antibodies; rabbit anti-glucagon 
antibody (1:400; Abcam, ab92517) and mouse anti-insulin antibody (1:1000; Abcam, 
ab6995) for 2 h at 37oC. Following washing with PBS sections were incubated with 
respective secondary antibodies; goat anti-mouse IgG (1:400; Alexa Fluor 594® 
Abcam ab150116), and goat anti-rabbit IgG (1:400; Alexa Fluor® 488 Abcam 
ab150077), for 1 h at 37oC. Subsequent to washing with PBS, sections were incubated 
with DAPI (4,6-diamidino-2-phenylindole), a nuclear stain for 10 min at room 
temperature. Following a final washing step, slides were mounted with anti-fade (PBS 
supplemented with 1:1 (v/v) glycerol). Imaging was carried out using a fluorescent 
microscope (Olympus system microscope, model BX51), under a FITC (488 nm) or 
TRITC filter (594 nm) and imaged using a DP70 camera adapter system. Subsequent 
analysis of islet parameters was carried out using CellF image analysis software 
(Olympus Soft Imaging Solutions, GmbH).  
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2.12 Statistical analysis 
GraphPad PRISM (Version 5) was used for statistical analysis. The results are 
expressed as mean ± SEM. Data was compared by one-way ANOVA followed by 
Student-Newman-Keuls post-hoc test or two-way ANOVA followed by Bonferroni 
post-tests, and unpaired student t-test where appropriate. Incremental insulin and 
glucose area under the curve (AUC) and area above the curve (AAC) were calculated 
using trapezoidal rule with baseline subtraction. Significant difference was considered 






Table 2.1 Structure of peptides in Chapters 3, 4, 5 and 6 
Name Purity Sequence 
(DAla2)GIP/Xenin-8-Gln >95% Y[DA]EGTFISDYSIAMHPQQPWIL-OH 
Exendin-4 >95% HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS - NH2 
Neurotensin >95% pELYENKPRRPYIL-OH 
Xenin-8-Gln >95% HPQQPWIL-OH 
Neurotensin(8-13) >95% RRPYIL-OH 
Acetyl-neurotensin(8-13) >95% Ac- RRPYIL-OH 
Acetyl-neurotensin(8-13)-xenin-8-Gln >95% Ac-RRPYIL-HPQQPWIL-OH 
Human GIP(1-42) Crude YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 
Human GIP(1-30) Crude YAEGTFISDYSIAMDKIHQQDFVNWLLA QK-NH2 
Mouse GIP(1-30) Crude YAEGTFISDYSIAMDKIRQQDFVNWLLA QR-NH2 
Human GIP(3-30) Crude EGTFISDYSIAMDKIHQQDFVNWLLAQ K-NH2 
Mouse GIP(3-30) Crude EGTFISDYSIAMDKIRQQDFVNWLLAQR-NH2 
Human Pro3GIP(3-30) Crude PGTFISDYSIAMDKIHQQDFVNWLLAQK-NH2 
Human GIP(3-42) Crude EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 
Human GIP(5-30) Crude TFISDYSIAMDKIHQQDFVNWLLAQK-NH2 





Figure 2.1 HPLC separation of iodinated bovine Insulin 




















































Iodinated I125-bovine insulin was separated by reverse-phase HPLC and eluting 
solvent B (70% acetonitrile, increased using linear gradients with percentage raised 
over time). Fractions were collected every minute by an automated fraction collector. 
The radioactivity level of fractions (5 µl) was determined on a gamma counter. Peak 
A correlates with fractions 5-6, containing unbound sodium iodide (Na125I) and peak 






















Investigating the biological actions and therapeutic efficacy of a 














3.1 Summary  
The regulatory enteroendocrine hormone GIP, secreted from enteroendocrine K cells 
in response to glucose and fat has important biological actions including glucose 
homeostasis, insulin biosynthesis and secretion, beta cell proliferation and anti-
apoptotic protection, as well as regulation of energy balance and bone turnover. 
However, under hyperglycaemic conditions of T2DM these beneficial actions become 
impaired and unlike the action of its sister incretin, GLP-1, cannot be restored by 
exogenous administration. However, the related regulatory enteroendocrine hormone 
xenin, also secreted from K-cells, can potentiate the biological actions of GIP under 
both normal glycaemia and T2DM. The current study has compared the biological 
actions and therapeutic efficacy of the hybrid peptide (DAla2)GIP/xenin-8-Gln either 
alone or in combination with exendin-4. In vitro assessment revealed that (DAla2)GIP-
xenin-8-Gln activated insulin secretion via GIPR cell signalling pathway and the GIP 
component is essential for activation of the adenylate cyclase pathway. (DAla2)GIP-
xenin-8-Gln also demonstrated significant (P<0.01 to P<0.001) beta cell proliferative 
and protective effects. In vivo, twice-daily administration of (DAla2)GIP/xenin-8-Gln 
in combination with exendin-4 improved (P<0.05 to P<0.001) glycaemic control and 
insulinotropic action and reduced (P<0.001) HbA1c concentrations. An improved 
(P<0.05) sensitivity to GIP and insulin was also noted, especially in the group treated 
with (DAla2)GIP/xenin-8-Gln in combination with exendin-4, with ex vivo isolated 
islets confirming improved (P<0.05 to P<0.001) insulin secretory action. Additionally, 
there was positive effects on islet morphology, where both treatment groups increased 
pancreatic beta cell area and decreased alpha cell area (P<0.05 to P<0.01), also in 
keeping with in vitro proliferation and apoptosis studies. Neither treatment group had 
any effects on body weight or energy intake. Interestingly, the percentage fat mass, 
total cholesterol and triglycerides were reduced (P<0.05 to P<0.01) by both treatment 
groups. Together, their data suggest that further evaluation of (DAla2)GIP/xenin-8-Gln 
either alone or in combination with exendin-4 is warranted for the potential treatment 







GIP secreted from enteroendocrine K cells in response to glucose and fat, contributes 
equivalently to the incretin effect under normal physiological conditions together with 
its sister incretin hormone, GLP-1 (Baggio and Drucker, 2007; Paschetta, Hvalryg and 
Musso, 2011). The biological actions of GIP encompass endocrine and exocrine 
effects, and these include but are not limited to: insulin biosynthesis and secretion, beta 
cell proliferation and anti-apoptotic protection, as well as regulation of appetite, satiety 
and bone turnover (Baggio and Drucker, 2007; Mabilleau et al., 2018; Paschetta, 
Hvalryg and Musso, 2011; Senio, Fukushima and Yabe, 2010). However, with the 
onset of T2DM resulting from persisting insulin resistance, impaired insulin secretion 
and loss of beta cell mass, GIP fails to yield a potent insulinotropic effect even though 
circulating levels have increased (Kaku, 2010). This impaired GIP incretin action is 
thought to be due to loss of sensitivity or down regulation of the GIP receptor (GIPR) 
on the pancreatic beta cell due to elevated hyperglycaemia, which further exacerbates 
resistance to GIP action (Paschetta, Hvalryg and Musso, 2011; Senio, Fukushima and 
Yabe, 2010).  
Interestingly, the biological actions of GLP-1 are also believed to be partially 
compromised in T2DM (Nauck, 2016). However, unlike GLP-1 action, which can be 
restored though elevation of circulating levels via administration of GLP-1 agonists, 
this is not the case for native GIP (Nauck, 2016; Paschetta, Hvalryg and Musso, 2011). 
Elevated levels of GIP fail to elicit a notable biological response on insulin secretion 
in T2DM (Gault, 2018; Paschetta, Hvalryg and Musso, 2011). Therefore, the 
therapeutic prospect of formulating an enzymatically stable, long-acting GIP agonist 
would appear somewhat redundant for T2DM (Paschetta, Hvalryg and Musso, 2011; 
Pathak et al., 2015a), however several such GIP analogues have been synthesised and 
characterised over the years (Gault, 2018).  
GIP is not the only gut hormone to be secreted from enteroendocrine K cells. Xenin, a 
25 amino acids peptide hormone with glucose homeostasis and energy balancing 
capabilities, is co-secreted with GIP in response to feeding (Craig, Gault and Irwin, 
2018). Furthermore, xenin has been demonstrated to potentate the biological actions 
of GIP under both normal glycaemia and hyperglycaemic conditions (Chowdhury et 
al., 2013; Craig, Gault and Irwin, 2018; Martin et al., 2012). With that said, the 
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biological half-life of these two gut hormones must also be considered when 
formulating a potential new pharmaceutical agent. GIP substituted with a D-alanine in 
position 2 termed (DAla2)GIP(1-42) was demonstrated to have improved enzymatic 
resistance to DPP-IV, increased GIP stimulated cAMP production and glucose 
tolerance (Hinke et al., 2002). Furthermore, the N-terminally truncated form of GIP, 
GIP(1-14), demonstrated similar biological actions as the parent peptide, 
(DAla2)GIP(1-42) (Hinke et al., 2004), highlighting that smaller bioactive regions of 
GIP could be useful for generating GIP-based drugs.    
Interestingly, xenin has a naturally occurring bioactive fragment, the C-terminally 
truncated xenin-8 (Feurle et al., 1997; Silvestre et al., 2003). Xenin-8 processes nearly 
all the biological capabilities of xenin-25, except possible induction of satiety (Craig, 
Gault and Irwin, 2018; Martin et al., 2014). Moreover, a modified xenin-8-Gln 
analogue, with Gln substitution of the Lys21 and Arg22 amino acid residues, has been 
shown to improve insulin sensitivity, glucose tolerance and most importantly to 
augment the glucose-lowering and insulinotropic responses of GIP in high fat fed 
(HFF) mice (Martin et al., 2016). 
The advantage of these fragmented, biologically active and enzymatically resistant 
analogues is the opportunity to formulate them into monomeric peptide therapeutics 
(Fosgerau and Hoffmann, 2015). Thus, combining individual peptides biological 
action(s) into a single therapeutic entity. This has been achieved to good effect with a 
number of other gut-derived peptide hormones (Fosgerau and Hoffmann, 2015). The 
dual agonism approach has been shown to exhibit synergistic beneficial effects in the 
treatment of T2DM (Finan, 2015; Sadry and Drucker, 2013). As such, this rationale is 
in keeping with a recent review by Skow and colleagues (2016) on the improved 
efficacy of a dual action, monomeric GLP-1 and GIP receptor agonist in the treatment 
of T2DM (Skow, Bergmann and Knop, 2016). Therefore, a GIP-xenin hybrid peptide 
with dual receptor agonism and augmentation abilities has the potential to revive 
sensitivity to GIP and mediate the biological activities of both hormones in T2DM. 
Similar actions have been documented in a review by Irwin and Flatt (2015), with 
hybrid peptides including GIP-oxyntomodulin, cholecystokinin-8-GLP-1 and gastrin-
GLP-1. All denoted hybrid peptides exhibited remarkable improvements over either 
parent peptide alone (Irwin and Flatt, 2015). 
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Employing this knowledge, our laboratory previously created a novel GIP/xenin 
hybrid peptide utilising the biologically active and enzymatically resistant regions of 
GIP and xenin, to create (DAla2)GIP-xenin-8-Gln (Hasib et al., 2017). (DAla2)GIP-
xenin-8-Gln was shown to be capable of activating GIP and xenin based cellular 
pathways, to restore GIP action in T2DM and impart notable therapeutic benefits in an 
animal model of T2DM (Hasib et al., 2017). The aim of this study was two-fold, to 
initially extend the scope of what is known surrounding this hybrid peptide through in 
vitro evaluation of insulinotropic and cAMP activity, as well as pancreatic beta cell 
proliferation and anti-apoptotic actions. Secondly, to build on previous work, the 
antidiabetic benefits of (DAla2)GIP-xenin-8-Gln was examined in HFF mice following 
a treatment with (DAla2)GIP-xenin-8-Gln alone and in combination with exendin-4. 
 
3.3 Materials and Methods 
3.3.1 Peptides 
All peptides were purchased from Syn Peptide Shanghai, China. Purity was confirmed 
by RP-HPLC and characterised by MALDI-TOF MS, (Sections 2.1, 2.2.3, and 2.2.4). 
For all experimental materials and methods please refer to Section 2.1, and relevant 
subsections.  
 
3.3.2 Acute effects of peptides alone and in the presence of receptor antagonists 
on in vitro insulin secretion from BRIN-BD11 cells 
The in vitro insulin secretory activity of test peptides on BRIN-BD11 cells is as 
described in Section 2.5.2. BRIN-BD11 cells were incubated with test peptides (10-6–
10-12 mol/l) alone or in the presence of specific GIP or neurotensin receptor antagonists 
namely: GIP(6-30)-CexGluPAL (Pathak et al., 2015b), SR488692 (neurotensin-1) and 
SR142984 (non-specific neurotensin) (at 10-7 mol/l or 10-6 mol/l)  for 20 min. 
Following test incubations, insulin was measured by RIA (Sections 2.5.2 and 2.5.4). 
 
3.3.3 In vitro proliferation 
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Effects of test peptides on cell proliferation in BRIN-BD11 was conducted as 
described in Section 2.6.2. Cells were incubated in RPMI media (Section 2.4.2) 
containing test peptides (10-8 to 10-6 mol/l). The primary antibody, anti-Ki-67 (1:250) 
and the secondary antibody, goat anti-rabbit Alexa Fluor® 594 (1:400), were used to 
detect proliferating beta cells by fluorescent microscopy. 
 
3.3.4 In vitro apoptosis 
The effects of test peptides on BRIN-BD11 cell apoptosis was conducted as described 
in Section 2.6.3. The cells were incubated in RPMI media (section 2.4.2) containing 
test peptides (10-8 to 10-6 mol/l) and apoptosis initiated by adding the caspase-3/7 
substrate reagent that results in cell lysis, followed by caspase cleavage of the substrate 
and detection of beta cell apoptosis by luminescence.  
 
3.3.5 In vitro cyclic AMP 
Effects of peptides on in vitro cyclic AMP production was examined using BRIN-
BD11 cells described in Section 2.7.2. Briefly, test peptides (10-9 to 10-6 mol/l) were 




The long-term study utilised HFF male Swiss mice, as described in Section 2.9.2. Prior 
to experimentation, mice were maintained on high fat diet for 10 weeks, resulting in 
overt obesity and hyperglycaemia. 
 
3.3.7 Long-term in vivo study in HFF mice 
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Twice daily intraperitoneal injections (09:00 and 17:00 h) of either saline vehicle 
(0.9% (w/v) NaCl), (DAla2)GIP-xenin-8-Gln alone or in combination with exendin-4 
(all peptides at 25 nmol/kg bw) for 32 days is described in Section 2.11.1. Assessed 
metabolic parameters included: circulating glucose and insulin, body weight and 
cumulative energy intake, monitored every 3-4 days (Sections 2.11.1). End of 
treatment assessment parameters included glucose tolerance (18 mmol/kg bw), 
HbA1c, blood glucose profile, GIP tolerance (25 nmol/kg bw), insulin sensitivity (25 
U/kg), insulin content, islet insulin secretory response, percentage fat mass, circulating 
triglycerides and cholesterol as well as islet morphology, as described in more detail 
within Sections 2.8.2, 2.8.3 and 2.11.2. 
 
3.3.8 Biochemical analysis 
Blood/plasma glucose, plasma and pancreatic insulin were assayed as described in 
Sections 2.5.4 and 2.10 
 
3.3.9 Statistical analysis 
As described in Section 2.12 
 
3.4 Results 
3.4.1 Effects of (D-Ala2)GIP-xenin-8-Gln alone, and in the presence of GIP and 
neurotensin receptor antagonists, on insulin secretion from BRIN-BD11 cells 
Figure 3.1 (A-C) demonstrates that (D-Ala2)GIP-xenin-8-Gln significantly (P<0.01 
and P<0.001) increases insulin secretion from BRIN-BD11 cells at 5.6 mmol/l glucose 
in a dose dependent manner. In the presence of the antagonist GIP(6-30)-CexGluPAL 
(10-7 and 10-6 mol/l), (D-Ala2)GIP-xenin-8-Gln induced insulin secretion was 
significantly (P<0.05 to P<0.001) inhibited at all concentrations (10-12 to 10-6 mol/l) 
examined (Figure 3A). Similarly, an inhibitory effect on (D-Ala2)GIP-xenin-8-Gln 
insulinotropic response (10-9 mol/l to 10-6 mol/l, P<0.05 to P<0.01) was demonstrated 
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in the presence of neurotensin 1 antagonist (Figure 3.1B). However, the non-specific 
neurotensin antagonist had no significant effect on (D-Ala2)GIP-xenin-8-Gln insulin 
secretory ability at 5.6 mmol/l glucose, except at 10-9 mol/l and 10-6 mol/l 
concentrations where there was a moderate reduction (Figure 3.1C). 
 
3.4.2 Effects of (D-Ala2)GIP, xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln on BRIN-
BD11 cell proliferation  
Culturing of BRIN-BD11 cells in the presence of GLP-1, exendin-4, (D-Ala2)GIP and 
(D-Ala2)GIP-xenin-8-Gln (at 10-6 mol/l or 10-8mol/l) for 18 hours significantly 
(P<0.01 and P<0.001) increased proliferation frequency in comparison to the untreated 
control culture (Figure 3.2A). However, xenin-8-Gln alone had no effect on beta cell 
proliferation (Figure 3.2A). The hybrid peptide, (D-Ala2)GIP-xenin-8-Gln (10-6 
mol/l), induced a significant (P<0.001) elevation of proliferation frequency (P<0.001) 
compared to either parent peptide alone (Figure 3.2A). Figure 3.2B shows 
representative images of proliferating cells under each culture condition. 
 
3.4.3 Effects of (D-Ala2)GIP, xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln on BRIN-
BD11 cell apoptosis 
BRIN-BD11 cells cultured in the presence of exendin-4, (D-Ala2)GIP, xenin-8-Gln, 
xenin-8, xenin-25, (D-Ala2)GIP-xenin-8-Gln (10-6mol/l or 10-8mol/l) for 18 hours 
demonstrated a significant (P<0.05 to P<0.001) protective effect against capase-3/7 
activated apoptosis compared to untreated control culture (Figure 3.3). 
 
3.4.4 Effects of (D-Ala2)GIP-xenin-8-Gln on intracellular cAMP production alone 
and in the presence of GIP or neurotensin antagonists in BRIN-BD11 cells 
BRIN-BD11 cells had increased (P<0.01- P<0.001) cAMP production at 5.6 mmol/l 
glucose in the presence of (D-Ala2)GIP-xenin-8-Gln (Figure 3.4). The neurotensin 1 
antagonist (10-9mol/l to 10-6 mol/l) had no impact on (D-Ala2)GIP-xenin-8-Gln 
induced cAMP formation (Figure 3.4). In contrast, GIP(6-30)-CexGluPAL (10-9mol/l 
to 10-6 mol/l) had a significant inhibitory (P<0.01 and P<0.001) effect on (D-Ala2)GIP-
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xenin-8-Gln induced cAMP production (Figure 3.4). Importantly, neither GIP(6-30)-
CexGluPAL nor the neurotensin 1 receptor antagonist affected basal cAMP 
accumulation in BRIN-BD11 cells (Figure 3.4). 
 
3.4.5 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on cumulative energy intake, body weight and 
percentage fat mass in HFF mice  
Following twice daily administration of all treatments for 32 days there was no 
significant effect on cumulative energy intake (Figure 3.5A). Although not significant, 
there was a progressive decline in body weight from day 4 in both treatment groups 
(Figure 3.5B). This reduction is also reflected in percentage fat mass, where all 
treatment groups had significantly reduced (P<0.05) percentage fat mass in 
comparison to saline control (Figure 3.5C). 
 
3.4.6 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on non-fasted glucose and insulin in HFF mice 
From the fourth day of treatment there was a progressive decline in non-fasting blood 
glucose in mice treated with (D-Ala2)GIP-xenin-8-Gln in combination with exendin-
4, with a significant decrease (P<0.05) on days 11 and 14 (Figure 3.6A). (D-Ala2)GIP-
xenin-8-Gln alone mice were also observed to have a non-significant progressive 
decrease in non-fasted blood glucose concentrations (Figure 3.6A). Plasma insulin 
concentrations of (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 mice 
progressively increased (P<0.05 to P<0.001) from the fourth treatment day and 
remained significantly elevated throughout the study, compared to saline controls 
(Figure 3.6B). (D-Ala2)GIP-xenin-8-Gln alone treatment lead to a non-significant 
elevation of circulating insulin when compared to saline treated control HFF mice. 
 
3.4.7 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln alone or in 




After administration of the twice daily peptide treatment regimens over the 32 day 
treatment period a 24 hour profile was conducted (Figure 3.7A). All treatment groups 
had sustained lower, albeit not significantly, blood glucose levels compared to the 
saline control HFF mice (Figure 3.7A). However, HbA1c was significantly reduced 
(P<0.001) on day 32 in both treatment groups of mice (Figure 3.7B). 
 
3.4.8 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on oral glucose tolerance in HFF mice 
The 32 day administration of (D-Ala2)GIP-xenin-8-Gln alone had no significant effect 
on glycaemic response post oral glucose load in comparison to saline control (Figure 
3.8A). Corresponding glucose-induced plasma insulin concentrations were non-
significantly elevated in (D-Ala2)GIP-xenin-8-Gln treatment group, when compared 
to saline treated mice (Figure 3.8B). However, (D-Ala2)GIP-xenin-8-Gln in 
combination with exendin-4 significantly (P<0.05) reduced the glycaemic excursion 
and elevated insulin secretion in comparison to the saline control (Figure 3.8AB). 
 
3.4.9 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on GIP tolerance test in HFF mice 
(D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 significantly (P<0.05) 
augmented the glucose-lowering action of GIP in terms of AUC (Figure 3.9A). In 
addition, the rise in blood glucose levels following combined glucose and GIP 
injection at observation points 15 and 30 min was significantly (P<0.05) reduced by 
32 days treatment with (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 
(Figure 3.9A). Interestingly, GIP-induced elevation of plasma insulin was not 
significantly different between groups (Figure 3.9B). 
 
3.4.10 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on insulin sensitivity and pancreatic insulin 
content in HFF mice 
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Following twice daily administration of (D-Ala2)GIP-xenin-8-Gln in combination 
with exendin-4 for 32 days in HFF mice, glucose levels were significantly (P<0.05) 
reduced in response to exogenous insulin, both at 15 and 30 min post-injection and in 
terms of AAC (Figure 3.10A). (D-Ala2)GIP-xenin-8-Gln alone had no significant 
effect on insulin sensitivity (Figure 3.10A). There was a significant (P<0.01 and 
P<0.001) reduction in pancreatic insulin in both treatment groups compared with 
saline control (Figure 3.10B). 
 
3.4.11 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on insulin secretory response of isolated islets in 
HFF mice 
Islets from HFF mice were isolated by collagenase digestion in day 32 and exposed to 
CaCl2, KCl, IBMX and PMA to assess insulin secretory performance (Figure 3.11). In 
response to either 3.3 or 16.7 mM glucose, there was no significant difference in 
insulinotropic responses between all groups of mice (Figure 3.11). However, in the 
presence of CaCl2, KCl, IBMX and PMA, there was a significant increase in insulin 
secretion (P<0.05 and P<0.001) from islets of both treatment groups, barring islets 
from (D-Ala2)GIP-xenin-8-Gln treated mice exposed to IBMX (Figure 3.11).  
 
3.4.12 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on total cholesterol, triglycerides, HDL and LDL 
in HFF mice  
Following 32 days of twice daily administration of both treatment regimens, there was 
a significant decrease in total cholesterol (P<0.01 and P<0.001) and triglycerides 
(P<0.001) compared to saline controls (Figure 3.12A,B). Furthermore, (D-Ala2)GIP-
xenin-8-Gln decreased (P<0.01) HDL and LDL (Figure 3.12C,D). Treatment with (D-
Ala2)GIP-xenin-8-Gln in combination with exendin-4 also lowered (P<0.05) LDL 
compared to saline treated controls (Figure 3.12D). 
 
3.4.13 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln alone or 
in combination with exendin-4 on pancreatic islet histology in HFF mice 
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Pancreatic islet area was not different between all groups of HFF mice (Figure 3.13A). 
However, (D-Ala2)GIP-xenin-8-Gln alone and in combination with exendin-4 
increased (P<0.05) beta cell area when compared to saline treated control (Figure 
3.13B). Furthermore, alpha cell area was decreased (P<0.05) by (D-Ala2)GIP-xenin-
8-Gln alone and in combination with exendin-4 (Figure 3.13C). Representative images 




Current T2DM therapeutics, although somewhat effective, have numerous limitations 
related to their efficacy and/or adverse effects (Capozzi et al., 2018; Irwin and Flatt, 
2015). These approved therapies all preferentially target a single receptor, ion channel, 
transporter or enzyme (Capozzi et al., 2018). Therefore, current research has been 
revised, focusing on the multiple targets contributing to T2DM, by employing 
synergistic hybrid peptides that target more than one cell signalling pathway (Capozzi 
et al., 2018; Irwin and Flatt, 2015). In T2DM, hyperglycaemia and hyperlipidaemia 
contribute to desensitisation of the insulinotropic effects of GIP, arbitrated by 
decreased expression and/or down regulation of GIPR (Irwin and Flatt, 2015; Pathak 
et al., 2014). Using this combined knowledge, previous work from our laboratory lead 
to the generation of (DAla2)GIP-xenin-8-Gln (Hasib et al., 2017). This hybrid peptide 
was shown to target two separate pathways and to restore GIP action in T2DM (Hasib 
et al., 2017), highlighting it as an exciting potential new T2DM therapeutic that 
requires more investigation.  
In the current study, characterisation of the predominant pathway used to employ 
biological activity of (DAla2)GIP-xenin-8-Gln was determined by utilising two 
neurotensin receptor antagonists, the commercially available SR488692 (neurotensin-
1) and SR142984 (non-specific neurotensin), as well as a GIPR specific, GIP(6-
30)Cex-K40[Pal] (Pathak et al., 2015b). The in vitro activation of insulin action by 
(DAla2)GIP-xenin-8-Gln was demonstrated to be favourable to GIPR cell signalling 
pathway rather than xenin. This concurs with previous studies demonstrating the 
bioactive region of GIP to be the N-terminus and xenin the C-terminus (Hinke et al., 
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2004; Craig, Gault and Irwin, 2018). Assessment of cAMP production by (DAla2)GIP-
xenin-8-Gln in clonal beta cells again revealed that the GIP component of (DAla2)GIP-
xenin-8-Gln was critical for activation of the adenylate cyclase pathway. This is in 
keeping with published literature that xenin does not alter cAMP accumulation in cells 
(Taylor et al., 2010), and previous research with (DAla2)GIP-xenin-8-Gln (Hasib et 
al., 2017).  
Building on this knowledge, and to further elucidate the beta cell actions of 
DAla2)GIP-xenin-8-Gln, proliferation and anti-apoptotic effects were evaluated using 
clonal BRIN-BD11 beta cells. The proliferative abilities of (DAla2)GIP were notable 
but xenin-8-Gln alone had no effect. Considering the latter, and the very significant 
beta cell proliferative actions of (DAla2)GIP-xenin-8-Gln, this is suggestive of xenin-
8-Gln and its ability to augment the biological actions of GIP (Martin et al., 2016). 
The anti-apoptotic benefits of (DAla2)GIP-xenin-8-Gln compared to (DAla2)GIP  were 
less pronounced, although both compounds did elicit notable apoptosis preventive 
effects in keeping with the action of GIP (Martin et al., 2013; Varol et al., 2014). Also, 
a recent study with xenin-25 suggests that this hormone may also be involved in beta 
cell proliferation and protection against apoptosis (Khan et al., 2017). These positive 
observations, along with corresponding recent literature on (DAla2)GIP-xenin-8-Gln 
(Hasib et al., 2017), prompted the next set of experiments to determine whether the 
antidiabetic benefits of (DAla2)GIP-xenin-8-Gln could be enhanced through 
concurrent administration with the clinically approved GLP-1 mimetic, exendin-4. The 
premise being that (DAla2)GIP-xenin-8-Gln would lead to upregulation of GIP activity 
and responsiveness, with exendin-4 activating the other arm of the incretin effect. 
Thus, together the two treatments would positively modulate the overall incretin effect 
that is known to be compromised in T2DM (Capozzi et al., 2018).   
As expected, chronic 32 day treatment with (DAla2)GIP-xenin-8-Gln in HFF mice 
resulted in sustained improvements in glycaemic control and insulinotropic action. 
(DAla2)GIP-xenin-8-Gln caused a progressive decrease in non-fasted circulating 
blood glucose. This beneficial action was further enhanced, albeit non-significantly, 
when administered in combination with the known GLP-1 agonist exendin-4 (Fusco 
et al., 2017). This correlated well with reduced HbA1c concentrations in all treated 
mice. More interestingly, circulating insulin levels were elevated by both treatments, 
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but the combination group clearly induced much higher circulating insulin levels. This 
might imply that the combined action of (DAla2)GIP-xenin-8-Gln and exendin-4 is 
having a positive effect at the level of the beta cell (Hasib et al., 2017; Pathak et al., 
2018a). All effects were largely independent of changes in body weight or energy 
intake, which is possibly a little surprising as exendin-4 is believed to induce satiety 
and lower body weight (Shah and Vella, 2014). However, a similar lack of effect of 
exendin-4 has previously been noted in this same strain of mice (Hasib et al., 2018a). 
These observations are also in line with the described loss of satiety action of xenin-
8-Gln when compared to xenin-25 (Craig, Gault and Irwin, 2018; Martin, 2016).  
GIP has been demonstrated to regulate lipid metabolism including adipocyte size, 
storage and inflammatory response (Freeman, 2009; Varol et al., 2014). A study using 
(DAla2)GIP by Varol and colleagues (2014) suggested that obesity-diabetes was 
related to adipose tissue inflammation by GIP resulting in dysregulation of lipid 
metabolism and storage, correlating with a study by Pathak and colleagues (2015). The 
study concluded that (DAla2)GIP repressed this inflammatory response thus resolving 
the lipid dysregulation and in turn improved insulin sensitivity (Pathak et al., 2015a). 
In the present study, this is supported by a reduction in triglyceride and total 
cholesterol levels in all treatment groups, with the combination of (D-Ala2)GIP-xenin-
8-Gln and exendin-4 also lowering LDL levels. Indeed, recent evidence suggests that 
GLP-1 receptor signalling could be inherently involved in lipid metabolism (Kooijman 
et al., 2015). Conversely, other aspects such as locomotor activity, energy expenditure, 
feeding behaviour and/or patterns could factor here, and warrant further assessment 
(Freeman, 2009; Pathak et al., 2015a; Varol et al., 2014). 
Glucose tolerance following 32 days treatment was not significantly improved by any 
of the treatments in HFF mice. However and more importantly, there was a distinct 
improvement in the sensitivity to both GIP and insulin, especially in the group of mice 
treated with (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4. This 
corroborates the idea that xenin can restore GIP action in T2DM (Hasib et al., 2017; 
Parthsarathy et al., 2016), and that the effect can be enhanced by GLP-1. Furthermore, 
secretory data derived directly from ex vivo isolated islets, following 32 days treatment 
in HFF mice confirms that insulin secretion and beta cell signalling pathways are 
enhanced by combined (DAla2)GIP-xenin-8-Gln and exendin-4 treatment. This is in 
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line with the notable beta cell benefits of GIP, GLP-1 and xenin (Fusco et al., 2017; 
Gault, 2018; Khan et al., 2017).  
Moreover, it is well understood that islet structure is altered by T2DM conditions as 
they undergo morphological changes. The beta cell mass is disrupted, and alpha cell 
mass has been shown to increase and to contribute to disease aetiology (Brereton et 
al., 2015). Therefore, it is pivotal for positive effects on islet cell architecture with the 
introduction of treatment interventions. Moreover, in this study there were positive 
effects on the pancreatic beta cell area as it was significantly augmented in this group 
of HFF mice. The beta cell mass was greatly increased by treatment with either 
(DAla2)GIP-xenin-8-Gln alone or in combination with exendin-4, in HFF mice. This 
was also in keeping with the proliferation and apoptosis studies and previous 
observations (Hasib et al., 2017). Additionally, the alpha cell mass was also reduced 
by treatment with either (DAla2)GIP-xenin-8-Gln alone or in combination with 
exendin-4, in HFF mice. Interestingly, for both treatment groups, the overall islet area 
was similar to the saline treated control suggesting that they both positively altered the 
beta to alpha cell ratio by upregulating islet beta cells. 
This study has shown (DAla2)GIP-xenin-8-Gln, a dual agonist monomeric therapeutic, 
had beneficial effects on the pathologies associated with T2DM. This was represented 
by notable positive effects in an established in vivo model of T2DM induced by high 
fat feeding. Moreover, the work confirms (DAla2)GIP-xenin-8-Gln can augment GIP 
action in diet induced T2DM (Hasib et al., 2017). Furthermore, the therapeutic efficacy 
of (DAla2)GIP-xenin-8-Gln was notably enhanced by exendin-4. This was particularly 
evident in terms of benefits on beta cell area, beta cell secretory responsiveness and 
circulating insulin levels in HFF mice, strongly suggesting the beta cell effects are key 
to these actions. There is clearly a need for further investigations into the therapeutic 
efficacy and applicability of this treatment approach, especially in a model of T2DM 






Figure 3.1 Effects of (D-Ala2)GIP-xenin-8-Gln alone and in the presence of a GIP 























BRIN-BD11 cells were incubated (20 min) with GIP hybrid (10-12 to 10-6 mol/l) in the 
presence of 5.6 mmol/l glucose and a GIP (A) neurotensin 1 (B) or non-specific 
neurotensin (C) receptor antagonist. Insulin was measured by RIA. Values are mean ± 
SEM (n=8) for insulin release. *P<0.05, **P<0.01 and ***P<0.001 compared to 5.6 








10-6 mol/l neurotensin 1 antagonist
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Figure 3.2 Effects of (D-Ala2)GIP, xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln on 


















Proliferation frequency in BRIN-BD11 cells cultured with GLP-1, exendin-4, (D-
Ala2)GIP, xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln (A) (at 10-6 or 10-8 mol/l) for 18 
h. Representative images (B) showing proliferating beta cells in the presence (18 h) of 
GLP-1, exendin-4, (D-Ala2)GIP, xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln. Arrows 
indicate proliferating cells. Values are mean ± SEM (n=4).  **P<0.01 and ***P<0.001 
compared to control culture. +++P<0.001 compared to respective (D-Ala2)GIP. 
∆∆∆P<0.001 compared to respective xenin-8-Gln.






















Apoptosis frequency in BRIN-BD11 cells cultured with exendin-4, (D-Ala2)GIP,  xenin-8-Gln, xenin-8, xenin-25, (D-Ala2)GIP-xenin-8-Gln (at 
10-6 or 10-8 mol/l) for 18 h. Caspase-3/7 activation was detected by luminescence. Values are mean ± SEM (n=3). *P<0.05, **P<0.01 and 































































Figure 3.4 Effects of (D-Ala2)GIP, xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln on 
intracellular cAMP production alone and in the presence of GIP or neurotensin 

















BRIN-BD11 cells were exposed to 5.6 mmol/l glucose control (with 100µm IBMX) 
and various concentrations (10-9 to 10-6 mol/l) of (D-Ala2)GIP-xenin-8-Gln in the 
presence of 5.6 mmol/l glucose with GIP(6-30)-CexGluPAL or neurotensin 1 receptor 
antagonist. Values are mean ± SEM (n=4) for cAMP production. **P<0.01 and 
***P<0.001 compared to 5.6 mmol/l glucose alone. ++P<0.01 and +++P<0.001 








































































































































































Figure 3.5 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone and in combination with exendin-4 on cumulative energy 












Variables were measured for 6 days before and 32 days during (indicated by black horizontal line), twice-daily treatment with saline, (D-Ala2)GIP-
xenin-8-Gln or (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 (each at 25 nmol/kg bw). Values represent mean ± SEM (n=6-8). *P<0.05 





































































Figure 3.6 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone 
and in combination with exendin-4 on non-fasting blood glucose and plasma 



















Blood glucose (A) and plasma insulin (B) was measured for 6 days before and 32 days 
during (indicated by black horizontal line) twice-daily treatment with saline, (D-
Ala2)GIP-xenin-8-Gln or (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 
(each at 25 nmol/kg bw). Values represent mean ± SEM (n=6-8). *P<0.05, **P<0.01 














































Figure 3.7 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln alone 
and in combination with exendin-4 on 24 hour blood glucose profile and % 





















The 24 hour blood glucose profile (A) and %HbA1c (B) were assessed following 32 
days of twice daily intraperitoneal administration of saline, (D-Ala2)GIP-xenin-8-Gln 
or (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 (each at 25 nmol/kg bw). 
Arrows indicate timing of treatment administration. Values represent mean ± SEM 



























































































































Figure 3.8 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln alone 


















Test were performed following 32 days of twice-daily intraperitoneal administration 
of saline, (D-Ala2)GIP-xenin-8-Gln or (D-Ala2)GIP-xenin-8-Gln in combination with 
exendin-4 (each at 25 nmol/kg bw). Mice were fasted for 10 h previously. Blood 
glucose (A) and plasma insulin (B) was measured prior to and after oral administration 
of glucose (18 mmol/kg bw). Blood AUC values for 0-120 min are also included. 






























































































Figure 3.9 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln 





















Test were performed following 32 days of twice-daily intraperitoneal administration 
of saline, (D-Ala2)GIP-xenin-8-Gln or (D-Ala2)GIP-xenin-8-Gln in combination with 
exendin-4 (each at 25 nmol/kg bw). Mice were fasted for 10 h previously. Blood 
glucose (A) and plasma insulin (B) was measured prior to and after intraperitoneal 
administration of glucose (18 mmol/kg bw) in combination with GIP (25 nmol/kg bw). 
Blood AUC values for 0-90 min are also included. Values represent mean ± SEM 
(n=6-8). *P<0.05 compared with saline control. 
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Figure 3.10 Effects of twice-daily administration of (D-Ala2)GIP-xenin-8-Gln 
alone and in combination with exendin-4 on insulin sensitivity and pancreatic 




















Test were performed following 32 days of twice-daily intraperitoneal administration 
of saline, (D-Ala2)GIP-xenin-8-Gln or (D-Ala2)GIP-xenin-8-Gln in combination with 
exendin-4 (each at 25 nmol/kg bw). Plasma glucose (A) was measured prior to and 
after i.p. administration of insulin (25 U/kg bw). Plasma AAC values for 0-60 min are 
also included. Pancreatic insulin content (B) was measured by RIA following 
pancreatic hormone extraction. Values represent mean ± SEM (n=6-8). *P<0.05, 

















































































































Figure 3.11 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln 
alone and in combination with exendin-4 on insulin secretory responsiveness of 












Effects of 32 days twice-daily i.p. administration of exendin-4, (D-Ala2)GIP-xenin-8-
Gln or a combination of both peptides (each at 25 nmol/kg bw) on pancreatic beta cell 
insulin secretory responsiveness in HFF mice. Pancreatic islets were isolated by 
standard collagenase digestion procedures. Values are mean ± SEM for (n=6-8). 




























































































































Figure 3.12 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln 
alone and in combination with exendin-4 on total cholesterol, triglycerides, HDL 


















Effects of 32 days twice-daily i.p. administration of saline, (D-Ala2)GIP-xenin-8-Gln 
or (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 (each at 25 nmol/kg bw) 
on total cholesterol (A), triglycerides (B), HDL (C) and LDL (D) in HFF mice. LDL 
was calculated as total cholesterol - HDL - (triglycerides/5). Values are mean ± SEM 







Figure 3.13 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln 




















Effects of 32 days twice-daily i.p. administration of saline, (D-Ala2)GIP-xenin-8-Gln 
or (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 (each at 25 nmol/kg bw) 
on islet area (A), beta cell area (B), and alpha cell area (C) in HFF mice. Values are 






















































































Figure 3.14 Effects of twice daily administration of (D-Ala2)GIP-xenin-8-Gln 


















Images were captured by an Olympus System Microscope BX51 (Olympus 
instruments, UK) and a DP70 camera adapter. CellF image analysis software was used 
to assess parameters, magnification was X40. Insulin (red), glucagon (green) and 
DAPI (blue) in pancreatic tissue harvested from HFF mice treated for 32 days twice-
daily with saline (A), (D-Ala2)GIP-xenin-8-Gln (B) or a combination of both peptides 

















Investigation of the antidiabetic and therapeutic potential of GIP-














Previously, the HFF mouse model of obesity-induced T2DM was utilised to 
investigate the therapeutic, antidiabetic effects of the (D-Ala2)GIP-xenin-8-Gln 
hybrid. However, no single animal model can fully replicate the complex aetiology of 
human T2DM. Therefore, the db/db mouse model, a genetically induced model of 
metabolic abnormalities including; dyslipidaemia, obesity, with well recognised beta 
cell dysfunction, representative of a severe manifestation of T2DM, was used to further 
investigate and evaluate the (D-Ala2)GIP-xenin-8-Gln hybrid. Twice daily 
intraperitoneal administration of (DAla2)GIP-xenin-8-Gln in db/db mice revealed no 
therapeutic effect on circulating glucose when treated with (DAla2)GIP-xenin-8-Gln 
alone. However, in combination with exendin-4, (DAla2)GIP-xenin-8-Gln improved 
glycaemic control throughout the observation period. Interestingly, only days 1 and 8 
saw circulating insulin levels increased (P<0.05- P<0.01), suggesting that 
extrapancreatic glucose-lowering action of GIP, xenin and GLP-1 could be important. 
The daily plasma glucose levels corresponded with improved glucose profile (24h) and 
decreased percentage glycated haemoglobin (HbA1c) levels. Cumulative energy 
intake but not body weight was also significantly lowered by exendin-4 and 
(DAla2)GIP-xenin-8-Gln in combination with exendin-4 (P<0.05 and P<0.001). 
Additionally, the percentage fat mass was also reduced in all treatment groups with 
(DAla2)GIP-xenin-8-Gln showing the greatest reduction (P<0.05 to P<0.001) 
suggestive of (DAla2)GIP-xenin-8-Gln having an influencing effect on body balancing 
factors. Glucose excursion was also improved by (DAla2)GIP-xenin-8-Gln in 
combination with exendin-4 (P<0.05). However, sensitivity to insulin and GIP was 
unaffected. Furthermore, the pancreatic insulin content and islet morphology 
correlates with progressive disease manifestation. The results suggest that at the latter 
stages of T2DM, even with pharmacological intervention of (DAla2)GIP-xenin-8-Gln 
alone or in combination with exendin-4, the progression of T2DM is difficult to halt 
and perhaps only applicable to earlier stages of disease manifestation, when beta cell 







The progression to the development of T2DM is denoted by five distinct phases 
marked by progressing pancreatic beta cell dysfunction (Weir and Bonner-Weir, 
2004). Phase one is compensation when insulin levels are increased along with beta 
cell mass due to increasing insulin resistance. Phase two is stable adaption with glucose 
levels increased, impaired glucose tolerance (IGT), loss of beta cell mass and 
increasing dysfunction. Phase three, unstable early decompensation and increasingly 
amplified hyperglycaemia within a brief time frame due to increasing insulin 
resistance and/or diminished beta cell mass. Phase four, stable decompensation: severe 
beta cell dedifferentiation. Phase five, severe decompensation: beta cell mass is 
extremely reduced resulting in overt diabetes (Weir and Bonner-Weir, 2004).  
Phases one to three are characteristic of early stage diabetes or what is termed pre-
diabetes and this infers the risk to development of diabetes (Fonseca, 2009; Weir and 
Bonner-Weir, 2004). T2DM has both genetic and environmental aetiologies and is a 
key element in the metabolic syndrome. Other characteristics include: high blood 
pressure, cholesterol, triglycerides and obesity that may also contribute to the 
pathogenesis of T2DM as well as the onset of beta cell dysfunction (O’Brien, 
Sakowski and Feldman, 2014). Therefore, it is of utmost importance to choose in vivo 
models that are representative of the various elements involved with the human 
condition (O’Brien, Sakowski and Feldman, 2014). 
In the previous chapter, HFF mouse model of obesity-induced T2DM was utilised to 
investigate the therapeutic, antidiabetic effects of (D-Ala2)GIP-xenin-8-Gln. This is a 
well-established experimental model pioneered by Surwit et al., 1988, and is 
considered to be clinically relevant for investigation of diet-induced dysregulation of 
metabolic syndromes. However, no single animal model can completely mimic the 
complex aetiology of human T2DM. Therefore, in this chapter we continue the 
investigation of (D-Ala2)GIP-xenin-8-Gln and its therapeutic effects in the db/db 
mouse model, a genetically induced model of T2DM that originated from the Jackson 
Laboratory in 1966. This model results from an autosomal recessive mutation on 
chromosome four that prevents the expression of the leptin receptor and compromises 
leptin signalling (Faita et al., 2018; King, 2012). Leptin is a hormone that regulates 
food intake and energy expenditure, the consequences of dysregulation can result in 
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an altered metabolism and endocrine function (Srinivasan and Ramarao, 2007). The 
db/db model is also considered a valid animal model for investigating metabolic 
abnormalities including; dyslipidaemia, obesity and T2DM. This model is 
characterised by hyperinsulinemia at around two weeks, obesity at three to four weeks, 
high levels of cholesterol and triglycerides as well as the development of persistent 
hyperglycaemia at approximately four to six weeks that is sustained over its life span. 
This is propelled by peripherally impaired insulin action and progressing failure of the 
pancreatic beta cell (Faita et al., 2018; Katsuda et al., 2013; King, 2012). This model 
is well recognised as a T2DM model of beta cell dysfunction (Faita et al., 2018), unlike 
HFF mice. 
Thus, rationale for assessing the therapeutic effects of (D-Ala2)GIP-xenin-8-Gln in 
two in vivo models of T2DM is because the HFF model is primarily representative of 
IGT and early T2DM, perceived by the development of insulin resistance and 
insufficient islet compensation. (Winzell and Ahren, 2004). Whereas db/db is 
considered a severe diabetes model with early on-set insulin resistance, a subsequent 
insulin secretory defect that results in profound hyperglycaemia and eventually ketosis 
(Katsuda et al., 2013; King, 2012). Therefore it is essential to uncover the potential 
therapeutic applicability of the (D-Ala2)GIP-xenin-8-Gln hybrid in both rodent 
models. The aim of this study was to assess the therapeutic effectiveness of the (D-
Ala2)GIP-xenin-8-Gln hybrid in the genetic db/db model of T2DM and to ascertain if 
there are any differences in its efficacious qualities or robustness as an antidiabetic 
therapeutic when the disease severity, aetiology and/or pathophysiology is altered 
compared to HFF mice (Chapter 3).  
 
4.3 Materials and Methods 
4.3.1 Peptides 
All peptides were purchased from Syn Peptide Shanghai, China. Purity was confirmed 
by RP-HPLC and characterised by MALDI-TOF MS, previously described in Sections 
2.1, 2.2.3, and 2.2.4. For all experimental materials and methods please refer to Section 





The long-term study utilised male diabetic (db/db) mice (BKS.Cg-+ Leprdb/+ 
Leprdb/OlaHsd, 6-8 weeks), as described in Section 2.9.3.  
 
4.3.3 Long-term in vivo study in db/db mice 
Twice daily intraperitoneal injections (09:00 and 17:00 h) were administered with 
either saline alone (0.9% (w/v) NaCl), exendin-4, (DAla2)GIP-xenin-8-Gln alone or in 
combination with exendin-4 (all peptides at 25 nmol/kg bw) for 29 days described in 
Section 2.11.1. Assessed metabolic parameters included: blood glucose, plasma 
insulin, body weight and cumulative energy intake, monitored every 3-4 days as 
described in Sections 2.11.1. End of treatment assessment parameters included glucose 
tolerance (18 mmol/kg bw), HbA1c, blood glucose profile, GIP tolerance, insulin 
sensitivity (50 U/kg), insulin content, percentage fat mass and islet morphology 
described in Sections 2.8.2, 2.8.3 and 2.11.2 
 
4.3.4 Biochemical analysis 
Blood/plasma glucose, plasma and pancreatic insulin were assayed as described in 
Sections 2.5.4 and 2.10 
 
4.3.5 Statistical analysis 
As described in Section 2.12 
 
4.4 Results 
4.4.1 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on cumulative energy intake, body weight and 
percentage fat mass in db/db mice 
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Following twice daily administration of all treatments for 29 days there was a 
significant lowering (P<0.05 to P<0.001) on cumulative energy intake compared to 
saline control (Figure 4.1A). Although not significant, there was a progressive decline 
in body weight in all groups (Figure 4.1B).  However, percentage fat mass was 
significantly reduced (1.2-1.3 fold decrease; P<0.05 and P<0.01) in all treatment 
groups compared to saline treated control, with (D-Ala2)GIP-xenin-8-Gln having the 
most significant decrease (1.3 fold decrease) (Figure 4.1C).  
 
4.4.2 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on non-fasted glucose and insulin in db/db mice 
Throughout the treatment period, non-fasted glucose was observed to be significantly 
decreased (P<0.001) when compared to saline treated control (Figure 4.2A). Treatment 
with (D-Ala2)GIP-xenin-8-Gln alone resulted in a significant decrease until day 8 
(P<0.001) but reverted to levels similar to that of saline treated control group from day 
8 onwards (Figure 4.2A). Non-fasted insulin concentrations were significantly 
increased (P<0.05 and P<0.01) by exendin-4 on days 11 and 18, with (D-Ala2)GIP-
xenin-8-Gln in combination with exendin-4 only increasing (P<0.01) insulin on day 1 
and 8, compared to saline control (Figure 4.2B).  
 
4.4.3. Effects of twice daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on 24 hour blood glucose profile and % HbA1c 
in db/db mice 
After twice daily administration of the peptide treatment regimens for 29 days (D-
Ala2)GIP-xenin-8-Gln and (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4 
significantly reduced (P<0.05) glucose levels at both 4 and 8 hour time points 
compared to saline control (Figure 4.3A). Moreover, exendin-4 further reduced 
(P<0.001) glucose levels at the same time points when compared to saline (Figure 
4.3A). The % HbA1c was reduced (P<0.05) in all exendin-4 treated db/db mice when 
compared to (D-Ala2)GIP-xenin-8-Gln alone but all were still elevated (P<0.001) 




4.4.4 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on glucose and insulin in response to an oral 
glucose challenge in db/db mice 
Twice daily administration of all treatment groups demonstrated limited effects on 
glycaemic response on post oral glucose load (Figure 4.4A). Glucose was unaffected 
by the treatment groups, except (D-Ala2)GIP-xenin-8-Gln in combination with 
exendin-4, which had reduced (P<0.05) glucose at 15 min time point with a 
significantly lower (P<0.05) overall AUC (Figure 4.4A). (D-Ala2)GIP-xenin-8-Gln 
had significantly lower (P<0.05) glucose-induced insulin secretion at time point 0 min 
after 10 hours fasting, and this remained reduced (P<0.05)  at the 15 min time point 
compared to saline controls (Figure 4.4B). Exendin-4 had significantly reduced 
(P<0.001) insulin at the 15 min time point only, (D-Ala2)GIP-xenin-8-Gln in 
combination with exendin-4 reduced (P<0.05) insulin at the same time point compared 
to saline control (Figure 4.4B). The AUC demonstrates that exendin-4 is the only 
treatment group to significantly effect insulin response as it reduced (P<0.05) AUC 
values (Figure 4.4B). 
 
4.4.5 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on glucose and insulin in response to GIP in 
db/db mice 
Glucose and GIP was administered in combination to assess GIP tolerance following 
twice daily peptide administration for 29 days. Interestingly, in terms of individual 
values all treatments had no significant effect on either glucose or insulin levels when 
compared to saline treated controls (Figure 4.5A-B). However, AUC values for 
exendin-4 show that overall, exendin-4 reduced (P<0.05) glucose and the 
corresponding insulin levels (P<0.01) when compared to (D-Ala2)GIP-xenin-8-Gln 
treatment alone (Figure 4.5A-B). 
 
4.4.6 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on insulin sensitivity and pancreatic insulin 
content in db/db mice  
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Following 29 days, twice daily administration of exendin-4 or (D-Ala2)GIP-xenin-8-
Gln alone had no effect on insulin sensitivity (Figure 4.6A). However, there was a 
significant effect by (D-Ala2)GIP-xenin-8-Gln in combination with exendin-4, which 
decreased (P<0.05) glucose at the 15 min time point compared to saline controls 
(Figure 4.6A). In addition, ACC shows that none of the treatment groups had a 
significant overall effect on insulin sensitivity (Figure 4.6A). Pancreatic insulin 
content was not significantly different across the treatment groups compared to saline 
controls (Figure 4.6B). However, all db/db mice had reduced (P<0.05) pancreatic 
insulin content when compared to lean mice (Figure 4.6B). 
  
4.4.7 Effects of twice daily administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln 
or a combination of both peptides on pancreatic histology in db/db mice 
Pancreatic islet area was unaffected by any of the treatment groups in comparison to 
saline treated controls (Figure 4.7A). In all db/db mice treated with exendin-4, 
pancreatic islet area was not significantly different from lean control mice (Figure 
4.7A). Pancreatic beta cell area was unaffected by all treatment groups compared to 
saline treated db/db control (Figure 4.7B). In comparison to lean mice beta cell area of 
all the db/db groups was significantly reduced (P<0.05 to P<0.01) (Figure 4.7B). 
Interestingly, there was no significant change in alpha cell area (Figure 4.7C). 
Representative images of islets from all groups of mice are shown in Figure 4.7A-E. 
 
4.5 Discussion 
This study investigated the therapeutic utility of (DAla2)GIP-xenin-8-Gln using a 
preclinical genetic db/db in vivo model useful for studying novel pharmacological 
targets to treat T2DM and other metabolic syndromes. This model presents with age-
dependent progression of diabetes, early insulin resistance followed by defective 
insulin secretion that ultimately results in extreme hyperglycaemia and is considered 
to replicate a fairly, severe manifestation of T2DM (Faita et al., 2018; King, 2012; 
Winzell and Ahren, 2004). In the previous chapter (DAla2)GIP-xenin-8-Gln was 
shown to have efficacious potential for treatment of obesity-diabetes as demonstrated 
in HFF mice (Chapter 3). Qualities included an enhanced glycaemic control and 
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insulinotropic effect along with potential restoration of GIP action which is lost as 
T2DM progresses (Hasib et al., 2017; Kaku, 2010). This present study was designed 
to investigate if such benefits would be achievable in a genetically induced, later stage 
rodent model of T2DM. 
The chronic 29 day treatment regimen, with twice daily intraperitoneal administration 
of (DAla2)GIP-xenin-8-Gln in db/db mice revealed no therapeutic effect on non-fasted 
glucose when treated alone. However, with the addition of exendin-4, (DAla2)GIP-
xenin-8-Gln markedly improved glycaemic control throughout the observation period. 
However, circulating insulin levels were only increased on day 1 and 8 of treatment, 
which was unexpected suggesting that the recognised extrapancreatic glucose-
lowering action of GIP, xenin and GLP-1 could be important (Al-Sabah, 2015; Baggio 
and Drucker, 2007; Capozzi et al., 2018; Parthsarathy et al., 2016; Psichas Reimann 
and Gribble, 2015). The blood profile (24h) and percentage glycated haemoglobin 
(HbA1c) levels emulated the daily glucose levels as (DAla2)GIP-xenin-8-Gln in 
combination with exendin-4 yielded greater glycaemic control. Moreover, even though 
glucose levels were reduced by peptide therapy, they remained at a significantly 
elevated level when compared to non-diabetic controls, this was in keeping with the 
described disease progression of profound hyperglycaemia in db/db mice (Faita et al., 
2018; Katsuda et al., 2013; King, 2012).  
 (DAla2)GIP-xenin-8-Gln in combination with exendin-4 had significant lowering 
effects on cumulative energy intake but not on body weight over the 29 day period. 
Moreover, throughout the treatment period the body weight of all db/db mice began to 
progressively decrease. When considering the decrease in body weight it is important 
to consider if its relevance is in relation to pharmacological intervention or if it is 
phenotypical to the in vivo model, as weight loss is characteristic of the db/db breed at 
the latter stage of the disease (Srinivasan and Ramarao, 2007). Other factors that must 
also be considered but not limited to, when interpreting information and data include 
the age of said mice and the rate/stage of disease progression, as this can vary between 
colonies (Srinivasan and Ramarao, 2007). However, exendin-4 is well known to 
reduce body weight (Kanoski, Hayes and Skibicka, 2016) and there are suggestions 
that GIP and xenin may also decrease body weight (Al-Sabah, 2015; Anlauf et al., 
2000; Campbell and Drucker, 2013; Craig, Gault and Irwin, 2018; Parthsarathy et al., 
2016). Interestingly, the percentage fat mass was also reduced in all treatment groups 
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but not the saline group. (DAla2)GIP-xenin-8-Gln elicited the greatest reduction 
closely followed by the exendin-4 and (DAla2)GIP-xenin-8-Gln in combination with 
exendin-4 treatment groups. This is suggestive that (DAla2)GIP-xenin-8-Gln may have 
an influencing effect on body balancing factors such as fat mass in db/db mice. Indeed, 
both GIP and xenin are known to play a role in lipid metabolism (Campbell and 
Drucker, 2013; Craig, Gault and Irwin, 2018). Further studies examining actions at 
adipocytes using in vitro models and ex vivo imaging would be important. 
The oral glucose challenge following the treatment period revealed improvement in 
glucose excursion in db/db mice treated with (DAla2)GIP-xenin-8-Gln in combination 
of exendin-4. However, sensitivity to insulin and GIP was unaffected by treatment 
with (DAla2)GIP-xenin-8-Gln alone or in combination with exendin-4. This is perhaps 
not surprising given the severe hyperglycaemia in this model. Similarly, the bolus of 
GIP administered may not have been high enough to elicit a basal response in these 
mice given the severity of beta cell dysfunction (Gault et al., 2002: King et al., 2012). 
In agreement, the pancreatic insulin content had no marked difference between the 
treatment groups, although insulin content was significantly reduced compared to the 
lean control highlighting the extreme level of beta cell dysfunction of this breed (Faita 
et al., 2018; Katsuda et al., 2013). Islet morphology also correlates with the 
progressive disease manifestation where pancreatic islets undergo atrophy and beta 
cell necrosis (Faita et al., 2018; Katsuda et al., 2013). None of the pharmacological 
interventions were able to fully prevent or protect against decline or death in either 
islets or beta cells, although exendin-4 alone and in combination with (DAla2)GIP-
xenin-8-Gln did appear most effective in this regard. However, overall islet and beta 
cell areas of the treatment groups was similar to that of the saline treated control 
(Katsuda et al., 2013). Although it is important to note this in vivo monogenetic model 
is absent of the inflammatory mechanism as well as other genetic and environmental 
factors that are apparent within the human manifestation of T2DM. Therefore, the 
complex interactions that lead to the diseased state in humans is not replicated fully by 
this model (Faita et al., 2018; Katsuda et al., 2013; Winzell and Ahren, 2004).   
Together these results suggest that at the end stages of disease, even with the 
pharmacological intervention of (DAla2)GIP-xenin-8-Gln alone or in combination 
with exendin-4, the progression of T2DM is difficult to halt (Paschetta, Hvalryg and 
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Musso, 2011; Senio, Fukushima and Yabe, 2010). Thus, the postulation that 
restoration of GIP sensitivity dramatically improves T2DM is perhaps only applicable 
to earlier stages of disease manifestation, when beta cell function is more apparent (Al-
Sabah, 2015; Irwin and Flatt, 2015). We were disappointed to some degree with the 
results using the db/db model, especially given positive effects using HFF mice. This 
was the first time we used this particular strain which appeared to exhibit a much more 
severe diabetes phenotype than we had initially expected. On reflection, we may well 
have initiated treatment earlier or if time and other resources had been available, we 
would have conducted a dose-finding pilot. 
To conclude, the data from this study largely correlates with the previous chapter, 
noting the ability of the monomeric, multi-targeting analogue, (DAla2)GIP-xenin-8-
Gln to have a positive effect on regulating energy balance in T2DM. This is most likely 
attributed to the biological action of xenin as it is the hormone with established appetite 
suppression and lipid metabolism modulating abilities, thought to be mediated by 
neurotensin receptors. Neurotensin, as a hormone and neurotransmitter, has also been 
shown to have protective effects on beta cells and modulate energy balance (Craig, 
Gault and Irwin, 2018; Mazella et al., 2012). Therefore, there may well be the 
possibility that xenin or neurotensin derived entities could represent an alternative area 
of study for development of novel antidiabetic therapeutics and forms the substance of 













Figure 4.1 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-
8-Gln or a combination of both peptides on cumulative energy intake, body 


















Variables were measured for 6 days before and 29 days during (indicated by black 
horizontal line (B)) twice-daily treatment with saline, exendin-4, (D-Ala2)GIP-xenin-
8-Gln or in combination of exendin-4 (each at 25 nmol/kg) on cumulative energy 
intake (A) and body weight (B) and percentage fat mass measured by DEXA, after 29 
days (C). Values represent mean ± SEM (n=6-8). *P<0.05, **P<0.01 and ***P<0.001 











































































































































































Figure 4.2 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-
8-Gln or a combination of both peptides on non-fasted plasma glucose and insulin 


















Blood glucose (A) and plasma insulin (B) was measured for 6 days before and 29 days 
during (indicated by black horizontal line) twice-daily treatment with saline, exendin-
4, (D-Ala2)GIP-xenin-8-Gln or in combination of exendin-4 (each at 25 nmol/kg bw). 
Values represent mean ± SEM (n=6-8). *P<0.05, **P<0.01 and ***P<0.001 compared 
with saline control.  
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Figure 4.3. Effects of twice daily administration of exendin-4, (D-Ala2)GIP-xenin-
8-Gln or a combination of both peptides on 24 hour blood glucose profile and % 


















The 24 hour blood glucose profile (A) and % HbA1c (B) were assessed following 29 
days of twice daily intraperitoneal administration of saline, exendin-4, (D-Ala2)GIP-
xenin-8-Gln or in combination of exendin-4 (each at 25 nmol/kg bw). Arrows are 
indicative of treatment administration. Values represent mean ± SEM (n=6-8). 
*P<0.05, **P<0.01 and ***P<0.001 compared with saline control or ΔP<0.05 



























































Figure 4.4 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-
8-Gln or a combination of both peptides on plasma glucose and plasma insulin in 




   














Test were performed following 29 days of twice-daily intraperitoneal administration 
of saline, exendin-4, (D-Ala2)GIP-xenin-8-Gln or in combination of exendin-4 (each 
at 25 nmol/kg bw). Mice were fasted for 10 h previously. Plasma glucose (A) and 
plasma insulin (B) was measured prior to and after oral administration of glucose alone 
(18 mmol/kg bw). Plasma AUC values for 0-120min are also included. Values 
represent mean ± SEM (n=6-8). *P<0.05, **P<0.01 and ***P<0.001 with saline 







































































































































































Figure 4.5 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-
8-Gln or a combination of both peptides on plasma glucose and plasma insulin in 



















Test were performed following 29 days of twice-daily intraperitoneal administration 
of saline, exendin-4, (D-Ala2)GIP-xenin-8-Gln or in combination of exendin-4 (each 
at 25 nmol/kg bw). Mice were fasted for 10 h previously. Plasma glucose (A) and 
plasma insulin (B) was measured prior to and after intraperitoneal administration of 
glucose (18 mmol/kg bw) in combination with GIP (25 nmol/kg bw). Plasma AUC 
values for 0-90min are also included. Values represent mean ± SEM (n=6-8). *P<0.05, 


















































































Figure 4.6 Effects of twice-daily administration of exendin-4, (D-Ala2)GIP-xenin-
8-Gln or a combination of both peptides on insulin sensitivity and pancreatic 
















Test were performed following 29 days of twice-daily intraperitoneal administration 
of saline, exendin-4, (D-Ala2)GIP-xenin-8-Gln or in combination of exendin-4 (each 
at 25 nmol/kg bw). Plasma glucose (A) was measured prior to and after i.p. 
administration of insulin (50 U/kg bw). Plasma AAC values for 0-60min are also 
included. Pancreatic insulin content (B) was measured by RIA following pancreatic 
hormone extraction. Values represent mean ± SEM (n=6-8). **P<0.01 and 
***P<0.001 compared with saline control or ΛΛP<0.01 and ΛΛΛP<0.001 compared to 
lean control.














































































































Figure 4.7 Effects of twice daily administration of exendin-4, (D-Ala2)GIP-xenin-



















Effects of twice-daily i.p. administration of exendin-4, (D-Ala2)GIP-xenin-8-Gln or a 
combination of both peptides (each at 25 nmol/kg bw) following 29 day administration 
on islet area (A), beta cell area (B), and alpha cell area (C) in db/db mice. Values are 
mean ± SEM (n=6-8). *P<0.05 and **P<0.01 compared with saline treated control. 
































































































Figure 4.8 Effects of twice daily administration of exendin-4, (D-Ala2)GIP-xenin-
















Images were captured by an Olympus System Microscope BX51 (Olympus 
instruments, UK) and a DP70 camera adapter. Cell^F image analysis software was 
used to assess parameters, magnification was X40. Insulin (red), glucagon (green) and 
DAPI (blue) in pancreatic tissue harvested from lean, (A) saline (B), exendin-4 (C), 


















Assessing the biological actions and application as an antidiabetic 














5.1 Summary  
Xenin based molecules appear to have notable antidiabetic potential and as such 
warrant further appraisal as a pharmacological therapeutic. In this study xenin-8-Gln 
was fused to a biologically active fragment of neurotensin (NT), acetyl-neurotensin(8-
13). Xenin is also said to mediate its biological actions via NTRs. It seems NT, like 
xenin, has biological actions within the endocrine system and that all three NTRs are 
involved in mediating glycaemic control, insulinotropic action, along with body 
balancing factors and protective effects. Thus, combining the biologically active 
fragments of NT and xenin may have therapeutic potential. Acetyl-neurotensin(8-13)-
xenin-8-Gln was chosen over the native peptide as it showed superior receptor binding 
and enhanced bioactivity with in vitro insulin secretion increased (P<0.01 to P<0.01). 
Acetyl-neurotensin(8-13)-xenin-8-Gln showed significant (P<0.001) beta cell 
proliferation and protection against apoptosis in BRIN-BD11 cells. Twice daily 
treatment of acetyl-neurotensin(8-13)-xenin-8-Gln in HFF mice resulted in a sustained 
improvement in glycaemic control and insulin secretion but was significantly (P<0.05 
to P<0.001) enhanced when in combination with exendin-4, also reflected in blood 
glucose profile and glycated haemoglobin (HbA1c) levels (P<0.05 to P<0.01). Glucose 
excursion had marked improvements (P<0.05) with acetyl-neurotensin(8-13)-xenin-8-
Gln in combination with exendin-4 as well as notably improved (P<0.05 to P<0.001) 
response to exogenous GIP and insulin sensitivity, reinforced by pancreatic insulin 
content. Additionally, islet and beta cell areas were unaffected by acetyl-
neurotensin(8-13)-xenin-8-Gln but were significantly increased (P<0.05 to P<0.01) 
when in combination with exendin-4. In relation to energy balance, acetyl-
neurotensin(8-13)-xenin-8-Gln only in combination with exendin-4 had weight 
reducing effects and yielded the greatest reduction (P<0.05 and P<0.001) in 
triglyceride levels. The data shows acetyl-neurotensin(8-13)-xenin-8-Gln has 
improved therapeutic efficacy in combination with exendin-4 and appears to enhance 
the therapeutic range of exendin-4 in several biological actions including glycaemic 
control, insulinotropic action and fat reduction. Thus, acetyl-neurotensin(8-13)-xenin-






As noted in previous chapters (Chapters 3,4), and in recent literature (Gault et al., 
2015; Hasib et al., 2017; Hasib et al., 2018a; Hasib et al., 2018b; Martin et al., 2016; 
Parthsarathy et al., 2016), xenin based molecules have notable antidiabetic potential. 
To further examine and appraise the pharmacological therapeutic potential of xenin, 
we have designed another novel hybrid peptide. On this occasion the modified 
biologically active region of xenin, xenin-8-Gln was fused to the biologically active 
fragment of neurotensin (NT), namely acetyl-neurotensin(8-13)-xenin-8-Gln. The 
truncated neurotensin fragment, neurotensin(8-13), was selected over the native 
thirteen amino acid parent peptide because it has shown superior receptor binding and 
enhanced bioactivity (Martin, 2016; Schroeder and Leinninger, 2018). The premise for 
this novel hybrid is of a similar nature to the previous (D-Ala2)GIP-xenin-8-Gln 
(Chapter 3). However, in this case xenin-8-Gln was linked to the structurally similar 
NT analogue, as both entities are believed to utilise the neurotensin receptor (NTR) to 
mediate their biological actions. (Craig, Gault and Irwin, 2018; Martin et al., 2012).   
A number of studies indicate that NT, as a neurotransmitter or as a circulating 
hormone, has a role within the endocrine system influencing glucose homeostasis and 
energy balance (Mazella et al., 2012; Schroeder and Leinninger, 2018). Satiety is the 
key in energy balance and is primarily regulated by leptin secreted from adipocytes, 
which controls food intake by acting as a hormone directly on satiety regions within 
the hypothalamus (Mazella et al., 2012; Schroeder and Leinninger, 2018). Recent 
studies have postulated that leptin may be controlled by NTSR1 expressing neurons as 
the effects of leptin were impaired in NTSR1-deficient mice (Mazella et al., 2012). 
Additionally, a study by Leinninger and colleagues (2011) revealed that NT neurons 
control leptin actions including the mesolimbic dopamine system, secretion of orexin 
and energy balance (Leinninger et al., 2011; Mazella et al., 2012). Moreover, NT has 
been implicated in the control of nutrient absorption particularly in conjunction with 
fatty acid (FA) rich food. Studies have determined that postprandially, the ingestion of 
FA substantially increases circulating levels of NT (Mazella et al., 2012). As such, NT 
is secreted from the gut in response to fat ingestion and this stimulates secretions from 
the pancreas to facilitate lipid digestion (Mazella et al., 2012).   
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Furthermore, NT has a role in glucose homeostasis, including regulating the release of 
endocrine pancreatic hormones and at low glucose levels stimulates glucagon and 
insulin release (Mazella et al., 2012). These endocrine actions have been confirmed in 
several studies (Coppola et al., 2008; Grunddal et al., 2016; Khan et al., 2017; Mazella 
et al., 2012). NT can directly mediate endocrine actions on the pancreas as this tissue 
expresses all three NTSRs (Khan et al., 2017; Mazella et al., 2012). It is postulated 
that NTSR2 initiates the effect of NT on insulin secretion, but the impact of 
NTSR3/sortilin has also been investigated (Mazella et al., 2012). This suggests that 
NTSR2 and NTSR3/sortilin beta cell pathways may work in tandem. Indeed, the 
literature confirms that within beta cells, NTSR2 and NTSR3/sortilin form 
heterodimers (Mazella et al., 2012). Interestingly, NT predominantly via NTSR2 has 
protective effects on beta cells against external cytotoxic agents including interlukin-
1 beta via the PI3 kinase pathway (Mazella et al., 2012). This protective effect is 
significant as beta cell death is a major factor in T2DM pathology (Khan et al., 2017; 
Mazella et al., 2012). Taken together, it is clear that NT, either as a neurotransmitter 
or circulating hormone, has an important role in the control of energy balance and 
glucose homeostasis (Mazella et al., 2012). 
As noted previously (Chapter 3,4), xenin derivatives have shown the ability to improve 
insulin sensitivity, augment insulinotropic response and decrease the overall 
glycaemic excursion in HFF models of obesity-T2DM. Xenin signalling can also 
regulate lipid metabolism via the NTR1 by acting directly on adipose tissue to 
stimulate lipolysis (Bhavya, Lew and Mizuno, 2018; Martin et al., 2016). Moreover, 
it seems that all three NTRs have a profound involvement in mediating glycaemic 
control, insulinotropic action, along with body balancing factors and protective effects, 
which are mediated by NT and xenin collectively, both centrally and peripherally 
(Bhavya, Lew and Mizuno, 2018; Martin et al., 2016; Mazella et al., 2012). Therefore, 
combining the biologically active fragments of NT and xenin to assemble a monomeric 
hybrid peptide, may result in an advantageous therapeutic, with improved practicality 
over individual agonists of either peptide (Irwin and Flatt, 2015).  
Within this study the biological actions and stability of the novel hybrid peptide acetyl-
neurotensin(8-13)-xenin-8-Gln were appraised. Acetyl-neurotensin(8-13)-xenin-8-
Gln was investigated both in vitro and in vivo to assess its potential as a T2DM 
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therapeutic. Given our previous negative experience with db/db mice and possible 
complications of leptin deficiency in application with NT, we decided to evaluate 
effects in HFF mice. 
 
5.3 Materials and Methods 
5.3.1 Peptides 
All peptides (Table 1) were purchased from Syn Peptide Shanghai, China. Purity was 
confirmed by RP-HPLC and characterised by MALDI-TOF MS, all previously 
described in Sections 2.1, 2.2.3, and 2.2.4. For all experimental materials and methods 
please refer to Section 2.1 and the relevant subsections.  
 
5.3.2 Plasma degradation 
The effect of murine plasma on peptide stability was assessed as described previously 
in section 2.3.2. 
 
5.3.3 Acute effects of peptides alone in the presence of GLP-1 or GIP on in vitro 
insulin secretion from BRIN-BD11 cells 
The in vitro insulin secretory activity of peptides in BRIN-BD11 cells was conducted 
as described in Section 2.5.2. BRIN-BD11 cells were incubated (20 min) with test 
peptides (10-6 – 10-12 mol/l) alone at 5.6 and 16.7 mol/l glucose and in the presence of 
GLP-1or GIP (10-7 mol/l). Following test incubations (20 min), insulin secretion was 
measured by RIA as previously described in Sections 2.5.2 and 2.5.4. 
 
5.3.4 In vitro proliferation 
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Effects of test peptides on cell proliferation in BRIN-BD11 cells was conducted as 
described in Section 2.6.2. Cells were incubated with test peptides (10-8 to 10-6 mol/l) 
for 18 hours. The primary antibody, anti-Ki-67 (1:250) and the secondary antibody, 
goat anti-rabbit Alexa Fluor® 594 (1:400) were used to detect proliferating beta cells 
by fluorescent microscopy. 
 
5.3.5 In vitro apoptosis 
The effects of test peptides on protection of BRIN-BD11 from cytokine-induced 
apoptosis was examined is as described in Section 2.6.3. Cells were incubated with 
test peptides (10-8 to 10-6 mol/l) for 18 hours and apoptosis initiated by adding caspase-
3/7 substrate reagent (ApoLive-Glow™ Multiplex assay) that results in cell lysis, 
followed by caspase cleavage of the substrate and detection of beta cell apoptosis by 
luminescence. 
 
5.3.6 In vitro cyclic AMP 
Effects of peptides on cAMP production was examined using BRIN-BD11 cells 
(Section 2.7.2). Briefly, test peptides (10-9 to 10-6 mol/l) were incubated with cells for 
60 mins, and cAMP measured using a cAMP Parameter® ELISA kit. 
 
5.3.7 Animals 
The long-term study utilised HFF male Swiss mice, as described in Section 2.9.2. Prior 
to experimentation, mice were maintained on high fat diet for 10 weeks, resulting in 
overt obesity and hyperglycaemia. 
 
5.3.8 Long-term in vivo study in high fat fed mice 
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Twice daily intraperitoneal (i.p.) injections (09:00 and 17:00 h) of either saline vehicle 
(0.9% (w/v) NaCl), exendin-4, acetyl-neurotensin(8-13)-xenin-8-Gln alone or in 
combination with exendin-4 (all peptides at 25 nmol/kg) were administered for 32 days 
(Section 2.11.1). Assessed metabolic parameters during the study included: circulating 
glucose and insulin, body weight and cumulative energy intake, monitored every 3-4 
days (Sections 2.11.1). End of treatment assessment parameters included: glucose 
tolerance (18 mmol/kg bw), HbA1c, blood glucose profile, GIP tolerance (25 nmol/kg 
bw), insulin sensitivity (25 U/kg), pancreatic insulin content, percentage fat mass, 
circulating triglycerides and cholesterol as well as islet morphology, as described in 
more detail within Sections 2.8.2, 2.8.3 and 2.11.2. 
 
5.3.9 Biochemical analysis 
Blood/plasma glucose, plasma and pancreatic insulin were assayed as described in 
Sections 2.5.4 and 2.10 
 
5.3.10 Statistical analysis 
As described in Section 2.12 
 
5.4 Results 
5.4.1 Peptide characterisation of native neurotensin, xenin-8-Gln, neurotensin(8-
13), acetyl-neurotensin(8-13) and acetyl-neurotensin(8-13)-xenin-8-Gln and 
stability in the presence of mouse plasma 
Following RP-HPLC on a C-18 analytical column, all peptides showed homogenous 
well-resolved peaks indicating a high degree of purity. Table 5.1 represents retention 
times which corresponded well with the purity information supplied by manufacturer. 
The experimental mass detected for each peptide corresponded to theoretical mass 
(Table 5.1), confirming successful synthesis. Moreover, the hybrid peptide acetyl-
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neurotensin(8-13)-xenin-8-Gln showed improved stability under plasma degradation 
for up to 8 hours (Table 5.1).  
 
5.4.2 Acute effects of neurotensin on insulin release from BRIN-BD11 cells  
Figure 5.1 (A-D) demonstrates the abilities of neurotensin to increase insulin secretion 
from BRIN-BD11 cells at various concentrations of glucose. Neurotensin increased 
(P<0.001) insulin secretion at 3.3 mmol/l glucose in a dose dependent manner 
compared to respective glucose control (Figure 5.1A). At 5.6 mmol/l glucose 
neurotensin only enhanced (P<0.05) insulin secretion at 10-6 mol/l when compared to 
control (Figure 5.1B). At higher glucose levels (11.1 and 16.7 mmol/l), neurotensin 
inhibited (P<0.05 to P<0.01) insulin secretion, especially at the higher concentrations 
examined (Figure 5.1C-D).  
 
5.4.3 Acute effects of neurotensin on insulin release from BRIN-BD11 cells in the 
presence of GIP and GLP-1  
When neurotensin was combined with GIP or GLP-1 at 5.6 mmol/l glucose, the levels 
of secreted insulin were significantly increased (P<0.001), compared glucose alone 
(Figure 5.2A-B). However, neurotensin did not augment GIP-induced insulin secretion 
(Figure 5.2A), and the insulin secretory ability of GLP-1 was actually reduced by 
neurotensin at 10-8 and 10-6 mol/l concentrations (Figure 5.2B).  
 
5.4.4 Acute effects of xenin-8-Gln on insulin release from BRIN-BD11 cells 
Figure 5.3 (A-D) demonstrates the ability of xenin-8-Gln to increase insulin secretion 
from BRIN-BD11 cells at various concentrations of glucose. Xenin-8-Gln increased 
(P<0.05 to P<0.01) insulin secretion at 11.1 and 16.7 mmol/l glucose in a dose 
dependent manner (Figure 5.3C-D), and this is also demonstrated at 5.6 mmol/l 
glucose, as higher concentrations (10-8 mol/l to 10-6 mol/l) of xenin-8-Gln increased 




5.4.5 Acute effects of xenin-8-Gln on insulin release from BRIN-BD11 cells in the 
presence of GIP and GLP-1  
When xenin-8-Gln was combined with GIP or GLP-1 at normal physiological levels 
of glucose (5.6 mmol/l) the levels of secreted insulin were significantly increased 
(P<0.001) compared glucose alone (Figure 5.4A-B). Xenin-8-Gln also enhanced 
(P<0.05 to P<0.01) the secretory ability of GIP at higher concentrations (10-8 mol/l to 
10-6 mol/l) compared to respective control (Figure 5.4A). However, this enhancement 
ability was not demonstrated in combination with GLP-1 (Figure 5.4B). 
 
5.4.6 Acute effects of acetyl-neurotensin(8-13) on insulin release from BRIN-
BD11 cells 
Acetyl-neurotensin(8-13) significantly increased (P<0.05 to P<0.001) insulin 
secretion from BRIN-BD11 cells at lower glucose levels (3.3 mmol/l) in a dose 
dependent manner when compared to respective control (Figure 5.5A). This increase 
(P<0.05 to P<0.01) was also shown at normal physiological glucose (5.6 mmol/l) 
(Figure 5.5B), but only at higher peptide concentrations (10-8 mol/l to 10-6 mol/l). 
Conversely, at higher glucose concentrations (11.1 and 16.7 mmol/l) acetyl-
neurotensin(8-13) induced insulin secretion decreased in a dose dependent manner, as 
such the higher the concentration (10-12 mol/l to 10-6 mol/l) the less insulin secreted 
(Figure 5.5C-D). Insulin secretion was significantly decreased (P<0.05 to P<0.001) at 
16.7 mmol/l glucose by acetyl-neurotensin(8-13)  (at 10-10 mol/l to 10-6 mol/l) 
compared to glucose control (Figure 5.5D). 
 
5.4.7 Acute effects of acetyl-neurotensin(8-13) on insulin release from BRIN-
BD11 cells in the presence of GIP and GLP-1 
Acetyl-neurotensin(8-13) combined with GIP or GLP-1 at normal physiological levels 
of glucose (5.6 mmol/l) significantly increased (P<0.001) levels of secreted insulin 
when compared to the 5.6 mmol/l glucose control (Figure 5.6A-B).  However, when 
compared to GLP-1 (at 10-6 mol/l) the level of insulin secretion was significantly 




5.4.8 Acute effects of acetyl-neurotensin(8-13)-xenin-8-Gln on insulin release 
from BRIN-BD11 cells 
Acetyl-neurotensin(8-13)-xenin-8-Gln) enhanced (P<0.05 to P<0.001) insulin 
secretion from BRIN-BD11 cells at all glucose concentrations (3.3, 5.6, 11.1 and 16.7 
mmol/l) tested, but only at higher peptide concentrations (10-8 mol/l to 10-6 mol/l) 
(Figure 5.7A-D). 
 
5.4.9 Acute effects of acetyl-neurotensin(8-13)-xenin-8-Gln on insulin release 
from BRIN-BD11 cells in the presence of GIP and GLP-1 
Acetyl-neurotensin(8-13)-xenin-8-Gln combined with GIP or GLP-1 at normal 
physiological levels of glucose (5.6 mmol/l) significantly increased (P<0.001) the 
levels of secreted insulin when compared to the 5.6 mmol/l glucose control (Figure 
5.8A-B). When compared to GIP, at higher (10-12 mol/l to 10-6 mol/l) concentrations 
of acetyl-neurotensin(8-13)-xenin-8-Gln insulin secretion was significantly increased 
(P<0.001), compared to the GIP control (Figure 5.8A). 
 
5.4.10 Effects of neurotensin analogues and neurotensin-xenin-8-Gln hybrids on 
insulin release from lean mouse islets 
Isolated islets from lean mice incubated with acetyl-neurotensin(8-13), neurotensin-
xenin-8-Gln or acetyl-neurotensin(8-13)-xenin-8-Gln (10-8 mol/l or 10-6 mol/l) at 3.3 
mmol/l glucose stimulated a significant increase (P<0.05 to P<0.01) of insulin 
secretion when compared to the glucose control (Figure 5.9A). However, xenin-8-Gln 
had no effect, and neurotensin elicited a response (P<0.05) only at a higher peptide 
concentration (10-6 mol/l) from isolated islets at 3.3 mmol/l glucose (Figure 5.9A). All 
concentrations of xenin-8-Gln, neurotensin-xenin-8-Gln and acetyl-neurotensin(8-
13)-xenin-8-Gln employed stimulated a significant increase (P<0.05 to P<0.001) of 
insulin secretion from islets at 16.7 mmol/l glucose and compared to neurotensin and 




5.4.11 The effects of xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-13) and 
acetyl-neurotensin(8-13)-xenin-8-Gln on BRIN-BD11 cell proliferation 
Culturing of BRIN-BD11 cells in the presence of exendin-4, acetyl-neurotensin(8-13), 
xenin-25 and acetyl-neurotensin(8-13)-xenin-8-Gln (A) (at 10-6 mol/l or 10-8mol/l) for 
18 hours significantly increased (P<0.001) the proliferation frequency in comparison 
to the control culture (Figure 5.10A-B). Xenin-8-Gln alone exhibited no enhancing 
effects, but when combined with acetyl-neurotensin(8-13) as a hybrid, namely acetyl-
neurotensin(8-13)-xenin-8-Gln, beta cell proliferation was dramatically (P<0.01 to 
P<0.001) increased (Figure 5.10A). However, this increase was significantly less 
(P<0.001) when compared to exendin-4. Representative images under each culture 
condition are shown in Figure 5.10B.  
 
5.4.12 The effects of exendin-4, xenin-8, xenin-8-Gln, neurotensin(8-13), acetyl-
neurotensin(8-13) and acetyl-neurotensin(8-13)-xenin-8-Gln on BRIN-BD11 cell 
apoptosis   
BRIN-BD11 cells cultured in the presence of exendin-4, neurotensin, xenin-8, xenin-
8-Gln, neurotensin(8-13), acetyl-neurotensin(8-13), xenin-25 and acetyl-
neurotensin(8-13)-xenin-8-Gln (at 10-6 or 10-8 mol/l) for 18 hours all demonstrated a 
significant (P<0.01 to P<0.001) protective effect against capase-3/7 activated 
apoptosis in comparison to the untreated control culture (Figure 5.11). 
 
5.4.13 Effects of twice-daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on cumulative energy intake, 
body weight and percentage fat in HFF mice 
Following twice daily administration of all treatments, barring exendin-4 alone, there 
was no significant effect on cumulative energy intake over the 32 days in HFF mice 
(Figure 5.12A). However, there was a significant decrease (P<0.05 to P<0.001) in 
body weight in all exendin-4 treated mice from the fourth day of treatment (Figure 
5.12B). The percentage body fat mass also reflects this reduction (P<0.05 and 
P<0.001) in both exendin-4 and acetyl-neurotensin(8-13)-xenin-8-Gln in combination 
with exendin-4 treated groups when compared to the HFF controls (Figure 5.12C). 
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5.4.14 Effects of twice-daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on non-fasted glucose and 
insulin in HFF mice  
From the fourth day of treatment there was a significant decrease (P<0.05 to P<0.001) 
in non-fast glucose in all exendin-4 treatment groups (Figure 5.13A). Acetyl-
neurotensin(8-13)-xenin-8-Gln induced a progressive decrease in glucose, but not 
significantly (Figure 5.13A). Non-fasted plasma insulin concentrations of exendin-4 
alone and acetyl-neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 
progressively increased (P<0.05 and P<0.001) from the fourth day of treatment 
(Figure5.13B). Treatment with acetyl-neurotensin(8-13)-xenin-8-Gln alone had no 
significant effect on non-fasted insulin over the treatment period, in comparison to 
HFF control mice (Figure 5.13B).  
 
5.4.15 Effects of twice daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on 24 hour blood glucose 
profile and %HbA1c in HFF mice 
Following administration over the 32 day treatment period, a 24 hour profile was 
conducted (Figure 5.14A). Non-fasted glucose levels demonstrated that exendin-4 
alone and acetyl-neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 
treatment modalities induced a sustained lowering of blood glucose over the 
observation period, compared to HFF controls (Figure 5.14A). Acetyl-neurotensin(8-
13)-xenin-8-Gln treatment maintained a reduced level compared to the HFF control 
mice, but this was not significant (Figure 5.14A). Moreover, this correlated with end 
of treatment percentage HbA1c levels, as treatment with exendin-4 alone and in 
combination with acetyl-neurotensin(8-13)-xenin-8-Gln resulted in significantly 
reduced (P<0.01) HbA1c concentrations in comparison to HFF controls (Figure 
5.14B). 
 
5.4.16 Effects of twice daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on glucose and insulin in 
response to an oral glucose challenge in HFF mice 
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Only administration of acetyl-neurotensin(8-13)-xenin-8-Gln in combination with 
exendin-4 demonstrated a significant (P<0.05) improvement in glycaemic response 
post oral glucose load (Figure 5.15A). This was also reflected by overall AUC, as 
acetyl-neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 significantly 
lowered (P<0.05) overall glycaemic excursion in comparison to acetyl-neurotensin(8-
13)-xenin-8-Gln, but not compared to controls (Figure 5.15B). However, none of the 
treatment groups had any significant effects on glucose-induced insulin secretion 
(Figure 5.15B). 
 
5.4.17 Effects of twice daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on glucose and insulin in 
response to GIP tolerance test in HFF mice 
Exendin-4 alone and in combination with acetyl-neurotensin(8-13)-xenin-8-Gln 
augmented the glucose-lowering action of GIP, as they maintained reduced glucose 
levels throughout assessed time points, although this effect was not significant (Figure 
5.16A). However, the AUC revealed an overall significant reduction (P<0.05) in 
glucose levels by acetyl-neurotensin(8-13)-xenin-8-Gln in combination with exendin-
4 compared with saline controls (Figure 5.16A). GIP-induced elevations of insulin for 
all HFF groups was not significantly different (Figure 5.16B). 
 
5.4.18 Effects of twice-daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on insulin sensitivity and 
pancreatic insulin content in HFF mice 
Twice daily administration of exendin-4 and acetyl-neurotensin(8-13)-xenin-8-Gln 
had no significant effect on individual glucose levels in response to exogenous insulin 
(Figure 5.17A). However, in acetyl-neurotensin(8-13)-xenin-8-Gln in combination 
with exendin-4 mice glucose levels were significantly reduced (P<0.05) at the 60 min 
time point, as well as AUC, when compared to controls and acetyl-neurotensin(8-13)-
xenin-8-Gln mice (Figure 5.17A). Pancreatic insulin content revealed that there was a 
significant (P<0.001) reduction in insulin concentrations by exendin-4 and acetyl-
neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 treatment, when 
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compared to saline controls and acetyl-neurotensin(8-13)-xenin-8-Gln alone (Figure 
5.17B). 
 
5.4.19 Effects of twice daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on bone mineral density and 
bone mineral content in HFF mice 
There was no significant effect on bone mineral density (BMD) or bone mineral 
content (BMC) post twice daily administration of exendin-4, acetyl-neurotensin(8-13)-
xenin-8-Gln and acetyl-neurotensin(8-13)-xenin-8-Gln in combination with exendin-
4 (Figure 5.18A-B). 
 
5.4.20 Effects of twice daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on total cholesterol, 
triglycerides, HDL and LDL in HFF mice 
Following 32 days twice daily administration of exendin-4 alone and in combination 
with acetyl-neurotensin(8-13)-xenin-8-Gln there was a significant decrease (P<0.01 
and P<0.001) in circulating total and LDL-cholesterol (Figure 5.19A,D), with a 
decrease (P<0.05 and P<0.01) in HDL levels in all treatment groups (Figure 5.19C). 
However, there was only a decrease (P<0.01) in LDL in mice treated with acetyl-
neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 (Figure 5.19B).  
 
5.4.21 Effects of twice daily administration of exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both peptides on pancreatic histology in HFF 
mice 
Islet and beta cell area were increased (P<0.001) in all the HFF groups compared to 
lean controls (Figure 5.20A-B). Pancreatic islet area after 32 days treatment revealed 
that there was a significant increase (P<0.05-P<0.001) in islet area with acetyl-
neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 (Figure 5.20A). 
Additionally, there was an elevation of beta cell area by acetyl-neurotensin(8-13)-
xenin-8-Gln in combination with exendin-4, with cell area significantly (P<0.01-
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P<0.001) enhanced in this treatment group compared to both lean and saline controls 
(Figure 5.20B). Moreover, both the islet and beta cell areas were significantly (P<0.05-
P<0.01) increased by acetyl-neurotensin(8-13)-xenin-8-Gln in combination with 
exendin-4 compared to acetyl-neurotensin(8-13)-xenin-8-Gln alone (Figure 5.20A-B). 
There was no significant effect on alpha cell area by any of the treatment regimens 




With the mediation of xenin and NT’s biological activity primarily underpinned by the 
activation of NTRs, it was essential to establish if this was maintained by the hybrid 
peptide analogue acetyl-neurotensin(8-13)-xenin-8-Gln. A recent study by Khan and 
colleagues (2017) involving the assessment of NTRs expression within the endocrine 
pancreas, supports the applicability of the initial in vitro assessment of insulin 
secretory activity, as well as beta cell growth and survival, of xenin-8-Gln, NT and 
NT-xenin analogue(s) in the BRIN-BD11 cell line and isolated mouse islets (Khan et 
al., 2017).  
The work by Khan and colleagues (2017), which was focused on the native forms of 
both peptides, correlates and corroborates the insulinotropic data generated in this 
study. Xenin-8-Gln can elicit superior insulin secretion at both low and high glucose 
concentrations, but it remains that NT and NT analogues can only enhance insulin 
secretion at lower glucose concentrations in BRIN-BD11 cells and mouse islets 
(Devader et al., 2013; Khan et al., 2017). However, the monomeric NT-xenin 
analogue, acetyl-neurotensin(8-13)-xenin-8-Gln overcomes this inability to increase 
insulin secretion at higher glucose concentrations. It appears that combining the 
modified biologically active fragment of xenin with acetylation of the active fragment 
of NT, not only extends the DPP-IV half-life of the peptide but enhances the 
insulinotropic abilities in BRIN-BD11 cells, and importantly with further insulin 
secretory superiority evidenced in isolated islets.  
Additionally, studies on the proliferative and protective effects of xenin and NT have 
noted xenin to increase proliferation. Both xenin and NT protect against streptozotocin 
induced cellular stress in BRIN-BD11 cells and NT has been shown to 
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exhibitprotective effects against caspase-3 activity (Coppola et al., 2008; Devader et 
al., 2013; Khan et al., 2017). In line with this published literature on NT (Khan et al., 
2017), acetyl-neurotensin(8-13)-xenin-8-Gln demonstrated significant beta cell 
proliferation and offered protection against beta cell apoptosis, via inhibition of the 
caspase 3/7 pathway. This suggests that the hybrid peptide may have beneficial effects 
on maintaining and/or increasing beta cell mass, with obvious positive implications 
for the treatment of diabetes (Halban et al., 2014).  
With such promising in vitro results further assessment of acetyl-neurotensin(8-13)-
xenin-8-Gln biological capabilities in vivo was warranted. Thus, a chronic 32 day 
investigation of acetyl-neurotensin(8-13)-xenin-8-Gln antidiabetic activity was 
conducted in the HFF mouse model of T2DM. The choice of animal model in which 
to study the biological effects of acetyl-neurotensin(8-13)-xenin-8-Gln was crucial to 
fully corroborating the efficacy of the hybrid peptide for the treatment of T2DM. This 
choice was of the utmost importance because of the studies linking NT to the control 
of the hormone leptin, as it acts directly on specific areas of the hypothalamus 
controlling food intake and energy expenditure (Mazella et al., 2012; Srinivasan and 
Ramarao, 2007). Therefore, the use of other genetic models of T2DM such as the 
previously utilised db/db model, which has a mutation on chromosome 4 inhibiting the 
expression of the leptin receptor, would restrict the full exploration of the true potential 
of the hybrid peptide (Faita et al., 2018; Mazella et al., 2012; Schroeder and 
Leinninger, 2018). 
Twice daily treatment of acetyl-neurotensin(8-13)-xenin-8-Gln in HFF mice resulted 
in a sustained improvement in glycaemic control and insulin secretion. Acetyl-
neurotensin(8-13)-xenin-8-Gln, although not significant, caused a progressive 
decrease in circulating glucose levels than those of the HFF saline treated control, 
similar to that seen with other xenin derived hybrid peptides (Hasib et al., 2017; Hasib 
et al., 2018a; Hasib et al., 2018b; Martin et al., 2016). Moreover, this action was 
significantly enhanced when administered in combination with the GLP-1 agonist 
exendin-4, suggesting the utility of its bioactivity to further reduce glucose levels 
(Fusco et al., 2017). This enhanced anti-diabetic action of xenin in combination with 
GLP-1 has also been demonstrated by Hasib and colleagues in HFF using a GIP-xenin 
hybrid peptide (Hasib et al., 2018b).  
113 
 
In addition, the blood glucose profile and HbA1c levels also confirm that acetyl-
neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 had a superior glucose 
lowering ability than the hybrid peptide alone. Moreover, the glucose tolerance test, 
following 32 days treatment with acetyl-neurotensin(8-13)-xenin-8-Gln in 
combination with exendin-4 showed marked improvements in the glucose excursion. 
This was also noted in response to exogenous GIP injection, along with improved 
insulin sensitivity. This is reinforced by pancreatic insulin content, which revealed that 
exendin-4 and acetyl-neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 
had significantly less insulin per µg/g protein, but insulin sensitivity was superior.  
Furthermore, the islet and beta cell areas were unaffected by acetyl-neurotensin(8-13)-
xenin-8-Gln alone but were significantly increased with acetyl-neurotensin(8-13)-
xenin-8-Gln in combination with exendin-4, which had similar effects to exendin-4 
alone. This is suggestive that while acetyl-neurotensin(8-13)-xenin-8-Gln does not 
enhance the action of exendin-4 it does not diminish its therapeutic action. These 
observations are in line with positive beta cell architecture effects of GLP-1 in 
numerous type 2 diabetes animal model studies (Moffett et al., 2015; Vasu et al., 
2014). This data collectively suggests that like results from previous Chapters and 
published literature, NT receptor signalling can augment sensitivity to GIP, and impart 
clear antidiabetic actions, positive attributes that are retained, or even enhanced by this 
NT-xenin hybrid (Al-Sabah, 2015; Hasib et al., 2017; Hasib et al., 2018b; Irwin and 
Flatt, 2015).   
In relation to energy balance, both NT and xenin have been shown to play a role in 
satiety, as both have anorexigenic abilities (Bhavya, Lew and Mizuno, 2018; Cooke et 
al., 2012). Initial studies indicated that this effect was influenced primarily via 
intracerebroventricularly (i.c.v.) administration, but more recently intraperitoneal (i.p.) 
administration has been shown to also facilitate these actions (Cooke et al., 2012; 
Ratner et al., 2018). The anorectic actions of NT through leptin are thought to be 
mediated via the ventral tegmental area (VTA) by the NT neurons located within the 
lateral hypothalamic area (LHA), as 15-30% of these NT neurons co-express the leptin 
receptor (Schroeder and Leinninger, 2018). Similarly, xenin is also thought to partially 
exert its influence over food intake via the hypothalamus (Kim et al., 2016). Both 
native peptides are believed to bind to the NTR1, located within the hypothalamus to 
induce their anorexic effects (Kim et al., 2016; Ratner et al., 2018).  
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Taking this into account, a recent study on a PEGylated NT peptide that induced a 
prolonged decrease in food intake (Ratner et al., 2018), along with the augmentative 
ability of a xenin hybrid, meant the potential for the dual receptor agonist, acetyl-
neurotensin(8-13)-xenin-8-Gln to effect energy balance was likely. However, acetyl-
neurotensin(8-13)-xenin-8-Gln alone or in combination with exendin-4 had no impact 
on cumulative energy intake over the 32 day treatment period in HFF mice. Thus, the 
discrepancy could be related to dose of peptide employed, as xenin appears to impact 
feeding only at high concentrations (Taylor et al., 2010), or perhaps the need for 
central administration (Cooke et al., 2012). In addition, lack of effect on feeding is 
paralleled by no significant body weight reduction in HFF mice. Indeed, it is only 
when in combination with exendin-4 that acetyl-neurotensin(8-13)-xenin-8-Gln had 
any weight reducing effects, probably linked to GLP-1 receptor effects on the 
hypothalamus (Kanoski, Hayes and Skibicka, 2016). Interestingly, GLP-1’s ability to 
reduce body weight loss via anorectic and orexigenic endocrine signals may be related 
to regulation of the expression of neuropeptides including NT (Dalvi et al., 2012; 
Good, 2012; Kanoski, Hayes and Skibicka, 2016).   
In contrast to the findings on food intake and body weight, where exendin-4 exerted 
superior body balancing effects, it was acetyl-neurotensin(8-13)-xenin-8-Gln in 
combination with exendin-4 that yielded the greatest reduction in percentage fat mass 
and triglyceride levels. Both xenin and NT have been linked with direct effects on 
adipocytes, and to play a role in lipid metabolism. Systemically, xenin has been shown 
to stimulate lipolysis on adipose tissue, and this is thought to be mediated by NTR1 as 
NTR1 mRNA is expressed on mouse adipose tissue (Bhavya, Lew and Mizuno, 2018). 
Furthermore, NT secreted from the intestine in response to postprandial fat ingestion 
has been shown to facilitate the absorption of fat. This influences the circulating levels 
of leptin as fat initiates the secretion of leptin from adipocytes (Barchetta et al., 2018; 
Mazella et al., 2012). Systemically leptin then initiates enteroendocrine cells to release 
their gastrointestinal peptides such as GLP-1 and GIP, thus working synergistically to 
regulate energy balance (Barchetta et al., 2018). This suggests that the superior 
reduction of percentage fat mass by acetyl-neurotensin(8-13)-xenin-8-Gln in 
combination with exendin-4 can be attributed to several mechanisms, with multiple 
hormone receptor pathways working in concert to elicit this effect. 
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In conclusion, this data reveals that acetyl-neurotensin(8-13)-xenin-8-Gln has 
improved therapeutic efficacy in combination with GLP-1R agonist exendin-4. In 
combination it also appears to improve the therapeutic range of exendin-4 in several 
biological actions including glycaemic control, insulinotropic action and fat reduction. 
Therefore, this novel hybrid with complementary effects in combination with GLP-1, 
may have the potential to treat not only T2DM but obesity related diabetes. 
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Table 5.1 Peptide characterisation of native neurotensin, xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-13) and acetyl-










Peptide sequences of native neurotensin, xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-13) and acetyl-neurotensin(8-13)-xenin-8-Gln. 
Purification of peptides confirmed by RP-HPLC, retention times recorded using ChromQuest software. Molecular mass confirmed using MALDI-
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Figure 5.1 Acute effects of neurotensin on insulin release from BRIN-BD11 cells  
 
 
BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) 3.3, (B) 5.6, (C) 11.1 and (D) 16.7 mmol/l glucose. Insulin was 
measured by RIA. Values are mean ± SEM (n=8) for insulin release. *P<0.05, 
**P<0.01 and ***P<0.001 compared to 5.6 mmol/l glucose control. +P<0.05, ++P<0.01 
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Figure 5.2 Acute effects of neurotensin in the presence of GIP and GLP-1 on 
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BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) GIP and (B) GLP-1 (both at 10-7 mol/l) at 5.6 mmol/l glucose. Insulin 
was measured by RIA. Values are mean ± SEM (n=8) for insulin release. ***P<0.001 
compared to 5.6 mmol/l glucose alone. +P<0.05 and ++P<0.01 compared to respective 
GIP or GLP-1 control. 
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Figure 5.3 Acute effects of xenin-8-Gln on insulin release from BRIN-BD11 cells 
 
 
BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) 3.3, (B) 5.6, (C) 11.1 and (D) 16.7 mmol/l glucose. Insulin was 
measured by RIA. Values are mean ± SEM (n=8) for insulin release. *P<0.05, 
**P<0.01 and ***P<0.001 compared to 5.6 mmol/l glucose control. +P<0.05, ++P<0.01 
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Figure 5.4 Acute effects of xenin-8-Gln in the presence of GIP and GLP-1 on 
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BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) GIP and (B) GLP-1 (both at 10-7 mol/l) at 5.6 mmol/l glucose. Insulin 
was measured by RIA. Values are mean ± SEM (n=8) for insulin release. ***P<0.001 
compared to 5.6 mol/l glucose alone. ++P<0.01 and +++P<0.001 compared to respective 




Figure 5.5 Acute effects of acetyl-neurotensin(8-13) on insulin release from BRIN-
BD11 cells  
 
 
BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) 3.3, (B) 5.6, (C) 11.1 and (D) 16.7 mmol/l glucose. Insulin was 
measured by RIA. Values are mean ± SEM (n=8) for insulin release. *P<0.05, 
**P<0.01 and ***P<0.001 compared to 5.6 mol/l glucose control. +P<0.05, ++P<0.01 
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Figure 5.6 Acute effects of acetyl-neurotensin(8-13) in the presence of GIP and 





















BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) GIP and (B) GLP-1 (both at 10-7 mol/l) at 5.6 mmol/l glucose. Insulin 
was measured by RIA. Values are mean ± SEM (n=8) for insulin release. **P<0.01 
and ***P<0.001 compared to 5.6 mmol/l glucose alone. +P<0.05 compared to 
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Figure 5.7 Acute effects of acetyl-neurotensin(8-13)-xenin-8-Gln on insulin 
release from BRIN-BD11 cells  
 
 
BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) 3.3, (B) 5.6, (C) 11.1 and (D) 16.7 mmol/l glucose. Insulin was 
measured by RIA. Values are mean ± SEM (n=8) for insulin release. *P<0.05 and 
***P<0.001 compared to 5.6 mol/l glucose control. +P<0.05 ang ++P<0.01 compared 
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Figure 5.8 Acute effects of acetyl-neurotensin(8-13)-xenin-8-Gln in the presence 






















BRIN-BD11 cells were incubated (20 min) with test peptide (10-12 to 10-6 mol/l) in the 
presence of (A) GIP and (B) GLP-1 (both at 10-7 mol/.) at 5.6 mmol/l glucose. Insulin 
was measured by RIA. Values are mean ± SEM (n=8) for insulin release. ***P<0.001 




















5.6 mmol/l Glucose + 10 mmol/l Alanine
5.6 mmol/l Glucose + GIP 10 -7 mol/l
5.6 mmol/l Glucose + Ac-NT(8-13)















































5.6 mmol/l Glucose + 10 mmol/l Alanine
5.6 mmol/l Glucose + GLP-1 10
-7
mol/l
5.6 mmol/l Glucose + Ac-NT(8-13)






































Figure 5.9 Effects of neurotensin analogues and neurotensin-xenin-8-Gln 




















Isolated mice islets were incubated for 60 min with 10-6 or 10-8 mol/l of neurotensin, 
xenin-8-Gln, acetyl-neurotensin(8-13), neurotensin-xenin-8-Gln or acetyl-
neurotensin(8-13)-xenin-8-Gln at (A) 3.3 and (B) 16.7 mmol/l glucose. Insulin release 
was measured using RIA. Values represent mean ± SEM (n=6).  *P<0.05 and 
**P<0.01 compared to respective glucose control. ++P<0.01 and ++P<0.001 compared 
































































































































Figure 5.10 The effects of xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-









Proliferation frequency in BRIN-BD11 cells cultured with exendin-4, neurotensin, 
xenin-8, xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-13), xenin-25 and 
acetyl-neurotensin(8-13)-xenin-8-Gln (A) (at 10-6 or 10-8 mol/l) for 18 h. 
Representative images (B) showing proliferating beta cells, arrows indicate 
proliferating cells. Values are mean ± SEM (n=4).  ***P<0.001 compared to control. 
ΔP<0.05, ΔΔP<0.01 and ΔΔΔP<0.001 compared to respective acetyl-neurotensin(8-13)-
xenin-8-Gln.
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Figure 5.11 The effects of exendin-4, xenin-8, xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-13) and acetyl-neurotensin(8-13)-xenin-











Apoptosis frequency in BRIN-BD11 cells cultured with exendin-4, neurotensin, xenin-8, xenin-8-Gln, neurotensin(8-13), acetyl-neurotensin(8-
13), xenin-25 or acetyl-neurotensin(8-13)-xenin-8-Gln (at 10-6 or 10-8 mol/l) for 18 h. Caspase-3/7 activation was detected by luminescence. Values 





































































































Figure 5.12 Effects of twice-daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on cumulative 


















Parameters were measured for 6 days before and 32 days during (indicated by black 
horizontal line (B)) twice-daily treatment with saline, exendin-4, acetyl-neurotensin(8-
13)-xenin-8-Gln or a combination of both (each at 25 nmol/kg) on cumulative energy 
intake (A) and body weight (B) and % fat mass (C), in HFF mice. Values represent 
































































































Figure 5.13 Effects of twice-daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on non-fasted 




















(A) Blood glucose and (B) plasma insulin was measured for 6 days before and 32 days 
during (indicated by black horizontal line) twice-daily treatment with saline, exendin-
4, acetyl-neurotensin(8-13)-xenin-8-Gln or a combination of both peptides (each at 25 
nmol/kg) in HFF mice. Values represent mean ± SEM (n=6-8). *P<0.05, **P<0.01 
and ***P<0.001 compared with saline control.  
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Figure 5.14 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on 24 hour 




















The 24 hour blood glucose profile (A) and %HbA1c (B) were assessed following 32 
days of twice daily i.p. administration of saline, exendin-4, acetyl-neurotensin(8-13)-
xenin-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) in HFF mice. 
Arrows are indicative of treatment administration. Values represent mean ± SEM 






















































Figure 5.15 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on glucose and 














Test were performed following 32 days twice-daily i.p. administration of saline, 
exendin-4, acetyl-neurotensin(8-13)-xenin-8-Gln or a combination of both peptides 
(each at 25 nmol/kg bw). Mice were fasted for 10 h previously. Blood glucose (A) and 
plasma insulin (B) was measured prior to and after oral administration of glucose alone 
(18 mmol/kg bw). Blood AUC values for 0-120min are also included. Values represent 
mean ± SEM (n=6-8). *P<0.05 compared with saline control. +P<0.05 compared with 
acetyl-neurotensin(8-13)-xenin-8-Gln.  
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Figure 5.16 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on glucose and 



















Test were performed following 32 days twice-daily i.p. administration of saline, 
exendin-4, acetyl-neurotensin(8-13)-xenin-8-Gln or a combination of both peptides 
(each at 25 nmol/kg bw) in HFF mice. Mice were fasted for 10 h previously. Blood 
glucose (A) and plasma insulin (B) was measured prior to and after i.p. administration 
of glucose (18 mmol/kg bw) in combination with GIP (25 nmol/kg bw). Blood AUC 
values for 0-90min are also included. Values represent mean ± SEM (n=6-8). *P<0.05 




























































Figure 5.17 Effects of twice-daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on insulin 


















Test were performed following 32 days twice-daily i.p. administration of saline, 
exendin-4, acetyl-neurotensin(8-13)-xenin-8-Gln or a combination of both peptides 
(each at 25 nmol/kg bw) in HFF mice. Blood glucose was measured prior to and after 
i.p. administration of insulin (25 U/kg bw). Blood AAC values for 0-60 min are also 
included. Pancreatic insulin content (B) was measured by RIA following pancreatic 
hormone extraction. Values represent mean ± SEM (n=6-8). *P<0.05, **P<0.01 and 













































































































Figure 5.18 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on bone mineral 


















Effect of twice daily administration of exendin-4, acetyl-neurotensin(8-13)-xenin-8-
Gln or a combination of both peptides on bone mineral density (A) and bone mineral 
content (B) measured by DEXA scanning in HFF and lean mice. Values represent 








Figure 5.19 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on total 










Effects of twice-daily i.p. administration of exendin-4, acetyl-neurotensin(8-13)-
xenin-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) following 32 
day administration on total cholesterol (A), triglycerides (B), HDL (C) and LDL (D) 
in HFF mice. LDL was calculated as total cholesterol - HDL - (triglycerides /5). Values 
are mean ± SEM (n=6-8). *P<0.05 **P<0.01 and ***P<0.001 compared with saline 






































































































Figure 5.20 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on pancreatic 


















Effects of twice-daily i.p. administration of exendin-4, acetyl-neurotensin(8-13)-
xenin-8-Gln or a combination of both peptides for 32 days (each at 25 nmol/kg bw) on 
islet area (A), beta cell area (B), and alpha cell area (C) in HFF mice. Values are mean 
± SEM (n=6-8). *P<0.05, **P<0.01 and ***P<0.001 compared with saline treated 































































































Figure 5.21 Effects of twice daily administration of exendin-4, acetyl-
neurotensin(8-13)-xenin-8-Gln or a combination of both peptides on pancreatic 
















Images were captured by an Olympus System Microscope BX51 (Olympus 
instruments, UK) and a DP70 camera adapter. CellF image analysis software was used 
to assess parameters, magnification was X40. Insulin (red), glucagon (green) and 
DAPI (blue) in pancreatic tissue harvested from lean control (A) and HFF mice treated 
twice-daily with saline (B), exendin-4 (C), acetyl-neurotensin(8-13)-xenin-8-Gln (D) 



















Attempts to optimise an unambiguous GIP receptor antagonist with 













6.1 Summary  
The prevalence of obesity is at an all time high with around 1 in 4 UK adults classified 
as obese. Obesity and associated insulin resistance is linked to the development of 
T2DM, but not all individuals go on to develop overt T2DM. Research suggests that 
hyper-secretion of the incretin hormone GIP has a key role to play in the development 
of obesity-T2DM. GIP is a key regulator of insulin secretion and lipid metabolism and 
these beneficial actions appear to be lost in individuals with obesity-T2DM. Studies 
with bariatric surgery show decreased GIP secretion and action as a main metabolic 
outcome which results in significant, long-term weight loss in these patients. Thus, 
there is an increasing interest in the less invasive approaches of GIP antagonism and/or 
disruption of GIPR action utilising peptide-based GIPR antagonists. However, it 
appears not to be essential to completely diminish GIP signalling, as reduction or 
partial reduction in GIP can produce beneficial anti-obesity effects. Yet, a specific 
GIPR antagonist continues to elude us. N- and C-terminally truncated GIP(3-30) and 
GIP(5-30) have recently been identified as competitive antagonists of the GIPR and 
questioned the efficacy of peer reviewed Pro3GIP antagonist. This study attempts to 
uncover a true GIPR antagonist utilising human and mouse sequences. Initial in vitro 
analysis at low and high glucose concentrations in BRIN-BD11 cells shows human 
GIP(3-30), human Pro3(3-30)GIP and mouse GIP(3-30) weakly stimulated insulin 
secretion, and significantly (P<0.01 to P<0.001) inhibited GIP-stimulated insulin 
secretion. In vivo analysis showed all peptides, with varying degrees had reduced 
(P<0.01) glucose lowering abilities when administered alone or in combination with 
human GIP (1-42). Interestingly, in those peptides with their C-terminus intact 
(position 31–42) the GIP receptor antagonistic quality was decreased. Further in vivo 
evaluation of human GIP(3-30) and GIP(5-30) and human Pro3GIP(3-30) 
demonstrated that the latter had superior antagonistic abilities (1.3-fold, P<0.05), with 
human GIP(5-30) marginally behind. Additionally, to evaluate the receptor blockading 
capacity the peptides were administered 30 min prior to a glucose plus GIP challenge. 
Human Pro3GIP(3-30) (1.4-fold, P<0.001), showed superior GIPR antagonistic 
activity in this system. These data concur with previous work on Pro3GIP and further 
evidence it as a GIPR antagonist warranting further analysis with potential for 





In recent years the development of T2DM has been linked to obesity and associated 
insulin resistance and aging (Al-Goblan, Al-Alfi and Khan, 2014). This increased risk 
is thought to occur when, over time, pancreatic beta cell function declines and can no 
longer compensate for increased insulin demand and decreased peripheral sensitivity 
to insulin. However, surprisingly many obese individuals do not go on to develop 
T2DM, as obesity has been shown to increase in beta cell mass by 50%, thus enhancing 
insulin response to glucose (Cantley and Ashcroft, 2015). However, it is when this 
compensatory mechanism fails that subsequently leads to the development of T2DM 
(Cantley and Ashcroft, 2015). The prevalence of obesity is at an all time high, with 
around 1 in 4 UK adults classified as obese and these figures are projected to rise from 
26% to 41–48% in men and from 26% to 35–43% in women by 2030 (Cantley and 
Ashcroft, 2015; Wang et al., 2011). Thus, the likelihood of developing T2DM is also 
increased.  
The incretin hormone GIP secreted in response to elevated glucose levels, has also 
been linked to obesity-T2DM through its actions as a key regulator of lipid metabolism 
(Al-Sabah, 2015; Seino and Yabe, 2010). Interestingly, patients with T2DM exhibit a 
decreased insulinotropic response to GIP and at the molecular level, and the loss of the 
incretin effect is a possible early pathophysiological indicator of T2DM (Al-Sabah, 
2015). Moreover, it is the associated overnutrition, primarily by chronic consumption 
of dietary fats, that is thought to increase the circulating levels of GIP. Thus, ingested 
fat is known to be a potent stimulus for GIP secretion (Al-Sabah, 2015). Therefore, it 
appears that circulating GIP levels are elevated in obesity and T2DM resulting in 
excessive accumulation of visceral and subcutaneous fat deposition (Irwin and Flatt, 
2009). Thus, increased action or secretion of GIP can predispose individuals to obesity 
(Irwin and Flatt, 2009; Paschetta, Hvalrug & Musso, 2011; Nakamura et al., 2018).  
A study by Zhou and colleagues (2005) provides further evidence for the link between 
GIP and obesity through studies using insulin receptor substrate (IRS)-1-deficient 
knockout mice. They observed that if the action of insulin was diminished, as is the 
case in T2DM, then GIP could switch from fat oxidation to fat accumulation, which 
ultimately resulted in increased triglyceride storage (Zhou et al., 2005). Genetic studies 
also provided evidence that links GIP to obesity. Vogel and colleagues (2009) analysed 
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the GIPR gene and found polymorphisms, single nucleotide repeats (SNPs) within the 
coding regions or regions adjacent to these which could attribute to genetic 
predisposition to obesity (Vogel et al., 2009). This is significant because the major 
causative factor of insulin resistance in obesity-related diabetes is found in those 
individuals with centrally distributed body fat and associated metabolic dysregulation. 
This includes increased levels of circulating free fatty acids (FFA), as this type of fat 
is more lipolytic and results in lipid toxicity, initiating an inflammatory response 
(Boden, 2011; Al-Goblan, Al-Alfi and Khan, 2014). This metabolic dysfunction 
results in insulin resistance that creates a hyperglycaemic state further exacerbating 
the T2DM disease state (Al-Goblan, Al-Alfi and Khan, 2014). 
With accumulating evidence linking elevated GIP levels to development of obesity 
and insulin resistance, there is growing interest in research surrounding GIP 
antagonism, and/or disruption of GIPR action and how it could be exploited to 
potential treat obesity-T2DM (Gasbjerg et al., 2018a). Currently, it is primarily 
bariatric surgery that results in significant long-term weight loss in patients with 
obesity-T2DM (Mingrone et al., 2012; 2015). Interestingly, a number of these studies 
point to decreased GIP secretion and action as a main metabolic outcome of the 
surgical process (Mingrone et al., 2009; Xiong et al., 2015). Until recently, the most 
widely used pharmacological agent for obesity was orlistat, but current clinical 
recommendations have seen the introduction of liraglutide, the GLP-1 agonist, as an 
adjunct therapeutic with diet and physical activity for weight management (Mehta, 
Marso and Neeland, 2017; Nakamura et al., 2018; Troke et al., 2014).  Liraglutide has 
been shown in several clinical trials to offer superior and sustainable weight loss, with 
5-10%, at the higher therapeutic dosage of 3 mg than at the normal therapeutic range 
(1.8 mg). However, the long-term efficacy of liraglutide has yet to be established for 
obesity, and adverse effects such as gastrointestinal disturbances and hypoglycaemia 
along with an increased risk of medullary thyroid carcinoma should not be overlooked 
(Mehta, Marso and Neeland, 2017).  
GIP antagonism studies have included work in animal models with genetic deletions 
of the GIPR (Zhou et al., 2008; Naitoh et al., 2008), small molecules that block the 
GIP receptor (Irwin et al., 2006; Nakamura et al., 2012), immunisation against GIP 
(Irwin et al., 2009; Ravn et al., 2013), and peptide-based antagonists (Gault et al., 
2007a; Kerr et al., 2011). Importantly, an interesting study has suggested that it is not 
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entirely necessary to completely obliterate GIP signalling to gain anti-obesity benefits, 
and a reduction or even a partial reduction in GIP secretion has been shown to yield 
the anti-obesity effect (Nasteska et al., 2014). Indeed, this approach would also be 
considered to have a less detrimental effect on GIP-induced insulin secretion, that 
would be beneficial in T2DM. Thus, development of an efficacious GIP antagonist 
could mimic positive results from bariatric surgeries, without the need for major 
surgery or adverse effects. 
The Diabetes Research Group (DRG) at Ulster have generated and developed several 
peptide antagonists of GIP. Key approaches have examined N-terminally truncated 
GIP peptides (Kerr et al., 2011), amino acid substituted analogues such as Pro3GIP 
(Gault et al., 2007b; McClean et al., 2007; McClean et al., 2008) and N- and C-
terminally truncated palmitoylated GIP peptides (Pathak et al., 2015a). These studies 
have shown beneficial effects on normalising glucose tolerance, improving insulin 
sensitivity and energy intake, reversing obesity and associated metabolic disturbances. 
Furthermore, adipocyte hypertrophy, adipose tissue mass and triglyceride deposition 
in the liver and muscle of high-fat fed mice were significantly reduced along with a 
significant reduction in circulating triglycerides, cholesterol and glucagon levels 
(Gault et al., 2007b; Gault et al., 2008; McClean et al., 2007; McClean et al., 2008; 
Pathak et al., 2015a). Pro3GIP has also been shown to prevent diabetes and the 
associated metabolic disturbances in mice with early administration (Irwin et al., 
2007). However, recent research has refuted Pro3GIP as full antagonist at the human 
GIPR but rather suggesting it is a partial GIP agonist, that is linked to interspecies 
variation at receptors and ligands between humans and rodents (Hansen et al., 2015; 
Nakamura et al., 2018; Sparre-Ulrich et al., 2015).  Therefore, we sought to build upon 
our work and recent work of others to optimise truncated GIP peptides and assess their 
potential antagonist properties in vitro and in vivo. Whilst availability of a potent GIP 
antagonist would be invaluable in determining full spectrum of GIP physiology there 
is also much opportunity that GIP antagonism could actually be beneficial as a 
potential therapeutic. 
 




All peptides were purchased from Syn Peptide Shanghai, China. Purity was confirmed 
by RP-HPLC and characterised by MALDI-TOF MS (Table 6.1), as previously 
described in Sections 2.2.2 to 2.2.4. For all experimental materials and methods please 
refer to Section 2.1, and the relevant subsections.  
 
6.3.2 Acute effects of peptides on in vitro insulin secretion from BRIN-BD11 cells 
The in vitro insulin secretory activity of test peptides was examined in BRIN-BD 11 
cells as described in Section 2.5.2. BRIN-BD11 cells were incubated with test peptides 
(10-6 – 10-12 mol/l) alone or in the presence of native GIP (1-42) at 5.6 and 16.7 mmol/l 
glucose for 20 min. Following test incubations, insulin was measured by RIA, as 
previously described in Sections 2.5.2 and 2.5.4.  
 
6.3.3 Animals 
Acute studies used male Swiss mice as described in Section 2.9.1-2.10.2. Experiments 
for glucose tolerance studies were conducted using test peptides in overnight fasted 
mice, as outlined in Sections 2.10.1-2.10.2. 
 
6.3.4 Biochemical analysis 
Blood glucose was measured directly by the Ascencia Contour glucose meter (Bayer, 
Newbury, UK), as described in Section 2.10. 
 
6.3.5 Statistical analysis 





6.4.1 Acute effects of human GIP(1-42), human GIP(1-30) and mouse GIP(1-30) 
on insulin release from BRIN-BD11 cells 
Figure 6.1(A-B) demonstrate the abilities of native human GIP(1-42) and C-terminally 
truncated human and mouse GIP(1-30) to increase insulin secretion from BRIN-BD11 
cells at both 5.6 and 16.7 mmol/l glucose in a dose-dependent (10-12 – 10-6 mol/l) 
manner compared to glucose control. However, human and mouse GIP(1-30) only 
significantly increase (P<0.01 to P<0.001) insulin secretion at higher peptide 
concentrations (10-8 mol/l to 10-6 mol/l) in 5.6 (Figure 6.1A) and 16.7 (Figure 6.1B) 
mmol/l glucose. Furthermore, the potency of human GIP(1-42) and (1-30) is 
significantly less (P<0.05 to P<0.01) in comparison to mouse GIP(1-30) at 
concentrations 10-10 mol/l and 10-8 mol/l at 16.7 mmol/l glucose (Figure 6.1B).  
 
6.4.2 Acute effects of human GIP(3-30) and mouse GIP(3-30) alone or in 
combination with native human GIP(1-42) on insulin release from BRIN-BD11 
cells 
Figure 6.2(A-D) shows human and mouse GIP(3-30), at 10-7 mol/l, significantly 
reduced (P<0.001) GIP-induced (10-12 to 10-6 mol/l) insulin secretion from BRIN-
BD11 cells at both 5.6 and 16.7 mmol/l glucose. Importantly, neither human nor mouse 
GIP(3-30) had any effect on insulin secretion from BRIN-BD11 cells at either 5.6 or 
16.7 mmol/l glucose (Figure 6.2A-D). 
 
6.4.3 Acute effects of human Pro3GIP(3-30) and human GIP(5-30) alone or in 
combination with native human GIP(1-42) on insulin release from BRIN-BD11 
cells 
Human Pro3GIP(3-30) significantly decreased (P<0.01 to P<0.001) GIP-induced (10-
12 mol/l to 10-6 mol/l) insulin secretion from BRIN-BD11 at both 5.6 and 16.7 mmol/l 
glucose (Figure 6.3A-B). However, human GIP(5-30) was unable to impede the 
insulinotropic action of GIP(1-42) (Figure 6.3C-D). Indeed, at 16.7 mmol/l glucose, 
human GIP(5-30) actually stimulated (P<0.01) insulin release when compared to 




6.4.4 Acute effects of human GIP(3-42) and human GIP(5-42) alone or in 
combination with native human GIP(1-42) on insulin release from BRIN-BD11 
cells 
Human GIP(3-42) was unable to block GIP-induced (10-12 to 10-6 mol/l) insulin 
secretion at 5.6 mmol/l glucose (Figure 6.4A), but was a moderately effective GIP 
blocker at 16.7 mmol/l glucose (Figure 6.4B). However, human GIP(5-42) did not 
impede the insulinotropic action of GIP at 5.6 or 16.7 mmol/l glucose (Figure 6.4C-
D), and actually evoked significant (P<0.05) insulin release when incubated alone with 
BRIN-BD11 cells at 16.7 mmol/l glucose (Figure 6.4D). 
 
6.4.5 Acute effects of native human GIP(1-42), human GIP(1-30) and mouse 
GIP(1-30) on glucose tolerance in lean mice 
The acute effects of native human GIP(1-42) and human and mouse GIP(1-30) on 
blood glucose in overnight fasted mice is shown in Figure 6.4. Human GIP(1-42) 
significantly lowered (P<0.05 to P<0.01) glucose levels (at 15, 30 and 60 min) and 
human GIP(1-30) at the 60 min time point compared to glucose control (Figure 6.5A). 
Mouse GIP(1-30) had no significant effect on glucose-lowering (Figure 6.5A). These 
observations correlate with the 0-60 min overall AUC values showing a reduction 
(P<0.05) in glucose by human GIP(1-42) and (1-30), but not mouse GIP(1-30) (Figure 
6.5B). No differences in efficacy were noted between human GIP(1-42) and human 
GIP(1-30). 
 
6.4.6 Acute effects of human GIP(3-30) alone or in combination with native 
human GIP(1-42) on glucose tolerance in lean mice 
Human GIP(3-30) alone or in combination with human GIP(1-42) demonstrated no 
significant effects on glucose levels in overnight fasted mice (Figure 6.6A-B). 
However, human GIP(3-30) blocked the ability of human GIP(1-42) ability to 




6.4.7 Acute effects of mouse GIP(3-30) alone or in combination with native human 
GIP(1-42) on glucose tolerance in le 
an mice 
Mouse GIP(3-30) in combination with human GIP(1-42) demonstrated a significant 
blocking (1.3-fold; P<0.05) effect on the ability of human GIP(1-42) to reduce glucose 
levels (Figure 6.7A-B). When administered alone, mouse GIP(3-30) had no effects on 
glucose levels, being similar to that of the  glucose control (Figure 6.7A-B). 
 
6.4.8 Acute effects of human Pro3GIP(3-30) alone or in combination with native 
human GIP(1-42) on glucose tolerance in lean mice 
Human Pro3GIP(3-30) alone displayed no significant effects on overall AUC blood 
glucose levels, but did decrease (P<0.05) individual glucose levels at 60 min post-
injection compared to glucose alone (Figure 6.8A-B). However, when human 
Pro3GIP(3-30) was combined with human GIP(1-42), the glucose-lowering effects of 
native GIP were lost (Figure 6.8A-B).  
 
6.4.9 Acute effects of human GIP(5-30) alone or in combination with native 
human GIP(1-42) on glucose tolerance in lean mice 
Human GIP(5-30) alone had no impact on glucose lowering in overnight fasted mice 
(Figure 6.9A-B). However, in combination with human GIP(1-42) there was a 
significant (P<0.05 to P<0.01) hindering effect on the glucose-lowering action of GIP, 
both in terms of individual and AUC values (Figure 6.9A-B).  
 
6.4.10 Acute effects of human GIP(3-42) alone or in combination with native 
human GIP(1-42) on glucose tolerance in lean mice 
Figure 6.10 reveals that human GIP(3-42) alone no effect on glucose homeostasis in 
mice (Figure 6.10A-B). In addition, human GIP(3-42) was unable to impede the 




6.4.11 Acute effects of human GIP(5-42) alone or in combination with native 
human GIP(1-42) on glucose tolerance in lean mice 
Similar to human GIP(3-42), glucose-homeostatic actions of human GIP(5-42) were 
not apparent in overnight fasted mice, either when injected alone or in combination 
with human GIP(1-42) Figure 6.11A-B). 
 
6.4.12 Acute effects of high dose human GIP(3-30), human Pro3GIP(3-30) or 
human GIP(5-30) on glucose tolerance in lean mice 
Higher dose (100 nmol/kg) of human GIP(3-30), human Pro3GIP(3-30) or human 
GIP(5-30) had a significant glucose-lowering (P<0.01) ability at least one observation 
point during the 60 min test (Figure 6.12A). Overall glucose AUC confirmed glucose-
lowering actions of all three peptides, similar to native GIP (Figure 6.12B; Table 6.2). 
However, the efficacy of human Pro3GIP(3-30) or human GIP(5-30) was significantly 
(P<0.05) reduced when compared to native GIP (Figure 6.12B; Table 6.2). 
 
6.4.13 Acute effects of early administration of high dose human GIP(3-30), 
human Pro3GIP(3-30) and human GIP(5-30) on glucose tolerance in lean mice  
The effects of early administration (at -30 min) of 100 nmol/kg human GIP(3-30), 
human Pro3GIP(3-30) and human GIP(5-30) are shown in Figure 6.13. Interestingly, 
only human Pro3GIP(3-30) was able to block the glucose-lowering action of native 
GIP when injected 30 mins prior to GIP challenge (Figure 6.13A-B; Table 6.2). As 
such, both human GIP(3-30) and human GIP(5-30) were ineffective (Figure 6.13A-B; 
Table 6.2).  
 
6.5 Discussion 
Research by Hansen and colleagues (2016), has identified N- and C-terminally 
truncated GIP(3-30) and GIP(5-30) as competitive antagonists of the GIPR. However, 
further research demonstrated that efficacy and possible therapeutic translatability of 
GIP based peptides is underpinned by interspecies variation in the structure/function 
of GIP (Gasbjerg et al., 2018b; Hansen et al., 2016; Sparre-Ulrich et al., 2015). The 
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data infers that alteration in amino sequence structure of GIP between species, even 
by just one amino acid, can cause a significant difference in potency and receptor 
binding affinity (Sparre-Ulrich et al., 2015). The GIPR is 81% conserved between 
human and rodent species, along with some variations within the ligand sequence 
(Sparre-Ulrich et al., 2016). This is more apparent within mouse GIP, as it has three 
substitutions compared to human GIP, whereas rat has two amino acid substitutions 
(Sparre-Ulrich et al., 2015). Both rodent species have substitutions that occur at 
position 18, where arginine present in human GIP is substituted with histidine (Sparre-
Ulrich et al., 2015).  In mouse, at position 30, lysine is substituted to arginine and at 
position 34, asparagine to serine when compared to human GIP (Sparre-Ulrich et al., 
2016).  In rat, the second amino acid substitution is isoleucine for leucine at position 
40 (Sparre-Ulrich et al., 2015). 
In addition, the present work reaffirms understanding that N- and C- terminals of GIP 
are a key consideration when designing potential therapeutics. GIP receptors are from 
the class B family of G-protein coupled receptors (GPCRs) and have a large 
extracellular N-terminal domain (NTD) linked to a 7-transmembrane helical domain 
(Al-Sabah, 2015). The C-terminal region of the peptide ligand binds to the receptors 
NTD, and this allows for secondary interaction between the N-terminus of the peptide 
and transmembrane domain (TMD). Research suggests that the first two amino acids 
of the GIP N-terminus are essential for agonist properties, and that if truncated, 
receptor activation does not occur (Hansen et al., 2016). Moreover, it has been 
determined that only amino acids from position 3-30 in GIP are essential for receptor 
binding (Hansen et al., 2016). The present study utilised this information to investigate 
the impact of truncating the N- and C- terminals of GIP and substituting a proline at 
position 3, thus Pro3GIP(3-30), and comparing this effect on both human and mouse 
GIP counterparts. 
The in vitro and in vivo assessment of human GIP(1-42) and GIP(1-30) revealed that 
they had equal potency to stimulate insulin secretion. This is in line with previous work 
by the DRG and the study by Hansen and colleagues (2016), which assessed 
functionality and showed both peptides to have full agonist properties with equal 
affinity for the GIPR (Gault et al., 2011; Hansen et al., 2016). Moreover, mouse GIP(1-
30) enhanced insulin secretion from BRIN-BD11 cells. This contrasts with the study 
by Sparre-Ulrich and colleagues (2015) on interspecies variation regarding receptor 
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and ligand binding. Both human and rat GIP(1-30) have a lysine at position 30, 
whereas the mouse sequence has an arginine at position 30. Therefore, if this 
interspecies variation was a factor influencing translatability to humans, a larger 
impact in terms of insulin secretion from a rat cell-line and glucose lowering in rodents 
would be expected (Sparre-Ulrich et al., 2015). In terms of biochemical structure, it is 
somewhat surprising that lysine to arginine substitution would have such a profound 
effect. It would seem unlikely that charge is the key factor here and more likely resides 
in orientation within the peptide. At both low and high glucose concentrations, human 
GIP(3-30), human Pro3(3-30)GIP and mouse GIP(3-30) weakly stimulated insulin 
secretion, but significantly inhibited GIP-stimulated insulin secretion. However, GIP-
stimulated insulin secretion was unaffected in combination with human GIP(5-30), 
GIP(3-42) or GIP(5-42). This result contrasts with previous work using related 
analogues and GIP(3-42) (Gault et al., 2002). It is not clear why this would be the case 
but could reside in peptide quality and/or precise application in the model system in 
BRIN-BD11 which differed in passage. 
Further in vivo analysis established that all peptide analogues, some more significant 
than others, had reduced glucose-lowering abilities when administered alone or in 
combination with human GIP (1-42). Effects on glucose control were possibly more 
apparent when administered at a higher dose (100 nmol/kg bw), but even at this dose, 
none of the peptides were as effective as native GIP to lower glucose. Interestingly, 
the GIP receptor antagonistic quality was decreased in peptides with their C-terminus 
intact (position 31–42), namely human GIP(3-42) and GIP(5-42), correlating with 
recent findings by Hansen and colleagues (Hansen et al., 2016). Converse to the early 
suggested interspecies variation discrepancies of mouse and human GIP(1-30), it was 
mouse GIP(3-30) that displayed the most superior GIP antagonistic abilities in vivo 
(Hansen et al., 2016; Sparre-Ulrich et al., 2015). This could well be due to the models 
used between the two studies. 
Interestingly, following evaluation of human, rat and mouse Pro3GIP, Sparre-Ulrich 
and colleagues (2015) noted that there was lower bioactivity within the rodent system 
than in humans. The same research team noted that human Pro3GIP at the human 
receptor had full agonism activity, and rodent ligands having a similar effect. 
However, on rodent GIPRs they suggested that Pro3GIP ligands act as partial agonists 
with competitive antagonistic properties (Sparre-Ulrich et al., 2015). Yet, it was the 
150 
 
human sequence of GIPR agonist, namely native GIP(1-42), that had a lower potency 
and efficacy on all three GIPRs in these same studies, with both rodent GIP 
demonstrating equal potency and efficacy on all GIPRs (Sparre-Ulrich et al., 2015). 
Furthermore, binding studies showed that these functional differences were not due to 
binding affinity (Sparre-Ulrich et al., 2015). Thus, with this confliction of reduced 
efficacy and potency of human GIP on all receptors compared to rodent ligands, further 
studies are required to confirm the exact consequences of different species of the GIP 
ligand on receptor activation. It could be possible that position 18 of GIP may have an 
important mechanistic activation role for the GIPR, and it has been shown that position 
18 arginine substitution can produce a much more formidable antagonistic effect than 
histidine (Sparre-Ulrich et al., 2017). Taking this, and related studies on truncated 
human GIP(3-30) and GIP(5-30) into account, it seems inappropriate to completely 
rule out Pro3GIP as a competitive GIPR antagonist (Hansen et al., 2016; Sparre-Ulrich 
et al., 2015; Sparre-Ulrich et al., 2017). 
Thus, the remainder of this study focused on the further assessment of human GIP(3-
30), GIP(5-30), and Pro3GIP(3-30) in vivo. Indeed, in the current study it was human 
Pro3GIP(3-30) that yielded superior antagonistic abilities over human GIP(3-30) and 
GIP(5-30), in terms of annulling the glucose-lowering ability of human GIP(1-42). 
The data shows that although the margin of superiority is slight, the modification of 
human Pro3GIP(3-30) augments the effects of the N- an C- terminal truncations 
further. Additionally, to further assess the receptor blockading capacity of these 
analogues they were administered 30 min prior to a glucose plus GIP challenge. Once 
again it was human Pro3GIP(3-30) that had superior GIPR antagonistic activity over 
both human GIP(3-30) and GIP(5-30) confirming superior biological effects. Thus, 
human Pro3GIP(3-30)  may have a greater affinity to the GIPR and/or a prolonged 
circulating half-life, perhaps due to the amino acid substitution resulting in increased 
efficacy as a GIPR antagonist and potential as a novel functional GIP antagonist. 
However, further studies would be required to confirm this. In support of these 
findings a subsequent study by Sparre-Ulrich and colleagues (2017), determined that 
even though rat GIP(3-30) had superior affinity as a competitive antagonist on the rat 
GIPR in vitro and in perfused rat pancreas, human GIP(3-30) still displayed 
antagonistic qualities (Sparre-Ulrich et al., 2017). There are some limitations within 
the current study, particularly related to the glucose homeostatic mechanism(s) of 
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action in the in vivo studies. Thus, GIP is known to potently augment insulin secretion 
(Campbell and Drucker, 2013), and this was not measured in the current study. In 
addition to this, GIP also has notable extrapancreatic glucose-lowering actions (Al-
Sabah, 2015; Baggio and Drucker, 2007), that would also need to be considered. 
However, it is clear that these peptides, and especially human Pro3GIP(3-30) had GIP 
blocking actions. 
Overall, these studies have called in to question some of the recent previous work on 
GIPR antagonists, and in particular, the impact of species variation in the amino acid 
sequences of both the GIP ligand and receptor (Hansen et al., 2016; Sparre-Ulrich et 
al., 2015; Sparre-Ulrich et al., 2017). In agreement with previous work on Pro3GIP(1-
42) (Gault et al., 2007ab; McClean et al., 2007; McClean et al., 2008), the current data 
confirms GIPR blocking ability of human Pro3GIP(3-30). Given that GIPR blockade 
has been suggested as a useful treatment option for obesity and obesity-driven forms 
of T2DM (Irwin et al., 2006; Irwin et al., 2009; Kerr et al., 2011; Naitoh et al., 2008; 
Nakamura et al., 2012; Pathak et al., 2015a; Ravn et al., 2013; Zhou et al., 2008) 










Table 6.1 Summary of purified native human GIP(1-42) and N- and C-terminally truncated GIP peptides; RP-HPLC retention times and 
MALDI-TOF MS of peptides 
 
 
Peptide was purified by injecting (1ml) into a Phenomenex Aeris peptide 3.6µ XB-C18 250*15mm HPLC column equilibrated with 0.12% 
(TFA)/H20 at a rate of 6 ml/min using 0.1% TFA in 70% acetonitrile/H20. Surveyor Plus Liquid Chromatograph/HPLC (Thermo Finnigan ,San 
Jose, California, USA). Absorbance was measured at 214 nm, retention times recorded using ChromQuest software. Molecular mass confirmed 
using MALDI-ToF, Voyager-DE BioSpectrometry Workstation and m/z ratio vs peak intensity. 






1 Human GIP(1-42) YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 4983.6 4982.8 19.8 
2 Human GIP(1-30) YAEGTFISDYSIAMDKIHQQDFVNWLLA QK-NH2 3531.9 3530.6 21.0 
3 Mouse GIP(1-30) YAEGTFISDYSIAMDKIRQQDFVNWLLA QR-NH2 3579.0 3578.4 21.3 
4 Human GIP(3-30) EGTFISDYSIAMDKIHQQDFVNWLLAQ K-NH2 3297.7 3296.3 20.7 
5 Mouse GIP(3-30) EGTFISDYSIAMDKIRQQDFVNWLLAQR-NH2 3344.7 3342.5 21.0 
6 Human Pro3GIP(3-30) PGTFISDYSIAMDKIHQQDFVNWLLAQK-NH2 3265.7 3263.4 20.9 
7 Human GIP(3-42) EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 4749.3 4749.2 19.3 
8 Human GIP(5-30) TFISDYSIAMDKIHQQDFVNWLLAQK-NH2 3111.5 3110.2 20.6 





Figure 6.1 Acute effects of human GIP(1-42), human GIP(1-30) and mouse 


















BRIN-BD11 cells were incubated (20 min) with test peptides (10-12 to 10-6 mol/l) in 
the presence of (A) 5.6, or (B) 16.7 mmol/l glucose. Insulin was measured by RIA. 
Values are mean ± SEM (n=8) for insulin release. *P<0.05, **P<0.01 and ***P<0.001 
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Figure 6.2 Acute effects of human GIP(3-30) and mouse GIP(3-30) alone or in 
















BRIN-BD11 cells were incubated (20 min) with test peptides (10-12 to 10-6 mol/l) alone 
or in combination with native human GIP(1-42) (10-7 mol/l) in the presence of (A & 
C) 5.6 or (B & D) 16.7 mmol/l glucose. Insulin was measured by RIA. Values are 
mean ± SEM (n=8) for insulin release. *P<0.05, **P<0.01 and ***P<0.001 compared 
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Figure 6.3 Acute effects of human Pro3GIP(3-30) and human GIP(5-30) alone or 





















BRIN-BD11 cells were incubated (20 min) with test peptides (10-12 to 10-6 mol/l) alone 
or in combination with native human GIP(1-42) (10-7 mol/l) in the presence of (A & 
C) 5.6 or (B & D) 16.7 mmol/l glucose. Insulin was measured by RIA. Values are 
mean ± SEM (n=8) for insulin release. *P<0.05, **P<0.01 and ***P<0.001 compared 
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Figure 6.4 Acute effects of human GIP(3-42) and human GIP(5-42) alone or in 






















BRIN-BD11 cells were incubated (20 min) with test peptides (10-12 to 10-6 mol/l) alone 
or in combination with native human GIP(1-42) (10-7 mol/l) in the presence of (A & 
C) 5.6 or (B & D) 16.7 mmol/l glucose. Insulin was measured by RIA. Values are 
mean ± SEM (n=8) for insulin release. *P<0.05, **P<0.01 and ***P<0.001 compared 








Figure 6.5 Acute effects of native human GIP(1-42), human GIP(1-30) and 

















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), human GIP(1-30) or mouse GIP(1-30) (each at 50 nmol/kg bw) in fasted 
mice. Glucose area under the curve (AUC) (B). Values for 0-60 min post injection are 
also shown. Values represent mean ± SEM (n=5-6). *P<0.05 and **P<0.01 compared 
with glucose alone. 






























































Figure 6.6 Acute effects of human GIP(3-30) alone or in combination with 
















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), human GIP(3-30), or human GIP(3-30) and native human GIP(1-42) 
combined (each at 50 nmol/kg bw) in fasted mice. Glucose area under the curve (AUC) 
(B) values for 0-60 min post injection are also shown. Values represent mean ± SEM 
(n=5-6). *P<0.05 and **P<0.01 compared with glucose alone. 
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Figure 6.7 Acute effects of mouse GIP(3-30) alone or in combination with native 






















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), mouse GIP(3-30), or mouse GIP(3-30) and native human GIP(1-42) 
combined (each at 50 nmol/kg bw) in fasted mice. Glucose area under the curve (AUC) 
(B) values for 0-60 min post injection are also shown. Values represent mean ± SEM 
(n=5-6). *P<0.05 compared with glucose alone or ΔP<0.05 compared to human GIP(1-
42). 
































































Figure 6.8 Acute effects of human Pro3GIP(3-30) alone or in combination with native 
























Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), human Pro3GIP(3-30), or human Pro3GIP(3-30) and native human GIP(1-
42) combined (each at 50 nmol/kg bw) in fasted mice. Glucose area under the curve 
(AUC) (B) values for 0-60 min post injection are also shown. Values represent mean 
± SEM (n=5-6). *P<0.05 and **P<0.01 compared with glucose alone. 



































































Figure 6.9 Acute effects of human GIP(5-30) alone or in combination with native 






















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), human GIP(5-30), or human GIP(5-30) and native human GIP(1-42) 
combined (each at 50 nmol/kg bw) in fasted mice. Glucose area under the curve (AUC) 
(B) values for 0-60 min post injection are also shown. Values represent mean ± SEM 
(n=5-6). *P<0.05 and **P<0.01 compared with glucose alone or ΔP<0.05 and 
ΔΔP<0.01 compared to human GIP(1-42). 
































































Figure 6.10 Acute effects of human GIP(3-42) alone or in combination with native 



















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), human GIP(3-42), or human GIP(3-42) and native human GIP(1-42) 
combined (each at 50 nmol/kg bw) in fasted mice. Glucose area under the curve (AUC) 
(B) values for 0-60 min post injection are also shown. Values represent mean ± SEM 
(n=5-6). *P<0.05 and **P<0.01 compared with glucose alone. 
































































Figure 6.11 Acute effects of human GIP(5-42) alone or in combination with native 



















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human GIP 
(1-42), human GIP (3-42), or human GIP (3-42) and native human GIP (1-42) 
combined (each at 50 nmol/kg bw) in fasted mice. Glucose area under the curve (AUC) 
(B) values for 0-60 min post injection are also shown. Values represent mean ± SEM 
(n=5-6). *P<0.05 compared with glucose alone. 
































































Figure 6.12 Acute effects of high dose human GIP(3-30), human Pro3GIP(3-30) 






















Blood glucose (A) concentrations were measured before and after intraperitoneal 
injection of glucose alone (18 mmol/kg bw), or in combination with native human 
GIP(1-42), human GIP(3-30), or human Pro3GIP (3-30) and native human GIP(1-42) 
combined (each at 100 nmol/kg bw) in fasted mice. Glucose area under the curve 
(AUC) (B) values for 0-60 min post injection are also shown. Values represent mean 
± SEM (n=5-6). *P<0.05, **P<0.01, ***P<0.001 compared with glucose alone or 
ΔP<0.05 and ΔΔP<0.01 compared to human GIP(1-42).














































































Figure 6.13 Acute effects of early administration of high dose human GIP (3-30), 

















Blood glucose (A) concentrations after early intraperitoneal injection of saline vehicle 
(0.9% (w/v), NaCl) or saline in combination with native human GIP(1-42), human 
GIP(3-30), human Pro3GIP(3-30) or human GIP(5-30), 30 min prior to administration 
of a glucose load (18 mmol/kg bw), alone or in combination with human GIP(1-42) 
(100 nmol/kg bw) in fasted mice. Glucose area under the curve (AUC) (B) values for 
-30-60 min post injection are also shown. Values represent mean ± SEM (n=5-6). 
*P<0.05, **P<0.01, ***P<0.001 compared with glucose alone or ΔP<0.05, ΔΔP<0.01 
and ΔΔΔP<0.001 compared to human GIP(1-42) or +++P<0.001 compared to human 
Pro3GIP(3-30). 





20 Saline at -30 min + Glucose at 0 min
Human GIP(1-42) at -30 min + Glucose + Human GIP(1-42) at 0 min
Human Pro3GIP(3-30) at -30 min + Glucose + Human GIP(1-42) at 0 min
*
***
Human GIP(5-30) at -30 min + Glucose + Human GIP(1-42) at 0 min

































Saline at -30 min + Glucose at 0 min
GIP(1-42) at -30 min + Glucose + GIP(1-42) at 0 min
GIP(3-30) at -30 min + Glucose + GIP(1-42) at 0 min
Pro3GIP(3-30) at -30 min + Glucose + GIP(1-42) at 0 min
































Table 6.2 Summary of acute effects of high dose and early administration of 
human GIP (3-30), human Pro3GIP (3-30) and human GIP(5-30) on glucose 
tolerance in lean mice 
 
 
Summary of  blood glucose concentrations measured before and after high dose 
intraperitoneal injection of glucose alone (18 mmol/kg bw), or in combination with 
native human GIP(1-42), human GIP(3-30), or human Pro3GIP (3-30) and native 
human GIP(1-42) combined (each at 100 nmol/kg bw) AUC values 0-60 min post 
injection (Figure 6.12) and early intraperitoneal injection of saline vehicle (0.9% (w/v), 
NaCl) or saline in combination with native human GIP(1-42), human GIP(3-30), 
human Pro3GIP(3-30) or human GIP(5-30), 30 min prior to administration of a glucose 
load (18 mmol/kg bw), alone or in combination with human GIP(1-42) (100 nmol/kg 
bw) in fasted mice AUC values -30-60 min post injection (Figure 6.13). Values 
represent mean ± SEM (n=5-6). *P<0.05, **P<0.01, ***P<0.001 compared with 
glucose alone or ΔP<0.05, ΔΔP<0.01 and ΔΔΔP<0.001 compared to human GIP(1-42) or 
+++P<0.001 compared to human Pro3GIP(3-30). 
Glucose tolerance test 
Treatment 
group 
Blood glucose AUC  
(mmol/l.min) 
Glucose 860.5 ± 72.29 
High dose human GIP(1-42) 544.9 ± 16.62*** 
High dose human GIP(3-30) 638.3 ± 31.22* 
High dose human Pro3GIP(3-30) 708.8 ± 66.84*Δ 
High dose human GIP(5-30) 687.7 ± 23.75*Δ 
Early administration glucose 1053 ± 39.25 
Early administration human GIP(1-42) 770.3 ± 55.18*** 
Early administration human GIP(3-30) 719.2 ± 45.42*** +++ 
Early administration human Pro3GIP(3-30) 1058 ± 28.10ΔΔΔ 





























7.1 Treating Type 2 diabetes 
T2DM is the major non-communicable disease pandemic that accounts for 90% of all 
diabetes cases (Public Health England, 2018). Presently, the risk prevalence of T2DM 
is exacerbated and driven forward by high calorific diets and obesity that today is 
considered a societal ‘norm’ (Public Health England, 2018). T2DM was ranked as the 
6th leading cause of death in 2015 and is a priority non-communicable disease targeted 
by world leaders across the globe (Public Health England, 2018; WHO, 2016).  In the 
UK alone, 3.8 million people live with T2DM and 200,000 people are newly diagnosed 
every year (Public Health England, 2018). T2DM is not only a major public health 
problem but also a financial burden, both directly and indirectly (Diabetes UK, 2014; 
NHS, 2018). Therefore, development of novel T2DM therapeutics is not only relevant, 
but essential in the management of T2DM. With all cases of T2DM and obesity, those 
who are detected and appropriately managed can generally prevent and/or delay the 
onset of associated complications and go on to live longer, better quality, healthier 
lives (Davies et al., 2018; WHO, 2016). 
The primary aim when treating T2DM is to develop safe and efficacious 
pharmaceuticals that are effective in terms of glycaemic control and maintaining 
HbA1c at or below target levels. Thus, reducing long-term microvascular and 
macrovascular risks associated with the disease (Davies et al., 2018; Marchetti et al., 
2009). Additionally, associated risk of atherosclerotic cardiovascular disease 
(ASCVD) and chronic kidney disease are now recommended to be considered for all 
T2DM therapeutic regimens (Davies et al., 2018). Currently, pharmaceutical agents 
such as biguanides, sulfonylureas, thiazolidinediones, SGLT2, DPP IV inhibitors and 
incretin mimetics aim to not only reduce glucose levels but assist in protecting and/or 
preventing pancreatic beta cell dysregulation and reduced sensitivity to insulin (Brandt 
et al., 2018; Marchetti et al., 2009). However, available agents for T2DM all have 
varying efficacy and adverse effects including increased risk of hypoglycaemia and 
weight gain, thus limiting their merit in being safe and effective.  
Additionally, in comparison to notable benefits of certain types of bariatric surgery 
that can restore metabolic control and sustain long-term weight loss (Irwin and Flatt, 
2015; Meek et al., 2016; Singh et al., 2015), none of the currently approved 
pharmaceutical agents are able to fully replicate this scenario (Capozzi et al., 2018). It 
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is postulated the metabolic changes in bariatric surgeries, such as Roux-en-Y Gastric 
Bypass (RYGB), are due to complex, multifaceted mechanisms and that 
pharmacological manipulation of a single metabolic pathway is unable to replicate this 
fully Currently, lifestyle changes and weight loss induced by very low calorie diets 
(624–700 kcal/day) is the only regimen that even come close to the success of bariatric 
surgery (Capozzi et al., 2018; Mehta, Marso and Neeland, 2017; Steven et al., 2016). 
However, compliance to these extreme lifestyle changes remains a key challenge to 
long-term sustainability and the regimes may not be applicable to all cases (Mehta, 
Marso and Neeland, 2017; Steven et al., 2016). The idea of targeting multiple 
receptors, rather than lone metabolic pathways, could represent one way to better 
replicate the benefits of bariatric surgeries for patients with T2DM (Brandt et al., 
2018). 
 
7.2 Single hybrid peptide multiple receptor agonists 
In recent times the beneficial antidiabetic actions of novel incretin-based therapies 
have been demonstrated, and these therapies have been suggested to protect beta cells 
against apoptosis and promote differentiation and proliferation (Brandt et al., 2018; 
Marchetti et al., 2009). As the variety of available incretin-based agents continues to 
grow, including pronounced longer-lasting action (for example formulations allowing 
for once weekly injection), the benefit to people living with T2DM should also 
dramatically increase (Bhat et al., 2013; Brandt et al., 2018; Finan et al., 2014; 
Rosenstock et al., 2015). However, these GLP-1 based therapies are still limited to 
modulation of a single receptor mediated pathway.  
As such, novel forms of incretin-based and incretin-like therapies are now being 
engineered as dual and triple monomeric/hybrid peptides (Bhat et al., 2013; Brandt et 
al., 2018; Finan et al., 2014; Rosenstock et al., 2015). Furthermore, utilising non-
classic intestinal and neuronal hormones has become increasingly popular within this 
paradigm, as it is now understood that neural/hormonal signals between the gut and 
brain have a major role in development of T2DM and obesity (Capozzi et al., 2018). 
Thus, novel hybrid peptide therapies aim to have an extended therapeutic scope in 
comparison to their single target counterparts as the receptors targets are extensively 
disseminated across tissues (Irwin and Flatt, 2015). Ultimately, this would lead to 
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improved therapeutic efficacy, with the potential for lower dosage, thereby reducing 
or eliminating adverse effects (Capozzi et al., 2018; Irwin and Flatt, 2015). There have 
been several proof-of-concept studies with dual acting peptide hormone agonists, and 
these include but not limited to GLP-1-GIP, GLP-1-oxyntomodulin and GLP-1-gastrin 
agonists (Capozzi et al., 2018; Fosgerau and Hoffmann, 2015). Interestingly, a very 
recent study has documented the remarkable benefits of a dual GIP and GLP-1 receptor 
agonist, LY3298176, in T2DM patients (Frias et al., 2018), that further promotes the 
usefulness of this avenue of therapeutics. 
This thesis has applied the principles of dual agonist technology to provide further 
proof of concept. In Chapters 3-5, the incretin hormone GIP was fused to the non-
classical xenin peptide hormone, as well as creation and characterisation of xenin-
neurotensin based hybrids. Initially, the studies built on work by Hasib et al., (2017), 
to augment therapeutic ability of GIP-xenin by combined treatment with the 
established GLP-1 agonist, exendin-4, in different models of T2DM (Capozzi et al., 
2018; Hasib et al., 2017). This work was progressed to establishing antidiabetic effects 
and anorectic benefits of xenin and neurotensin, as well as related hybrid peptides in a 
mouse model of T2DM-obesity. Finally, the focus in Chapter 6 was to further 
investigate an alternative approach to GIP therapeutics by development of a specific 
GIPR antagonist that has the potential to be utilised as a therapeutic in obesity-
diabetes. These studies also build from previous positive work on GIPR antagonism at 
Ulster (Gault et al., 2007a; Gault et al., 2008; Irwin et al., 2007; Kerr et al., 2011; 
McClean et al., 2007; McClean et al., 2008; Pathak et al., 2015a).   
 
7.3 GIP-xenin hybrid 
It is now well understood that under hyperglycaemic conditions of T2DM in humans, 
the insulin releasing action of GIP is reduced, even with exogenous administration of 
large doses (Capozzi et al., 2018). It is only when the hyperglycaemia is alleviated that 
the insulinotropic action of GIP is restored (Capozzi et al., 2018). Thus, a single 
targeting GIP therapy may not provide prominent therapeutic value in the treatment of 
T2DM (Capozzi et al., 2018; Hasib et al., 2017). Therefore, the rationale that 
augmenting GIP action, using the co-secreted hormone xenin known to potentiate GIP 
effects, was demonstrated by Hasib et al., (2017) by the dual agonist hybrid, 
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(DAla2)GIP/xenin-8-Gln. Chapters 3 and 4 have assessed (DAla2)GIP/xenin-8-Gln 
alone, and in combination with exendin-4, in two separate mouse models of contrasting 
T2DM aetiology, namely diet-induced HFF and genetically induced db/db mice (Faitia 
et al., 2018; Katsuda et al., 2013; King, 2012; Winzell and Ahren, 2004). Thus, it has 
already been established that the loss of endogenous GLP-1 and its glucose-lowering 
effects can be overcome in T2DM by exogenous administration of stable GLP-1 
analogues such as exendin-4 (Nauck, 2016). This combined treatment approach could 
potentially enhance the effects of the GIP-xenin hybrid by activation of an additional 
signalling pathway and by concomitantly reducing hyperglycaemia (Capozzi et al., 
2018; Hasib et al., 2017). Comparatively, Chapters 3 and 4 had some similar outcomes, 
but there was also evidence of contrasting effects, likely related to the mouse model 
employed. 
To summarise, over the treatment period used, circulating glucose and HbA1c levels 
were lowered in both mouse models by (DAla2)GIP-xenin-8-Gln in combination with 
exendin-4. Notably, circulating insulin were much greater in response to treatments in 
HFF mice than db/db mice, and this likely reflects the beta cell dysfunction that is 
apparent in db/db mice (Faita et al., 2018). Thus, it could suggest that the benefits of 
(DAla2)GIP-xenin-8-Gln and exendin-4 are both somewhat dependent on intact beta 
cell function. Assessment of insulin secretion from islets isolated from HFF mice at 
the end of the study confirmed this view. However, glucose tolerance in the HFF model 
was not improved by either treatment group, yet benefits were apparent in the db/db 
model, especially in mice treated with (DAla2)GIP-xenin-8-Gln in combination with 
exendin-4. This could imply that activation of multiple target pathways results in 
glucose-lowering actions independent of insulin. Indeed, it is well known that GIP and 
GLP-1 possess important extrapancreatic antihyperglycaemic actions (Al-Sabah, 
2015; Campbell and Drucker, 2013; Capozzi et al., 2018; Marín-Penalver et al., 2016). 
In relation to this, insulin sensitivity was unaffected in the db/db model, whereas the 
HFF had improvement in the (DAla2)GIP-xenin-8-Gln treatment group and more so 
in the combination group. In addition, lipid metabolism, as evidenced by total 
cholesterol and triglycerides levels, was improved by treatment regimens in HFF mice, 
possibly by augmentation of GIP action and/or sensitivity facilitated or enhanced by 
xenin, as it too plays a role in lipid metabolism (Capozzi et al., 2018; Craig, Gault and 
Irwin, 2018; Hasib et al., 2017). Finally, both the HFF single treatment groups had 
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improved sensitivity to GIP with the combination group most improved, contrary to 
the db/db model as this parameter was unaffected by either treatment. This may well 
be linked to differences in disease severity and ambient glucose levels between the two 
mouse models. Histological staining and assessment of pancreatic architecture would 
also conform to this viewpoint. 
Comparatively, these two contrasting models of T2DM show the strengths and 
limitations of (DAla2)GIP-xenin-8-Gln as a single dual agonist treatment option and 
as a combined therapeutic approach with exendin-4. In the less severe HFF model with 
intact beta cell function, (DAla2)GIP-xenin-8-Gln alone, was as effective as 
(DAla2)GIP-xenin-8-Gln in combination with exendin-4. However, the main benefits 
in db/db mice were largely observed only when (DAla2)GIP-xenin-8-Gln was 
combined with exendin-4. This is suggestive that hyperglycaemia in this model is so 
severe, that GLP-1 is required to reduce hyperglycaemia to allow (DAla2)GIP-xenin-
8-Gln to exert positive effects. Indeed, a number of studies in animals and humans 
have shown that the antidiabetic effects of GIP can be restored by concomitant 
reductions of hyperglycaemic (Frias et al., 2017; Gault, 2018; Skow, Bergmann, and 
Knop, 2016). It is presumed that the same scenario is important in db/db mice. 
Overall Chapters 3 and 4 have demonstrated that (DAla2)GIP-xenin-8-Gln alone or in 
combination with exendin-4 is primarily suited as a T2DM therapeutic in less severe 
presentations of the disease. Whereas the more severe manifestation of T2DM, the 
db/db model, it was clear that (DAla2)GIP-xenin-8-Gln therapeutic action was only 
enhanced by the addition of exendin-4 and significantly inhibited alone even with its 
dual agonist attributes (Hasib et al., 2017). Thus, possible pharmacological 
intervention with (DAla2)GIP-xenin-8-Gln alone or in combination with exendin-4 
may need to be further considered in relation to disease status of the patient. 
 
7.4 Neurotensin-xenin hybrid 
With the premise that novel xenin-containing hybrid peptides are effective antidiabetic 
agents, neurotensin was considered a good candidate for development into a hybrid 
peptide. Neurotensin (NT) has several antidiabetic actions and is known to facilitate 
absorption of fatty acids in the small intestine (Barchetta et al., 2018; Mazella et al., 
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2012). Additionally, xenin is structurally related to neurotensin (NT), with similar 
biological actions including appetite suppression, modulation of lipid metabolism and 
glucose homeostasis (Anlauf et al., 2000; Craig, Gault and Irwin, 2018; Khan et al., 
2017; Mazella et al., 2012). Thus, combining elements of these two peptides, forming 
acetyl-neurotensin(8-13)-xenin-8-Gln, had the potential to modulate several 
regulatory pathways including glucose and energy balance, and as with (DAla2)GIP-
xenin-8-Gln, this may also be augmented by addition of exendin-4 to the regimen. 
Preliminary studies with acetyl-neurotensin(8-13)-xenin-8-Gln established that 
receptor binding and activation was intact, an important quality when developing and 
fusing novel hybrid peptides (Al-Sabah, 2015; Capozzi et al., 2018; Fosgerau and 
Hoffmann, 2015). Acetyl-neurotensin(8-13)-xenin-8-Gln in vitro, and ex vivo in 
isolated islets, greatly increased insulin secretion at higher glucose levels compared to 
acetyl-neurotensin(8-13) and native NT, which only enhanced at lower concentrations. 
This is consistent with published literature (Khan et al., 2017). Furthermore, acetyl-
neurotensin(8-13)-xenin-8-Gln maintained the proliferative and anti-apoptotic 
qualities shown by both parent peptides (Khan et al., 2017). Thus, these data confirm 
that the key antidiabetic actions for the NT/xenin hybrid remain, and further in vivo 
assessment was warranted. 
The model of choice was HFF mice, based on previous observations in Chapters 3 and 
4. Biological assessment revealed that acetyl-neurotensin(8-13)-xenin-8-Gln had 
reduced efficacy in terms of glucose-lowering and insulin secretion capabilities when 
compared to exendin-4 alone, or both drugs in combination, following sub-chronic 
injection regimens. However, more importantly, in some instances acetyl-
neurotensin(8-13)-xenin-8-Gln in combination with exendin-4 outperformed exendin-
4 alone in terms of antidiabetic benefits, particularly in relation to glucose tolerance 
and insulin sensitivity.  Interestingly, it was exendin-4 alone that had superior effects 
on satiety and body weight, even though both NT and xenin are known to have roles 
in regulating energy balance pathways (Barchetta et al., 2018; Craig, Gault and Irwin, 
2018; Mazella et al., 2012). However, acetyl-neurotensin(8-13)-xenin-8-Gln in 
combination with exendin-4 did positively modulate lipid metabolism as both 
triglycerides and fat mass were reduced in this group of mice. It is also postulated that 
NT modulates leptin concentrations and signalling in the periphery as well as in the 
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central nervous system (Barchetta et al., 2018), and assessment of leptin action may 
have been a useful addition to these studies.  
To summarise, initial in vitro actions of acetyl-neurotensin(8-13)-xenin-8-Gln 
suggested promise as an antidiabetic, but these were not fully translated to the in vivo 
setting in HFF mice. Although there does seem to be potential if acetyl-neurotensin(8-
13)-xenin-8-Gln is utilised as a combined therapeutic, as shown in this study with 
exendin-4. When in combination with exendin-4, acetyl-neurotensin(8-13)-xenin-8-
Gln proved to have equally desirable or superior therapeutic attributes than exendin-4 
alone, and thus may still have potential as a T2DM therapeutic. More detailed studies 
using this molecule and in particular, effects on other physiological parameters are 
warranted.  
 
7.5 GIP antagonism 
As previously discussed, under T2DM conditions GIP action becomes dysregulated, 
with GIPR signalling linked to obesity development as elevated GIP levels increase 
fat deposition (Al-Sabah, 2015; Capozzi et al., 2018; Gasbjerg et al., 2018a). This is 
further evidenced by decreased GIP secretion and action being suggested as a primary 
metabolic benefit associated with bariatric surgery (Mingrone et al., 2009; Xiong et 
al., 2015). The focus of Chapter 7 was therefore to elucidate a GIPR antagonist as the 
validity of currently characterised GIPR antagonistic have been called into question 
(Gasbjerg et al., 2018a; Gasbjerg et al., 2018b; Hansen et al., 2016; Sparre-Ulrich et 
al., 2017). 
The study utilised GIP-based peptides with various amino acid substitutions and N- 
and C-terminus variations from the native sequence. As with the previous studies, it 
was essential to uncover which peptides maintained receptor binding, but on this 
occasion have lost activation capabilities, ensuring receptor antagonistic qualities 
(Hansen et al., 2016). Keeping in mind that to procure benefits from GIPR antagonism, 
it is not entirely necessary to fully eliminate GIPR signalling, as a partial reduction of 
GIP signalling can yield the beneficial in obesity (Nasteska et al., 2014). Moreover, 
the GIPR antagonist, (Pro3)GIP, that was shown to have various benefits in rodent 
models obesity and T2DM (Gault et al., 2007a; Gault et al., 2008; Irwin et al., 2007; 
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Kerr et al., 2011; McClean et al., 2007; McClean et al., 2008; Pathak et al., 2015a), 
has now been confirmed as a weak partial GIPR agonist rather than a full GIPR 
antagonist (Sparre-Ulrich et al., 2017; Pathak et al., 2015a). 
Initial in vitro assessment identified human GIP(3-30), human Pro3(3-30)GIP and 
mouse GIP(3-30) to significantly inhibit GIP-stimulated insulin secretion, which was 
unaffected by human GIP(5-30), GIP(3-42) or GIP(5-42). As would be expected, all 
peptides had reduced glucose-lowering ability when compared to native GIP, although 
peptides with their C-terminus intact, namely human GIP(3-42) or GIP(5-42) were less 
potent as GIPR antagonists. The findings were indicative of the C-termini importance 
in receptor activation and consistent with published literature (Hansen et al., 2016). 
This was further supported by findings that at higher dosages, the C-terminally 
truncated human GIP(3-30), Pro3(3-30)GIP and GIP(5-30) displayed superior GIP 
antagonistic properties. Although further assessment would be required to be 
definitive, the data suggest that human Pro3(3-30)GIP has greater ligand affinity 
without receptor activation, which could be attributed to addition of a proline at 
position 3, as these attributes are not displayed by human GIP(3-30). Therefore, human 
Pro3(3-30)GIP appeared to represent the most useful GIPR antagonist. 
The findings of this study further support the previous literature on Pro3GIP as a tool 
to block full GIP receptor activation (Gault et al., 2007a; Irwin et al., 2007; McClean 
et al., 2007; Pathak et al., 2015a). However, more in depth analysis including insulin 
secretion analysis, binding studies and assessment of longer-term biological effects in 
a suitable in vivo model would be required to be totally definitive. In addition, use of 
CRISPR/Cas9 and targeted genome editing (Nishimura and Fukagawa, 2017) to create 
a cell-line with specific knockout of the GIPR would also be useful to confirm 
specificity of these peptides. 
 
7.6 Advancements of work and related limitations 
The dual agonist peptides assessed in this thesis have shown that, under certain 
instances, there are major advantages of modulating naturally occurring peptides into 
multifunctional, dual receptor agonists. This approach broadens therapeutic 
applicability, which can be further enhanced by combining the dual agonist with 
another treatment option, such as a GLP-1 mimetic. However, it must also be noted 
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that there are limitations when developing monomeric peptides in comparison to the 
predictability of single receptor agents. This would include prediction of translation of 
benefits from the in vitro to the in vivo setting, as noted with acetyl-neurotensin(8-13)-
xenin-8-Gln hybrid. More significantly, this may also raise the question of 
applicability of translation from the animal model to the clinical setting, due to the 
multifaceted mechanisms of T2DM (Fosgerau and Hoffmann, 2015). However, the 
data also encourage the premise of enhanced therapeutic applicability with triple gut 
hormone receptor agonism, by use of a GLP-1 mimetic in combination with either the 
GIP/xenin of NT/xenin hybrid peptides. This does raise the possibility of potential for 
generation of a single tri-agonist peptide for diabetes. Indeed, of late there has been 
some headway made in terms of generating and characterising triple-acting hybrid 
peptides that show clear antidiabetic promise (Capozzi et al., 2018; Finan et al., 2015; 
Fosgerau and Hoffmann, 2015), and this could be considered as a future avenue for 
the dual acting hybrids described here.  
In addition, the work from this thesis also highlights the issues of interpretation and 
understanding of data derived from different established mouse models of diabetes. 
Thus, despite best efforts, no animal model can completely and accurately mimic the 
complex aetiology of human T2DM. Despite this obvious limitation, it is still 
noteworthy that for new T2DM drugs to make it towards human use, they must first 
show efficacy and safety in such rodent models. Further to this, modulation of GIP 
structure to produce a specific GIPR antagonist demonstrated how N- and C- termini 
truncations of the native peptide can dramatically alter the biological action. This 
could, as evidenced in Chapter 6, lead to generation of a suitable GIPR antagonist for 
the treatment of obesity and related diabetes (Irwin and Flatt, 2015). The limitations 
of currently characterised GIPR antagonists has been aptly described in a number of 
recent publications (Gasbjerg et al., 2018ab; Hansen et al., 2016; Pathak et al., 2015a; 
Sparre-Ulrich et al., 2017). However, it should also be noted that a recently 
characterised dual GIP and GLP-1 receptor antagonist evoked significant reductions 
in body weight in T2DM patients (Frias et al., 2018). Thus, the full impact of GIPR 
signalling on the development of obesity and related T2DM may well require further 
characterisation. Nonetheless, taken together, the current studies would suggest that 
whilst manipulating and integrating peptide structures to produce multi-acting hybrid 
peptides is encouraging, care is required to ensure that the overall impact on each 
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individual receptor binding and activation is not compromised. As such, small 
alterations in the structure of GIP can result in generation of potent GIPR antagonists. 
The timing of peptide administration could be another consideration as inducing beta 
cell rest during the light phase in mice and beta cell stimulation during their active 
dark phase has been shown to improved treatment effects such as reducing glucose 
concentrations and enhancing insulin sensitivity compared to other dosing regimens 
(Pathak et al., 2017b). A final obvious limitation of peptide based therapies is the route 
of administration in humans, and the need for subcutaneous injection as opposed to 
oral delivery (Scheen et al., 2017). However, recent advancements with possible oral 
delivery of the GLP-1 mimetic, semaglutide (Scheen, 2017), could dramatically 
change the landscape of incretin based therapies for diabetes.  
 
7.7 Future work 
This thesis has provided invaluable data and evidence of the therapeutic utility of gut-
derived peptides with regards to T2DM and obesity therapy. However, further analysis 
is warranted to fully elucidate their treatment potential, including assessment of safety 
and testing in humans. In addition, investigation of the sustainability of therapeutic 
effects of the hybrids when the treatment regimen has ceased would be interesting, 
thus determining their potential treatment longevity. Essentially, long-lived benefits 
would suggest disease altering effects of the hybrid peptides would certainly be 
considered as a benefit. Additionally, a lipid challenge test as a supplementary 
assessment parameter following treatment would also be helpful with further 
understanding of lipid metabolism and flow cytometry to analyse ex vivo adipose tissue 
to assess inflammatory response variation amongst treatment groups.  With molecular 
targets now a major focus in drug therapy, the analysis of peptides effects on micro 
RNAs (miRNAs) should also not be neglected. As such, miRNAs are now considered 
to be key regulators of gene expression within T2DM disease pathology including 
pancreatic beta cell dysfunction, proliferation and apoptosis as well as adipocyte 
regulation and related cardiovascular pathophysiology (Ding, Sun and Shan, 2017; 
Feng, Xing and Xie, 2016; Shantikumar et al., 2012). Furthermore, knockout mice 
could be utilised to understand receptor activation as well as the utility of 
CRISPR/Cas9 technology to knockout specific receptors within cell-lines to establish 
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receptor balance of each hybrid is also of importance. In addition, an assay to directly 
assess the pharmacokinetic profile of each of the novel peptides would also provide 
valuable information for future work with experimental drugs, by offering more 
information in relation to optimum dosing schedules. With these additional studies, 
the ultimate aim would be to generate a scientific rationale for progression of these 
novel peptide therapies towards studies in humans.  
 
7.8 Overall conclusion  
Collectively the data accumulated from this thesis demonstrates that designer hybrid 
peptides and combination therapy can elicit positive biological effects and improved 
therapeutic efficacy in T2DM. The observed benefits on glycaemic control and 
circulating lipids are directly in line with the new 2018 treatment goals published by 
the American Diabetes Association (ADA) and the European Association for the study 
of Diabetes (EASD). This consortium have noted that antidiabetic drugs should reduce 
hyperglycaemia, minimise weight gain and lower cardiovascular risk (Davies et al., 
2018). It is clear that the novel drugs described within this thesis warrant further 
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